|
G
|
Slco1b2
|
solute carrier organic anion transporter family member 1B2
|
decreases activity
|
ISO
|
akebia saponin D results in decreased activity of SLCO1B3 protein
|
CTD |
PMID:38761881 |
|
NCBI chr 4:176,282,577...176,355,557
Ensembl chr 4:176,282,584...176,351,083
|
|
|
G
|
Tacr1
|
tachykinin receptor 1
|
multiple interactions
|
ISO
|
[alpha-amyrin co-treated with beta-amyrin] inhibits the reaction [Cyclophosphamide results in increased expression of TACR1 protein]
|
CTD |
PMID:18210232 |
|
NCBI chr 4:116,478,617...116,647,492
Ensembl chr 4:116,478,617...116,647,492
|
|
|
G
|
Bad
|
BCL2-associated agonist of cell death
|
multiple interactions
|
ISO EXP
|
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased expression of BAD protein] arjunolic acid inhibits the reaction [Streptozocin results in increased expression of BAD protein]
|
CTD |
PMID:19682444 PMID:21420465 |
|
NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions
|
EXP ISO
|
arjunolic acid inhibits the reaction [Streptozocin results in increased expression of BCL2 protein] arjunolic acid inhibits the reaction [Cadmium Chloride results in decreased expression of BCL2 protein]
|
CTD |
PMID:19682444 PMID:21420465 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bcl2l1
|
Bcl2-like 1
|
multiple interactions
|
EXP
|
arjunolic acid inhibits the reaction [Streptozocin results in increased expression of BCL2L1 protein]
|
CTD |
PMID:19682444 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907 Ensembl chr 1:161,745,540...161,764,907
|
|
G
|
Bid
|
BH3 interacting domain death agonist
|
multiple interactions
|
ISO
|
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased expression of BID protein]
|
CTD |
PMID:21420465 |
|
NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:155,785,377...155,808,275
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
EXP ISO
|
arjunolic acid inhibits the reaction [Acetaminophen results in increased cleavage of and results in increased activity of CASP3 protein]; arjunolic acid inhibits the reaction [Streptozocin results in increased activity of CASP3 protein] arjunolic acid inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]
|
CTD |
PMID:19133311 PMID:19682444 PMID:19922764 PMID:20053369 PMID:21420465 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
multiple interactions
|
ISO
|
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased expression of CASP8 protein]
|
CTD |
PMID:21420465 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
multiple interactions
|
ISO
|
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased activity of CASP9 protein]
|
CTD |
PMID:21420465 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
ISO EXP
|
arjunolic acid inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; arjunolic acid inhibits the reaction [sodium arsenite affects the activity of CAT protein]; arjunolic acid inhibits the reaction [sodium arsenite results in decreased activity of CAT protein] arjunolic acid inhibits the reaction [Streptozocin results in decreased activity of CAT protein]
|
CTD |
PMID:18273903 PMID:18434106 PMID:19133311 PMID:19682444 PMID:20053369 PMID:21420465 More...
|
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Chuk
|
component of inhibitor of nuclear factor kappa B kinase complex
|
multiple interactions
|
ISO
|
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased phosphorylation of CHUK protein]
|
CTD |
PMID:21420465 |
|
NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273
|
|
G
|
Cycs
|
cytochrome c, somatic
|
multiple interactions
|
EXP
|
arjunolic acid inhibits the reaction [Streptozocin affects the localization of CYCS protein]
|
CTD |
PMID:19682444 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816 Ensembl chr18:80,982,668...80,984,816
|
|
G
|
Fas
|
Fas cell surface death receptor
|
multiple interactions
|
ISO
|
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased expression of FAS protein]
|
CTD |
PMID:21420465 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104
|
|
G
|
G6pd
|
glucose-6-phosphate dehydrogenase
|
multiple interactions
|
EXP
|
arjunolic acid inhibits the reaction [Streptozocin results in decreased activity of G6PD protein]
|
CTD |
PMID:19133311 PMID:19682444 |
|
NCBI chr X:157,352,364...157,372,144
Ensembl chr X:157,352,373...157,372,144
|
|
G
|
Gsr
|
glutathione-disulfide reductase
|
multiple interactions
|
ISO EXP
|
arjunolic acid inhibits the reaction [Cadmium Chloride results in decreased activity of GSR protein]; arjunolic acid inhibits the reaction [sodium arsenite affects the activity of GSR protein]; arjunolic acid inhibits the reaction [sodium arsenite results in decreased activity of GSR protein] arjunolic acid inhibits the reaction [Streptozocin results in decreased activity of GSR protein]
|
CTD |
PMID:18273903 PMID:18434106 PMID:19682444 PMID:20053369 PMID:21420465 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394
|
|
G
|
Ifng
|
interferon gamma
|
multiple interactions
|
EXP
|
arjunolic acid inhibits the reaction [Streptozocin results in decreased expression of IFNG protein]
|
CTD |
PMID:20053369 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
G
|
Ikbkb
|
inhibitor of nuclear factor kappa B kinase subunit beta
|
multiple interactions
|
ISO
|
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased phosphorylation of IKBKB protein]
|
CTD |
PMID:21420465 |
|
NCBI chr16:76,021,968...76,075,717
Ensembl chr16:76,022,008...76,081,911
|
|
G
|
Il2
|
interleukin 2
|
multiple interactions
|
EXP
|
arjunolic acid inhibits the reaction [Streptozocin results in decreased expression of IL2 protein]
|
CTD |
PMID:20053369 |
|
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672
|
|
G
|
Map3k7
|
mitogen activated protein kinase kinase kinase 7
|
multiple interactions
|
EXP
|
Arjunolic acid promotes the reaction [Map3k7 protein binds to Ppara protein in cardiac fibroblasts]
|
RGD |
PMID:28821620 |
RGD:155804266 |
NCBI chr 5:51,149,524...51,212,012
Ensembl chr 5:51,154,352...51,212,012
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
EXP
|
arjunolic acid inhibits the reaction [Streptozocin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; arjunolic acid inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:19133311 PMID:19682444 PMID:20053369 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
EXP
|
arjunolic acid inhibits the reaction [Streptozocin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; arjunolic acid inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:19133311 PMID:19682444 PMID:20053369 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
ISO EXP
|
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased degradation of and results in decreased expression of NFKBIA protein] arjunolic acid inhibits the reaction [Streptozocin results in decreased expression of NFKBIA protein]; arjunolic acid inhibits the reaction [Streptozocin results in increased phosphorylation of NFKBIA protein]
|
CTD |
PMID:20053369 PMID:21420465 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
EXP
|
arjunolic acid inhibits the reaction [Acetaminophen results in increased expression of NOS2 protein]; arjunolic acid inhibits the reaction [Cisplatin results in increased expression of NOS2]
|
CTD |
PMID:19922764 PMID:25130312 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
increases expression
|
EXP
|
arjunolic acid increases expression of Nr1h4 mRNA in steatotic liver
|
RGD |
PMID:30257410 |
RGD:15090799 |
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions
|
ISO
|
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased cleavage of PARP1 protein]
|
CTD |
PMID:21420465 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Prkcd
|
protein kinase C, delta
|
multiple interactions
|
EXP
|
arjunolic acid inhibits the reaction [Streptozocin results in increased expression of PRKCD protein]
|
CTD |
PMID:19682444 |
|
NCBI chr16:5,775,681...5,806,122
Ensembl chr16:5,775,681...5,805,839
|
|
G
|
Prkce
|
protein kinase C, epsilon
|
multiple interactions
|
EXP
|
arjunolic acid inhibits the reaction [Streptozocin results in increased expression of PRKCE protein]
|
CTD |
PMID:19682444 |
|
NCBI chr 6:13,718,050...14,204,931
Ensembl chr 6:13,718,050...14,204,288
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
ISO EXP
|
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased expression of RELA protein] arjunolic acid inhibits the reaction [Streptozocin results in increased expression of RELA protein]; arjunolic acid inhibits the reaction [Streptozocin results in increased phosphorylation of RELA protein]
|
CTD |
PMID:19133311 PMID:19682444 PMID:20053369 PMID:21420465 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Sod1
|
superoxide dismutase 1
|
multiple interactions
|
EXP
|
arjunolic acid inhibits the reaction [Streptozocin results in decreased activity of SOD1 protein]
|
CTD |
PMID:20053369 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
G
|
Sod2
|
superoxide dismutase 2
|
multiple interactions
|
EXP
|
arjunolic acid inhibits the reaction [Streptozocin results in decreased activity of SOD2 protein]
|
CTD |
PMID:20053369 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
EXP
|
arjunolic acid inhibits the reaction [Acetaminophen results in increased expression of TNF protein]; arjunolic acid inhibits the reaction [Cisplatin results in increased expression of TNF]; arjunolic acid inhibits the reaction [Streptozocin results in increased expression of TNF protein]
|
CTD |
PMID:19682444 PMID:19922764 PMID:20053369 PMID:25130312 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions decreases phosphorylation
|
EXP ISO
|
asiatic acid inhibits the reaction [Streptozocin results in decreased expression of AKT1 protein] Wortmannin promotes the reaction [asiatic acid results in decreased phosphorylation of AKT1 protein]
|
CTD |
PMID:26286522 PMID:38567545 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions decreases expression
|
EXP ISO
|
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased expression of BAX protein] asiatic acid results in decreased expression of BAX mRNA [Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased expression of BAX mRNA]; asiatic acid inhibits the reaction [Glucose results in increased expression of BAX mRNA]
|
CTD |
PMID:29108773 PMID:30802477 PMID:38527925 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions increases expression
|
EXP ISO
|
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of BCL2 protein] asiatic acid results in increased expression of BCL2 mRNA asiatic acid inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]]
|
CTD |
PMID:29108773 PMID:30802477 PMID:38527925 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions decreases expression
|
EXP ISO
|
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased expression of CASP3 protein] asiatic acid results in decreased expression of CASP3 mRNA [Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased activity of CASP3 protein]; asiatic acid inhibits the reaction [Glucose results in increased activity of CASP3 protein]
|
CTD |
PMID:29108773 PMID:30802477 PMID:38527925 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp9
|
caspase 9
|
multiple interactions
|
EXP
|
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased expression of CASP9 protein]
|
CTD |
PMID:29108773 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
EXP
|
asiatic acid inhibits the reaction [Streptozocin results in decreased activity of CAT protein]
|
CTD |
PMID:26286522 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ccnd1
|
cyclin D1
|
multiple interactions
|
EXP
|
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of CCND1 protein]
|
CTD |
PMID:29108773 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
multiple interactions
|
EXP
|
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased activity of CYP2E1 protein]
|
CTD |
PMID:29108773 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495
|
|
G
|
Dnmt3a
|
DNA methyltransferase 3 alpha
|
multiple interactions
|
EXP
|
asiatic acid inhibits the reaction [cypermethrin results in decreased expression of DNMT3A protein]
|
CTD |
PMID:34794910 |
|
NCBI chr 6:32,507,316...32,621,678
Ensembl chr 6:32,512,070...32,614,970
|
|
G
|
Dnmt3b
|
DNA methyltransferase 3 beta
|
multiple interactions
|
EXP
|
asiatic acid inhibits the reaction [cypermethrin results in decreased expression of DNMT3B protein]
|
CTD |
PMID:34794910 |
|
NCBI chr 3:162,590,777...162,629,313
Ensembl chr 3:162,604,037...162,629,313
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
ISO
|
asiatic acid inhibits the reaction [Streptozocin results in increased expression of IL1B protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased expression of IL1B protein]] [Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased secretion of IL1B protein]; asiatic acid inhibits the reaction [Glucose results in increased secretion of IL1B protein]
|
CTD |
PMID:30802477 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
ISO
|
asiatic acid inhibits the reaction [Streptozocin results in increased expression of IL6 protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased expression of IL6 protein]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased expression of IL6 protein]] [Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased secretion of IL6 protein]; asiatic acid inhibits the reaction [Glucose results in increased secretion of IL6 protein]
|
CTD |
PMID:30802477 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Ins1
|
insulin 1
|
multiple interactions
|
ISO EXP
|
[Carnosine co-treated with asiatic acid] inhibits the reaction [Streptozocin results in decreased expression of INS1 protein]; asiatic acid inhibits the reaction [Streptozocin results in decreased expression of INS1 protein]
|
CTD |
PMID:26286522 PMID:30802477 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682
|
|
G
|
Insr
|
insulin receptor
|
multiple interactions
|
EXP
|
asiatic acid inhibits the reaction [Streptozocin results in decreased expression of INSR protein]
|
CTD |
PMID:26286522 |
|
NCBI chr12:5,991,135...6,129,275
Ensembl chr12:5,981,835...6,128,803
|
|
G
|
Irs1
|
insulin receptor substrate 1
|
multiple interactions
|
EXP
|
asiatic acid inhibits the reaction [Streptozocin results in decreased expression of IRS1 protein]
|
CTD |
PMID:26286522 |
|
NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:90,993,519...91,054,538
|
|
G
|
Irs2
|
insulin receptor substrate 2
|
multiple interactions
|
EXP
|
asiatic acid inhibits the reaction [Streptozocin results in decreased expression of IRS2 protein]
|
CTD |
PMID:26286522 |
|
NCBI chr16:85,190,310...85,214,543
Ensembl chr16:85,190,111...85,214,543
|
|
G
|
Mapk8
|
mitogen-activated protein kinase 8
|
multiple interactions
|
ISO
|
[Carnosine co-treated with asiatic acid] inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK8 protein]; asiatic acid inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK8 protein]
|
CTD |
PMID:30802477 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
G
|
Mmp1
|
matrix metallopeptidase 1
|
multiple interactions decreases expression
|
ISO
|
asiatic acid inhibits the reaction [SP1 protein results in increased expression of MMP1 protein]; Wortmannin promotes the reaction [asiatic acid results in decreased expression of MMP1 mRNA]; Wortmannin promotes the reaction [asiatic acid results in decreased expression of MMP1 protein] asiatic acid results in decreased expression of MMP1 mRNA; asiatic acid results in decreased expression of MMP1 protein
|
CTD |
PMID:38567545 |
|
NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
multiple interactions
|
EXP
|
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased activity of NQO1 protein]
|
CTD |
PMID:29108773 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
G
|
Pcna
|
proliferating cell nuclear antigen
|
multiple interactions
|
EXP
|
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of PCNA protein]
|
CTD |
PMID:29108773 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901
|
|
G
|
Por
|
cytochrome p450 oxidoreductase
|
multiple interactions
|
EXP
|
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased activity of POR protein]
|
CTD |
PMID:29108773 |
|
NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809
|
|
G
|
Ppargc1a
|
PPARG coactivator 1 alpha
|
multiple interactions
|
ISO
|
[Glutamic Acid co-treated with asiatic acid] results in increased expression of PPARGC1A protein
|
CTD |
PMID:22447225 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
ISO
|
asiatic acid inhibits the reaction [Streptozocin results in increased activity of PTGS2 protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased activity of PTGS2 protein]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased activity of PTGS2 protein]]
|
CTD |
PMID:30802477 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
ISO
|
asiatic acid inhibits the reaction [Streptozocin results in increased expression of RELA protein]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased expression of RELA protein]]
|
CTD |
PMID:30802477 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Slc2a4
|
solute carrier family 2 member 4
|
multiple interactions
|
EXP
|
asiatic acid inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 protein]
|
CTD |
PMID:26286522 |
|
NCBI chr10:55,164,721...55,170,289
Ensembl chr10:55,164,721...55,170,270
|
|
G
|
Sp1
|
Sp1 transcription factor
|
multiple interactions decreases expression
|
EXP ISO
|
asiatic acid inhibits the reaction [cypermethrin results in decreased phosphorylation of SP1 protein] asiatic acid inhibits the reaction [SP1 protein results in increased expression of MMP1 protein]; Wortmannin promotes the reaction [asiatic acid results in decreased expression of SP1 mRNA]; Wortmannin promotes the reaction [asiatic acid results in decreased expression of SP1 protein] asiatic acid results in decreased expression of SP1 mRNA; asiatic acid results in decreased expression of SP1 protein
|
CTD |
PMID:34794910 PMID:38567545 |
|
NCBI chr 7:135,419,864...135,450,513
Ensembl chr 7:135,420,050...135,450,513
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO
|
asiatic acid inhibits the reaction [Glucose results in increased secretion of TNF protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Glucose results in increased secretion of TNF protein]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Glucose results in increased secretion of TNF protein]] asiatic acid inhibits the reaction [Streptozocin results in increased expression of TNF protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased expression of TNF protein]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased expression of TNF protein]]
|
CTD |
PMID:30802477 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Vdac1
|
voltage-dependent anion channel 1
|
multiple interactions
|
ISO
|
asiatic acid inhibits the reaction [Hydrogen Peroxide results in increased expression of VDAC1 mRNA]; asiatic acid inhibits the reaction [Rotenone results in increased expression of VDAC1 mRNA]; asiatic acid inhibits the reaction [Rotenone results in increased expression of VDAC1 protein]
|
CTD |
PMID:18802751 |
|
NCBI chr10:37,029,377...37,060,542
Ensembl chr10:37,023,145...37,060,541
|
|
|
G
|
Bdnf
|
brain-derived neurotrophic factor
|
multiple interactions increases expression
|
EXP
|
asiaticoside inhibits the reaction [Rotenone results in decreased expression of BDNF mRNA] asiaticoside results in increased expression of BDNF mRNA
|
CTD |
PMID:28238857 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
EXP
|
asiaticoside inhibits the reaction [Rotenone results in decreased activity of CAT protein]
|
CTD |
PMID:28238857 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Cyp2c6
|
cytochrome P450, family 2, subfamily C, polypeptide 6
|
decreases activity
|
ISO
|
asiaticoside results in decreased activity of CYP2C19 protein
|
CTD |
PMID:21349323 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
decreases activity
|
ISO
|
asiaticoside results in decreased activity of CYP3A4 protein
|
CTD |
PMID:21349323 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Mapk14
|
mitogen activated protein kinase 14
|
multiple interactions
|
EXP
|
asiaticoside inhibits the reaction [Rotenone results in decreased expression of MAPK14 protein]
|
CTD |
PMID:28238857 |
|
NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294
|
|
G
|
Mtor
|
mechanistic target of rapamycin kinase
|
multiple interactions
|
EXP
|
[asiaticoside co-treated with Rotenone] results in decreased expression of MTOR protein
|
CTD |
PMID:28238857 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435
|
|
G
|
Ngf
|
nerve growth factor
|
increases expression multiple interactions
|
EXP
|
asiaticoside results in increased expression of NGF protein asiaticoside inhibits the reaction [Rotenone results in decreased expression of NGF protein]
|
CTD |
PMID:28238857 |
|
NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:192,589,582...192,643,834
|
|
G
|
Pdpk1
|
3-phosphoinositide dependent protein kinase-1
|
multiple interactions
|
EXP
|
asiaticoside inhibits the reaction [Rotenone results in decreased expression of PDPK1 mRNA]; asiaticoside inhibits the reaction [Rotenone results in decreased expression of PDPK1 protein]
|
CTD |
PMID:28238857 |
|
NCBI chr10:13,610,000...13,687,226
Ensembl chr10:13,610,063...13,679,181
|
|
G
|
Pebp1
|
phosphatidylethanolamine binding protein 1
|
multiple interactions
|
EXP
|
asiaticoside inhibits the reaction [Rotenone results in increased expression of PEBP1 mRNA]
|
CTD |
PMID:28238857 |
|
NCBI chr12:44,946,307...44,967,890
Ensembl chr12:44,963,675...44,971,780
|
|
G
|
Pik3r6
|
phosphoinositide-3-kinase, regulatory subunit 6
|
multiple interactions
|
EXP
|
asiaticoside inhibits the reaction [Rotenone results in decreased expression of PIK3R6 mRNA]
|
CTD |
PMID:28238857 |
|
NCBI chr10:53,702,821...53,754,113
Ensembl chr10:53,704,682...53,754,497
|
|
G
|
Slc18a2
|
solute carrier family 18 member A2
|
multiple interactions
|
EXP
|
asiaticoside inhibits the reaction [Rotenone results in decreased expression of SLC18A2 mRNA]
|
CTD |
PMID:28238857 |
|
NCBI chr 1:268,399,815...268,435,229
Ensembl chr 1:268,400,016...268,435,231
|
|
G
|
Stx1a
|
syntaxin 1A
|
multiple interactions
|
EXP
|
[Rotenone co-treated with asiaticoside] results in decreased expression of STX1A mRNA
|
CTD |
PMID:28238857 |
|
NCBI chr12:27,278,517...27,306,547
Ensembl chr12:27,278,517...27,306,471
|
|
G
|
Synj1
|
synaptojanin 1
|
multiple interactions
|
EXP
|
[asiaticoside co-treated with Rotenone] results in decreased expression of SYNJ1 mRNA
|
CTD |
PMID:28238857 |
|
NCBI chr11:43,678,709...43,755,526
Ensembl chr11:43,678,709...43,755,526
|
|
G
|
Th
|
tyrosine hydroxylase
|
multiple interactions
|
EXP
|
[asiaticoside co-treated with Rotenone] results in decreased expression of TH protein
|
CTD |
PMID:28238857 |
|
NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:207,500,962...207,557,227
|
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
EXP
|
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of AKT1 mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of AKT1 protein
|
CTD |
PMID:32344236 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Aqp9
|
aquaporin 9
|
increases expression
|
ISO
|
astragaloside A results in increased expression of AQP9 mRNA; astragaloside A results in increased expression of AQP9 protein
|
CTD |
PMID:37918281 |
|
NCBI chr 8:80,678,027...80,718,273
Ensembl chr 8:80,678,030...80,717,240
|
|
G
|
Atp2a2
|
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2
|
multiple interactions
|
EXP
|
astragaloside A inhibits the reaction [Isoproterenol results in decreased expression of and results in decreased activity of ATP2A2 protein]; astragaloside A inhibits the reaction [Isoproterenol results in decreased expression of ATP2A2 mRNA]
|
CTD |
PMID:17509559 |
|
NCBI chr12:39,733,519...39,782,942
Ensembl chr12:39,733,458...39,782,934
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
ISO
|
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein]; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein]
|
CTD |
PMID:22278385 PMID:33285147 PMID:36322813 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions
|
ISO
|
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein]
|
CTD |
PMID:33285147 PMID:36322813 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bcs1l
|
BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone
|
multiple interactions
|
ISO
|
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCS1L protein]
|
CTD |
PMID:22278385 |
|
NCBI chr 9:83,614,045...83,618,052
Ensembl chr 9:83,613,975...83,618,257
|
|
G
|
Cacna1c
|
calcium voltage-gated channel subunit alpha1 C
|
multiple interactions
|
ISO
|
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein]
|
CTD |
PMID:33285147 |
|
NCBI chr 4:153,431,169...154,051,932
Ensembl chr 4:153,436,427...154,051,762
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
ISO EXP
|
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased cleavage of CASP3 protein]; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of CASP3 protein modified form] astragaloside A inhibits the reaction [Cisplatin results in increased expression of CASP3 protein]
|
CTD |
PMID:22278385 PMID:30842369 PMID:33285147 PMID:36322813 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Ccnd1
|
cyclin D1
|
increases expression
|
ISO
|
astragaloside A results in increased expression of CCND1 protein
|
CTD |
PMID:37918281 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Chuk
|
component of inhibitor of nuclear factor kappa B kinase complex
|
multiple interactions
|
ISO
|
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein]
|
CTD |
PMID:33285147 |
|
NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273
|
|
G
|
Dusp5
|
dual specificity phosphatase 5
|
decreases expression multiple interactions
|
ISO
|
astragaloside IV decreases expression Dusp5 mRNA and protein in thoracic aorta astragaloside IV inhibits the reaction [beta-Glycerophosphate increases expression of DUSP5 mRNA and protein in Vascular smooth muscle cells]
|
RGD |
PMID:30529164 PMID:30529164 |
RGD:243048424, RGD:243048424 |
NCBI chr 1:262,543,774...262,557,201
Ensembl chr 1:262,543,738...262,562,417
|
|
G
|
Egfr
|
epidermal growth factor receptor
|
multiple interactions
|
EXP
|
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of EGFR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of EGFR mRNA
|
CTD |
PMID:32344236 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358
|
|
G
|
Fth1
|
ferritin heavy chain 1
|
multiple interactions
|
ISO
|
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein]
|
CTD |
PMID:33285147 |
|
NCBI chr 1:216,052,037...216,054,325
Ensembl chr 1:216,051,998...216,055,214
|
|
G
|
Gja4
|
gap junction protein, alpha 4
|
multiple interactions
|
ISO
|
astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of GJA4 protein]
|
CTD |
PMID:36322813 |
|
NCBI chr 5:144,917,791...144,920,324
Ensembl chr 5:144,914,147...144,921,216
|
|
G
|
Glul
|
glutamate-ammonia ligase
|
multiple interactions
|
EXP
|
astragaloside A inhibits the reaction [bisphenol A results in decreased activity of GLUL protein]
|
CTD |
PMID:34434659 |
|
NCBI chr13:68,519,500...68,585,554
Ensembl chr13:68,576,067...68,585,520
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
multiple interactions
|
EXP
|
astragaloside A inhibits the reaction [Cisplatin results in increased expression of GPT protein]
|
CTD |
PMID:30842369 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
G
|
Grin2a
|
glutamate ionotropic receptor NMDA type subunit 2A
|
multiple interactions
|
EXP
|
astragaloside A inhibits the reaction [bisphenol A affects the expression of GRIN2A mRNA]
|
CTD |
PMID:34434659 |
|
NCBI chr10:6,136,458...6,560,003
Ensembl chr10:6,138,037...6,551,378
|
|
G
|
Grin2b
|
glutamate ionotropic receptor NMDA type subunit 2B
|
multiple interactions
|
EXP
|
astragaloside A inhibits the reaction [bisphenol A affects the expression of GRIN2B mRNA]
|
CTD |
PMID:34434659 |
|
NCBI chr 4:170,297,811...170,775,420
Ensembl chr 4:170,322,617...170,773,570
|
|
G
|
H19
|
H19 imprinted maternally expressed transcript
|
increases expression multiple interactions
|
ISO
|
astragaloside IV increases expression H19 RNA in thoracic aorta astragaloside IV inhibits the reaction [beta-Glycerophosphate decreases expression of H19 RNA in Vascular smooth muscle cells]
|
RGD |
PMID:30529164 PMID:30529164 |
RGD:243048424, RGD:243048424 |
NCBI chr 1:207,160,175...207,162,851
|
|
G
|
Hdac9
|
histone deacetylase 9
|
multiple interactions
|
ISO
|
astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of HDAC9 protein]
|
CTD |
PMID:36322813 |
|
NCBI chr 6:56,489,472...57,351,654
Ensembl chr 6:56,490,988...57,351,835
|
|
G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions increases expression
|
ISO
|
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein astragaloside A results in increased expression of HMOX1 mRNA; astragaloside A results in increased expression of HMOX1 protein
|
CTD |
PMID:25422538 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
EXP
|
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL1B protein; astragaloside A inhibits the reaction [Cisplatin results in increased expression of IL1B protein]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B protein]
|
CTD |
PMID:25604657 PMID:30842369 PMID:32344236 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
EXP ISO
|
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL6 protein; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein] astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]
|
CTD |
PMID:25604657 PMID:32344236 PMID:33285147 PMID:36322813 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Khdrbs1
|
KH RNA binding domain containing, signal transduction associated 1
|
decreases expression multiple interactions
|
ISO
|
astragaloside IV decreases expression of Khdrbs1 protein in thoracic aorta astragaloside IV inhibits the reaction [beta-Glycerophosphate astragaloside IV increases expression of KHDRBS1 protein in Vascular smooth muscle cells]
|
RGD |
PMID:30529164 PMID:30529164 |
RGD:243048424, RGD:243048424 |
NCBI chr 5:147,337,048...147,374,604
Ensembl chr 5:147,347,904...147,373,448
|
|
G
|
Maoa
|
monoamine oxidase A
|
multiple interactions
|
EXP
|
astragaloside A inhibits the reaction [bisphenol A results in increased expression of MAOA protein]
|
CTD |
PMID:33666843 |
|
NCBI chr X:8,615,239...8,681,372
Ensembl chr X:8,615,239...8,682,631
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
ISO
|
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:33285147 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
ISO
|
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:33285147 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions
|
EXP
|
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of MMP9 protein
|
CTD |
PMID:32344236 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
EXP
|
astragaloside A inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein]
|
CTD |
PMID:25604657 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Mtor
|
mechanistic target of rapamycin kinase
|
multiple interactions increases phosphorylation
|
EXP ISO
|
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of MTOR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MTOR mRNA astragaloside IV inhibits the reaction [beta-Glycerophosphate decreases phoshorylation of MTOR protein in Vascular smooth muscle cells] astragaloside IV increases phosphorylation Mtor protein in thoracic aorta
|
CTD RGD |
PMID:32344236 PMID:30529164 PMID:30529164 |
RGD:243048424, RGD:243048424 |
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435
|
|
G
|
Muc5ac
|
mucin 5AC, oligomeric mucus/gel-forming
|
multiple interactions
|
EXP
|
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5AC mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of MUC5AC protein
|
CTD |
PMID:32344236 |
|
NCBI chr 1:206,293,717...206,326,006
Ensembl chr 1:206,293,869...206,326,006
|
|
G
|
Muc5b
|
mucin 5B, oligomeric mucus/gel-forming
|
multiple interactions
|
EXP
|
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5B mRNA
|
CTD |
PMID:32344236 |
|
NCBI chr 1:206,346,400...206,378,367
Ensembl chr 1:206,346,400...206,378,367
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions affects localization
|
ISO
|
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein astragaloside A affects the localization of NFE2L2 protein
|
CTD |
PMID:25422538 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
EXP ISO
|
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein]
|
CTD |
PMID:25604657 PMID:33285147 PMID:36322813 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Nfkbib
|
NFKB inhibitor beta
|
multiple interactions
|
EXP
|
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB protein]
|
CTD |
PMID:25604657 |
|
NCBI chr 1:93,173,817...93,181,387
Ensembl chr 1:93,173,820...93,326,366
|
|
G
|
Nlrp3
|
NLR family, pyrin domain containing 3
|
multiple interactions
|
EXP
|
astragaloside A inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]
|
CTD |
PMID:30842369 |
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394
|
|
G
|
Pcna
|
proliferating cell nuclear antigen
|
increases expression
|
ISO
|
astragaloside A results in increased expression of PCNA protein
|
CTD |
PMID:37918281 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901
|
|
G
|
Pln
|
phospholamban
|
multiple interactions
|
EXP
|
astragaloside A inhibits the reaction [Isoproterenol results in decreased phosphorylation of PLN protein]
|
CTD |
PMID:17509559 |
|
NCBI chr20:33,166,512...33,182,241
Ensembl chr20:33,172,494...33,182,241
|
|
G
|
Ptpn1
|
protein tyrosine phosphatase, non-receptor type 1
|
increases expression
|
EXP
|
Astragaloside IV increases expression of Ptpn1 protein in the hypothalamus
|
RGD |
PMID:29562733 |
RGD:401976390 |
NCBI chr 3:177,056,588...177,106,424
Ensembl chr 3:177,057,659...177,106,416
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
EXP ISO
|
astragaloside A inhibits the reaction [Taurocholic Acid affects the localization of RELA protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein]
|
CTD |
PMID:25604657 PMID:33285147 PMID:36322813 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Rho
|
rhodopsin
|
multiple interactions
|
ISO
|
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RHO mRNA]
|
CTD |
PMID:33285147 |
|
NCBI chr 4:150,653,205...150,658,367
Ensembl chr 4:150,653,205...150,658,367
|
|
G
|
Rpe65
|
retinoid isomerohydrolase RPE65
|
multiple interactions
|
ISO
|
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RPE65 mRNA]
|
CTD |
PMID:33285147 |
|
NCBI chr 2:251,425,228...251,457,209
Ensembl chr 2:251,425,368...251,457,156
|
|
G
|
Slc11a2
|
solute carrier family 11 member 2
|
multiple interactions
|
ISO
|
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein]
|
CTD |
PMID:33285147 |
|
NCBI chr 7:133,381,878...133,429,921
Ensembl chr 7:133,381,878...133,418,941
|
|
G
|
Sod1
|
superoxide dismutase 1
|
multiple interactions
|
EXP
|
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 protein]
|
CTD |
PMID:25604657 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
G
|
Sod2
|
superoxide dismutase 2
|
multiple interactions
|
EXP
|
astragaloside A promotes the reaction [Taurocholic Acid results in decreased expression of SOD2 protein]; astragaloside A promotes the reaction [Taurocholic Acid results in increased expression of SOD2 mRNA]
|
CTD |
PMID:25604657 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168
|
|
G
|
Sqstm1
|
sequestosome 1
|
multiple interactions
|
EXP
|
astragaloside A inhibits the reaction [Cisplatin results in increased expression of SQSTM1 protein]
|
CTD |
PMID:30842369 |
|
NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750
|
|
G
|
Tfrc
|
transferrin receptor
|
multiple interactions
|
ISO
|
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein]
|
CTD |
PMID:33285147 |
|
NCBI chr11:81,668,478...81,690,318
Ensembl chr11:81,668,478...81,690,318
|
|
G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
multiple interactions
|
EXP
|
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of TIMP1 protein
|
CTD |
PMID:32344236 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
EXP ISO
|
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of TNF protein; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein] astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]
|
CTD |
PMID:25604657 PMID:32344236 PMID:33285147 PMID:36322813 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tph2
|
tryptophan hydroxylase 2
|
multiple interactions
|
EXP
|
astragaloside A affects the reaction [bisphenol A affects the expression of TPH2 mRNA]
|
CTD |
PMID:33666843 |
|
NCBI chr 7:52,571,909...52,676,305
Ensembl chr 7:52,571,911...52,675,639
|
|
|
G
|
Arg1
|
arginase 1
|
multiple interactions
|
ISO
|
beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of ARG1 mRNA]
|
CTD |
PMID:29501766 |
|
NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:22,295,322...22,307,713
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
EXP
|
beta-amyrin inhibits the reaction [Dimethylnitrosamine results in increased cleavage of CASP3 protein]; beta-amyrin inhibits the reaction [Dimethylnitrosamine results in increased expression of CASP3 mRNA]
|
CTD |
PMID:27009110 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Gja1
|
gap junction protein, alpha 1
|
multiple interactions
|
EXP
|
beta-amyrin inhibits the reaction [Glycerol results in increased expression of GJA1 mRNA]
|
CTD |
PMID:32081053 |
|
NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689
|
|
G
|
Ifng
|
interferon gamma
|
multiple interactions
|
ISO
|
beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of ARG1 mRNA]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL1B mRNA]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL1B protein]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL6 mRNA]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL6 protein]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PTGS2 mRNA]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF mRNA]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]
|
CTD |
PMID:29501766 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
ISO
|
beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL1B mRNA]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL1B protein]
|
CTD |
PMID:29501766 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
ISO
|
beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL6 mRNA]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL6 protein]
|
CTD |
PMID:29501766 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Nes
|
nestin
|
decreases expression multiple interactions
|
EXP
|
beta-amyrin results in decreased expression of NES mRNA beta-amyrin inhibits the reaction [Glycerol results in increased expression of NES mRNA]
|
CTD |
PMID:32081053 |
|
NCBI chr 2:175,735,715...175,745,631
Ensembl chr 2:175,736,551...175,746,228
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
ISO
|
beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]
|
CTD |
PMID:29501766 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
ISO
|
beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PTGS2 mRNA]
|
CTD |
PMID:29501766 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Tacr1
|
tachykinin receptor 1
|
multiple interactions
|
ISO
|
[alpha-amyrin co-treated with beta-amyrin] inhibits the reaction [Cyclophosphamide results in increased expression of TACR1 protein]
|
CTD |
PMID:18210232 |
|
NCBI chr 4:116,478,617...116,647,492
Ensembl chr 4:116,478,617...116,647,492
|
|
G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
multiple interactions
|
EXP
|
beta-amyrin inhibits the reaction [Dimethylnitrosamine results in increased expression of TIMP1 protein]
|
CTD |
PMID:27009110 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO EXP
|
beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF mRNA]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein] beta-amyrin inhibits the reaction [Dimethylnitrosamine results in increased expression of TNF protein]
|
CTD |
PMID:27009110 PMID:29501766 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Vim
|
vimentin
|
multiple interactions decreases expression
|
EXP
|
beta-amyrin inhibits the reaction [Glycerol results in increased expression of VIM mRNA] beta-amyrin results in decreased expression of VIM mRNA
|
CTD |
PMID:32081053 |
|
NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746
|
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
multiple interactions
|
ISO
|
betulin inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin]; betulin inhibits the reaction [ABCB1 protein results in increased export of Rhodamine 123]
|
CTD |
PMID:33321149 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
multiple interactions
|
EXP
|
betulin inhibits the reaction [Ethanol results in increased expression of ACTA2 protein]
|
CTD |
PMID:21172400 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Ahr
|
aryl hydrocarbon receptor
|
multiple interactions
|
EXP
|
betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AHR protein]
|
CTD |
PMID:33759307 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
increases phosphorylation
|
ISO
|
betulin results in increased phosphorylation of AKT1 protein
|
CTD |
PMID:32190974 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Arnt
|
aryl hydrocarbon receptor nuclear translocator
|
multiple interactions
|
EXP
|
betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of ARNT protein]
|
CTD |
PMID:33759307 |
|
NCBI chr 2:185,686,703...185,745,546
Ensembl chr 2:185,680,683...185,745,546
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression
|
ISO
|
betulin results in increased expression of BAX protein
|
CTD |
PMID:33181113 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions
|
ISO
|
[betulin co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein
|
CTD |
PMID:33181113 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Birc5
|
baculoviral IAP repeat-containing 5
|
multiple interactions decreases expression
|
ISO
|
betulin analog promotes the reaction [Oxygen deficiency results in decreased expression of BIRC5 protein] betulin analog results in decreased expression of BIRC5 protein
|
CTD |
PMID:26540049 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155
|
|
G
|
Braf
|
B-Raf proto-oncogene, serine/threonine kinase
|
multiple interactions
|
ISO
|
betulin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; betulin affects the reaction [BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]]; betulin affects the reaction [BRAF protein affects the susceptibility to Vemurafenib]
|
CTD |
PMID:29950559 |
|
NCBI chr 4:69,329,772...69,476,931
Ensembl chr 4:69,342,813...69,476,931
|
|
G
|
Ca9
|
carbonic anhydrase 9
|
multiple interactions
|
ISO
|
betulin analog inhibits the reaction [Oxygen deficiency results in increased expression of CA9 protein]
|
CTD |
PMID:26540049 |
|
NCBI chr 5:62,559,024...62,565,626
Ensembl chr 5:62,558,823...62,565,626
|
|
G
|
Casp3
|
caspase 3
|
increases cleavage multiple interactions
|
ISO
|
betulin results in increased cleavage of CASP3 protein Chloroquine inhibits the reaction [betulin results in increased cleavage of CASP3 protein]
|
CTD |
PMID:32190974 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
increases cleavage
|
ISO
|
betulin results in increased cleavage of CASP8 protein
|
CTD |
PMID:32190974 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
increases cleavage
|
ISO
|
betulin results in increased cleavage of CASP9 protein
|
CTD |
PMID:32190974 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
EXP
|
betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CAT protein]
|
CTD |
PMID:33759307 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ctnnb1
|
catenin beta 1
|
multiple interactions
|
ISO
|
[betulin co-treated with Oxygen deficiency] results in decreased expression of CTNNB1 protein
|
CTD |
PMID:33181113 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions
|
EXP
|
betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 protein]
|
CTD |
PMID:33759307 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Egfr
|
epidermal growth factor receptor
|
multiple interactions decreases phosphorylation
|
ISO
|
[Gefitinib co-treated with betulin] results in decreased expression of and results in decreased phosphorylation of EGFR protein betulin results in decreased phosphorylation of EGFR protein
|
CTD |
PMID:27447558 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358
|
|
G
|
Eif4ebp1
|
eukaryotic translation initiation factor 4E binding protein 1
|
decreases phosphorylation
|
ISO
|
betulin results in decreased phosphorylation of EIF4EBP1 protein
|
CTD |
PMID:32190974 |
|
NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874
|
|
G
|
Fasn
|
fatty acid synthase
|
decreases expression
|
ISO
|
betulin results in decreased expression of FASN mRNA; betulin results in decreased expression of FASN protein
|
CTD |
PMID:27378817 PMID:27447558 |
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583
|
|
G
|
G6pc1
|
glucose-6-phosphatase catalytic subunit 1
|
decreases expression
|
ISO
|
betulin results in decreased expression of G6PC1 protein
|
CTD |
PMID:34500009 |
|
NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,757,899...86,818,033
|
|
G
|
Gsk3b
|
glycogen synthase kinase 3 beta
|
multiple interactions
|
ISO
|
[betulin co-treated with Oxygen deficiency] affects the phosphorylation of GSK3B protein
|
CTD |
PMID:33181113 |
|
NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249
|
|
G
|
Hif1a
|
hypoxia inducible factor 1 subunit alpha
|
decreases expression multiple interactions
|
ISO
|
betulin analog results in decreased expression of HIF1A protein; betulin results in decreased expression of HIF1A protein betulin analog inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]
|
CTD |
PMID:26540049 PMID:33181113 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323
|
|
G
|
Hmgcr
|
3-hydroxy-3-methylglutaryl-CoA reductase
|
decreases expression
|
ISO
|
betulin results in decreased expression of HMGCR mRNA; betulin results in decreased expression of HMGCR protein
|
CTD |
PMID:27378817 PMID:27447558 |
|
NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:29,720,553...29,754,533
|
|
G
|
Hmgcs1
|
3-hydroxy-3-methylglutaryl-CoA synthase 1
|
decreases expression
|
ISO
|
betulin results in decreased expression of HMGCS1 mRNA
|
CTD |
PMID:27378817 |
|
NCBI chr 2:53,379,457...53,399,807
Ensembl chr 2:53,382,643...53,399,802
|
|
G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions
|
EXP
|
betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of HMOX1 protein]
|
CTD |
PMID:33759307 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Ifng
|
interferon gamma
|
increases secretion
|
ISO
|
betulin results in increased secretion of IFNG protein
|
CTD |
PMID:25756279 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
G
|
Il12a
|
interleukin 12A
|
multiple interactions increases expression
|
ISO
|
betulin results in increased secretion of [IL12A protein binds to IL12B protein] betulin results in increased expression of IL12A mRNA
|
CTD |
PMID:25756279 |
|
NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:155,275,625...155,282,997
|
|
G
|
Il12b
|
interleukin 12B
|
multiple interactions
|
ISO
|
betulin results in increased secretion of [IL12A protein binds to IL12B protein]
|
CTD |
PMID:25756279 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
ISO
|
betulin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]
|
CTD |
PMID:34500009 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il2
|
interleukin 2
|
increases secretion
|
ISO
|
betulin results in increased secretion of IL2 protein
|
CTD |
PMID:25756279 |
|
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672
|
|
G
|
Keap1
|
Kelch-like ECH-associated protein 1
|
multiple interactions
|
EXP
|
betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of KEAP1 protein]
|
CTD |
PMID:33759307 |
|
NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions increases phosphorylation
|
ISO
|
[betulin co-treated with Oxygen deficiency] results in increased phosphorylation of MAPK1 protein betulin results in increased phosphorylation of MAPK1 protein
|
CTD |
PMID:33181113 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
increases phosphorylation multiple interactions
|
ISO EXP
|
betulin results in increased phosphorylation of MAPK3 protein betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MAPK3 mRNA] [betulin co-treated with Oxygen deficiency] results in increased phosphorylation of MAPK3 protein
|
CTD |
PMID:33181113 PMID:33759307 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mapk8
|
mitogen-activated protein kinase 8
|
multiple interactions
|
EXP
|
betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MAPK8 mRNA]
|
CTD |
PMID:33759307 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
G
|
Marveld1
|
MARVEL domain containing 1
|
decreases expression
|
ISO
|
betulin results in decreased expression of MARVELD1 mRNA
|
CTD |
PMID:27447558 |
|
NCBI chr 1:250,903,342...250,907,393
Ensembl chr 1:250,903,342...250,907,393
|
|
G
|
Mki67
|
marker of proliferation Ki-67
|
multiple interactions
|
ISO
|
[Gefitinib co-treated with betulin] results in decreased expression of MKI67 protein
|
CTD |
PMID:27447558 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
multiple interactions
|
EXP
|
betulin inhibits the reaction [Ethanol results in increased expression of MMP2 protein]
|
CTD |
PMID:21172400 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
G
|
Mtor
|
mechanistic target of rapamycin kinase
|
decreases phosphorylation
|
ISO
|
betulin results in decreased phosphorylation of MTOR protein
|
CTD |
PMID:32190974 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435
|
|
G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
multiple interactions
|
ISO
|
[betulin co-treated with Oxygen deficiency] results in decreased expression of MYC protein
|
CTD |
PMID:33181113 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions
|
EXP
|
betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of NFE2L2 protein]
|
CTD |
PMID:33759307 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nr3c1
|
nuclear receptor subfamily 3, group C, member 1
|
multiple interactions
|
ISO
|
betulin binds to and affects the localization of NR3C1 protein
|
CTD |
PMID:34500009 |
|
NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions increases cleavage
|
ISO
|
[betulin co-treated with Oxygen] results in increased cleavage of PARP1 protein; betulin analog promotes the reaction [Oxygen deficiency results in increased expression of PARP1 protein modified form]; Chloroquine inhibits the reaction [betulin results in increased cleavage of PARP1 protein]
|
CTD |
PMID:26540049 PMID:32190974 PMID:33181113 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Pck1
|
phosphoenolpyruvate carboxykinase 1
|
increases expression
|
ISO
|
betulin results in increased expression of PCK1 protein
|
CTD |
PMID:34500009 |
|
NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:182,348,572...182,354,561
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
EXP
|
betulin inhibits the reaction [Ethanol results in increased phosphorylation of RELA protein]
|
CTD |
PMID:21172400 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Scd
|
stearoyl-CoA desaturase
|
decreases expression
|
ISO
|
betulin results in decreased expression of SCD mRNA; betulin results in decreased expression of SCD protein
|
CTD |
PMID:27378817 PMID:27447558 |
|
NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785
|
|
G
|
Slc10a1
|
solute carrier family 10 member 1
|
multiple interactions
|
ISO
|
betulin affects the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; betulin inhibits the reaction [SLC10A1 protein results in increased uptake of Taurolithocholic Acid]
|
CTD |
PMID:34079822 |
|
NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:106,344,319...106,357,944
|
|
G
|
Slc10a2
|
solute carrier family 10 member 2
|
multiple interactions
|
ISO
|
betulin affects the reaction [SLC10A2 protein results in increased uptake of Taurolithocholic Acid]
|
CTD |
PMID:34079822 |
|
NCBI chr16:91,088,089...91,111,025
Ensembl chr16:91,076,423...91,111,025
|
|
G
|
Slc10a6
|
solute carrier family 10 member 6
|
multiple interactions
|
ISO
|
betulin affects the reaction [SLC10A6 protein results in increased uptake of Dehydroepiandrosterone Sulfate]; betulin inhibits the reaction [SLC10A6 protein results in increased uptake of Taurolithocholic Acid]
|
CTD |
PMID:34079822 |
|
NCBI chr14:6,385,348...6,407,532
Ensembl chr14:6,385,537...6,408,894
|
|
G
|
Smad3
|
SMAD family member 3
|
multiple interactions
|
EXP
|
betulin inhibits the reaction [Ethanol results in increased phosphorylation of SMAD3 protein]
|
CTD |
PMID:21172400 |
|
NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324
|
|
G
|
Srebf1
|
sterol regulatory element binding transcription factor 1
|
decreases cleavage multiple interactions decreases expression
|
ISO
|
betulin results in decreased cleavage of SREBF1 protein [Gefitinib co-treated with betulin] results in decreased expression of SREBF1 protein; betulin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]] betulin results in decreased expression of SREBF1 protein
|
CTD |
PMID:27447558 PMID:29950559 |
|
NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164
|
|
G
|
Sult2a1
|
sulfotransferase family 2A member 1
|
increases sulfation
|
ISO
|
SULT2A1 protein results in increased sulfation of betulin
|
CTD |
PMID:30776358 |
|
NCBI chr 1:84,582,011...84,639,001
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
EXP
|
betulin inhibits the reaction [Ethanol results in increased expression of TGFB1 protein]
|
CTD |
PMID:21172400 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
multiple interactions
|
EXP
|
betulin inhibits the reaction [Ethanol results in increased expression of TIMP1 protein]
|
CTD |
PMID:21172400 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
G
|
Timp2
|
TIMP metallopeptidase inhibitor 2
|
multiple interactions
|
EXP
|
betulin inhibits the reaction [Ethanol results in increased expression of TIMP2 protein]
|
CTD |
PMID:21172400 |
|
NCBI chr10:104,041,604...104,089,214
Ensembl chr10:104,041,604...104,089,214
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO
|
betulin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
|
CTD |
PMID:34500009 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Ugt1a2
|
UDP glucuronosyltransferase 1 family, polypeptide A2
|
increases glucuronidation
|
ISO
|
UGT1A3 protein results in increased glucuronidation of betulin
|
CTD |
PMID:30776358 |
|
NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt1a5
|
UDP glucuronosyltransferase family 1 member A5
|
increases glucuronidation
|
ISO
|
UGT1A4 protein results in increased glucuronidation of betulin
|
CTD |
PMID:30776358 |
|
NCBI chr 9:96,210,053...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
|
G
|
Acsl4
|
acyl-CoA synthetase long-chain family member 4
|
multiple interactions
|
ISO
|
[Betulinic Acid co-treated with regorafenib] results in decreased expression of ACSL4 protein; Betulinic Acid inhibits the reaction [pirinixic acid results in increased expression of ACSL4 mRNA]
|
CTD |
PMID:39067772 |
|
NCBI chr X:110,739,633...110,803,416
Ensembl chr X:110,739,648...110,803,261
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
multiple interactions
|
EXP
|
Betulinic Acid inhibits the reaction [Ethanol results in increased expression of ACTA2 protein]; Betulinic Acid inhibits the reaction [Thioacetamide results in increased expression of ACTA2]
|
CTD |
PMID:21172400 PMID:22285267 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
increases phosphorylation multiple interactions
|
ISO
|
Betulinic Acid results in increased phosphorylation of AKT1 protein 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Betulinic Acid results in increased phosphorylation of AKT1 protein]
|
CTD |
PMID:16077934 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Bak1
|
BCL2-antagonist/killer 1
|
increases expression multiple interactions
|
ISO
|
Betulinic Acid results in increased expression of BAK1 protein [Betulinic Acid co-treated with Oxygen deficiency] results in increased expression of BAK1 protein
|
CTD |
PMID:33181113 |
|
NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
ISO
|
[2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with Betulinic Acid analog] results in increased activity of BAX protein; CA 074 methyl ester inhibits the reaction [[2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with Betulinic Acid analog] results in increased activity of BAX protein]
|
CTD |
PMID:23000516 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression multiple interactions
|
ISO
|
Betulinic Acid results in decreased expression of BCL2 protein [Betulinic Acid co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein
|
CTD |
PMID:30136359 PMID:33181113 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Birc5
|
baculoviral IAP repeat-containing 5
|
multiple interactions decreases response to substance decreases expression increases expression
|
ISO
|
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Betulinic Acid results in increased expression of BIRC5]; Betulinic Acid promotes the reaction [Oxygen deficiency results in decreased expression of BIRC5 protein]; Erlotinib Hydrochloride inhibits the reaction [Betulinic Acid results in decreased expression of BIRC5 protein] BIRC5 protein results in decreased susceptibility to Betulinic Acid
|
CTD |
PMID:16077934 PMID:26540049 PMID:30136359 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155
|
|
G
|
Bmi1
|
BMI1 proto-oncogene, polycomb ring finger
|
increases expression decreases expression
|
ISO
|
Betulinic Acid results in increased expression of BMI1 protein Betulinic Acid results in decreased expression of BMI1 protein
|
CTD |
PMID:33157086 |
|
NCBI chr17:86,240,683...86,250,044
Ensembl chr17:86,243,491...86,250,024
|
|
G
|
Ca9
|
carbonic anhydrase 9
|
decreases activity multiple interactions
|
ISO
|
Betulinic Acid analog results in decreased activity of CA9 protein Betulinic Acid inhibits the reaction [Oxygen deficiency results in increased expression of CA9 protein]
|
CTD |
PMID:26540049 PMID:29454615 |
|
NCBI chr 5:62,559,024...62,565,626
Ensembl chr 5:62,558,823...62,565,626
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions increases cleavage increases activity
|
ISO
|
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [Betulinic Acid analog results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; CA 074 methyl ester inhibits the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [Betulinic Acid analog results in increased cleavage of CASP3 protein]]; VDAC1 protein inhibits the reaction [Betulinic Acid results in increased expression of CASP3 protein modified form] Betulinic Acid analog results in increased cleavage of CASP3 protein; Betulinic Acid results in increased cleavage of CASP3 protein Betulinic Acid analog results in increased activity of CASP3 protein; Betulinic Acid results in increased activity of CASP3 protein
|
CTD |
PMID:22260869 PMID:23000516 PMID:26772157 PMID:28578903 PMID:29454615 PMID:30136359 PMID:30482226 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp7
|
caspase 7
|
multiple interactions increases activity
|
ISO
|
VDAC1 protein inhibits the reaction [Betulinic Acid results in increased expression of CASP7 protein modified form] Betulinic Acid results in increased activity of CASP7 protein
|
CTD |
PMID:22260869 PMID:30136359 |
|
NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512
|
|
G
|
Casp8
|
caspase 8
|
increases activity
|
ISO
|
Betulinic Acid results in increased activity of CASP8 protein
|
CTD |
PMID:26772157 PMID:29454615 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
increases activity
|
ISO
|
Betulinic Acid analog results in increased activity of CASP9 protein; Betulinic Acid results in increased activity of CASP9 protein
|
CTD |
PMID:26772157 PMID:29454615 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
EXP
|
Betulinic Acid inhibits the reaction [Dimethylnitrosamine results in decreased activity of CAT protein]
|
CTD |
PMID:34472159 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ccnb1
|
cyclin B1
|
decreases expression
|
ISO
|
Betulinic Acid results in decreased expression of CCNB1 protein
|
CTD |
PMID:33181113 |
|
NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225
|
|
G
|
Ccnd1
|
cyclin D1
|
decreases expression multiple interactions
|
ISO
|
Betulinic Acid analog results in decreased expression of CCND1 protein; Betulinic Acid results in decreased expression of CCND1 protein [Betulinic Acid co-treated with Oxygen deficiency] results in decreased expression of CCND1 protein
|
CTD |
PMID:28254521 PMID:33181113 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Cdk6
|
cyclin-dependent kinase 6
|
multiple interactions
|
ISO
|
Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of CDK6 protein]; Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of CDK6 protein]
|
CTD |
PMID:30136359 |
|
NCBI chr 4:31,592,384...31,784,732
Ensembl chr 4:31,601,192...31,781,701
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression
|
ISO
|
Betulinic Acid analog results in increased expression of CDKN1A protein
|
CTD |
PMID:28254521 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Cebpb
|
CCAAT/enhancer binding protein beta
|
multiple interactions decreases expression
|
ISO
|
Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form] Betulinic Acid results in decreased expression of CEBPB protein modified form
|
CTD |
PMID:30482226 |
|
NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072
|
|
G
|
Ctnnb1
|
catenin beta 1
|
multiple interactions decreases expression
|
ISO
|
[Betulinic Acid co-treated with Erlotinib Hydrochloride] results in decreased expression of CTNNB1 protein; [Betulinic Acid co-treated with Oxygen deficiency] results in decreased expression of CTNNB1 protein Betulinic Acid results in decreased expression of CTNNB1 protein
|
CTD |
PMID:30136359 PMID:33181113 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662
|
|
G
|
Ctsk
|
cathepsin K
|
multiple interactions
|
ISO
|
Betulinic Acid inhibits the reaction [TNFSF11 protein results in increased secretion of CTSK protein]
|
CTD |
PMID:24463094 |
|
NCBI chr 2:185,747,548...185,758,512
Ensembl chr 2:185,747,165...185,765,582
|
|
G
|
Ddit3
|
DNA-damage inducible transcript 3
|
multiple interactions
|
ISO
|
Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]
|
CTD |
PMID:30482226 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
G
|
Egfr
|
epidermal growth factor receptor
|
multiple interactions increases phosphorylation
|
ISO
|
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Betulinic Acid results in increased phosphorylation of EGFR protein]; Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of EGFR protein modified form]
|
CTD |
PMID:16077934 PMID:30136359 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358
|
|
G
|
Gsk3b
|
glycogen synthase kinase 3 beta
|
increases phosphorylation multiple interactions
|
ISO
|
Betulinic Acid results in increased phosphorylation of GSK3B protein [Betulinic Acid co-treated with Oxygen deficiency] results in increased phosphorylation of GSK3B protein
|
CTD |
PMID:33181113 |
|
NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249
|
|
G
|
Hif1a
|
hypoxia inducible factor 1 subunit alpha
|
decreases expression multiple interactions
|
ISO
|
Betulinic Acid results in decreased expression of HIF1A protein [Betulinic Acid co-treated with Oxygen deficiency] affects the expression of HIF1A protein
|
CTD |
PMID:26540049 PMID:33181113 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323
|
|
G
|
Hk2
|
hexokinase 2
|
multiple interactions
|
ISO
|
[VDAC1 protein results in decreased susceptibility to Betulinic Acid] which results in increased expression of HK2 protein
|
CTD |
PMID:30136359 |
|
NCBI chr 4:116,792,258...116,841,275
Ensembl chr 4:116,792,258...116,841,275
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
EXP
|
Betulinic Acid inhibits the reaction [Dimethylnitrosamine results in increased expression of IL6 protein]
|
CTD |
PMID:34472159 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Map1lc3b
|
microtubule-associated protein 1 light chain 3 beta
|
multiple interactions increases expression
|
ISO
|
Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in increased expression of MAP1LC3B protein modified form]
|
CTD |
PMID:30136359 |
|
NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358 Ensembl chr16:66,574,407...66,584,358
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions increases phosphorylation
|
ISO
|
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Betulinic Acid results in increased phosphorylation of MAPK1 protein]; [Betulinic Acid co-treated with Oxygen deficiency] results in increased phosphorylation of MAPK1 protein; [Betulinic Acid co-treated with pirinixic acid] results in decreased phosphorylation of MAPK1 protein; [Betulinic Acid co-treated with regorafenib] results in decreased phosphorylation of MAPK1 protein
|
CTD |
PMID:16077934 PMID:33181113 PMID:39067772 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
increases phosphorylation multiple interactions
|
ISO
|
Betulinic Acid results in increased phosphorylation of MAPK3 protein 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Betulinic Acid results in increased phosphorylation of MAPK3 protein]; [Betulinic Acid co-treated with Oxygen deficiency] results in increased phosphorylation of MAPK3 protein; [Betulinic Acid co-treated with pirinixic acid] results in decreased phosphorylation of MAPK3 protein; [Betulinic Acid co-treated with regorafenib] results in decreased phosphorylation of MAPK3 protein
|
CTD |
PMID:16077934 PMID:33181113 PMID:39067772 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mir24-2
|
microRNA 24-2
|
multiple interactions affects response to substance
|
ISO
|
MIR24-2 mRNA affects the susceptibility to [Betulinic Acid co-treated with Gemcitabine] MIR24-2 mRNA affects the susceptibility to Betulinic Acid
|
CTD |
PMID:25841339 |
|
NCBI chr19:40,859,455...40,859,562
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
multiple interactions
|
EXP ISO
|
Betulinic Acid inhibits the reaction [Ethanol results in increased expression of MMP2 protein] Betulinic Acid affects the reaction [TGFB1 protein affects the expression of and affects the secretion of MMP2 protein] Betulinic Acid inhibits the reaction [TNFSF11 protein results in increased secretion of MMP2 protein]
|
CTD |
PMID:21172400 PMID:24463094 PMID:28578903 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions
|
ISO
|
Betulinic Acid inhibits the reaction [TNFSF11 protein results in increased secretion of MMP9 protein]
|
CTD |
PMID:24463094 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
multiple interactions
|
ISO
|
[Betulinic Acid co-treated with Oxygen deficiency] results in decreased expression of MYC protein; [Betulinic Acid co-treated with pirinixic acid] results in decreased expression of MYC protein; [Betulinic Acid co-treated with regorafenib] results in decreased expression of MYC protein
|
CTD |
PMID:33181113 PMID:39067772 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
EXP
|
Betulinic Acid inhibits the reaction [Ethanol results in increased phosphorylation of NFKBIA protein]
|
CTD |
PMID:21172400 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Nos1
|
nitric oxide synthase 1
|
multiple interactions
|
ISO
|
Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of NOS1 protein]
|
CTD |
PMID:30482226 |
|
NCBI chr12:44,276,011...44,456,371
Ensembl chr12:44,287,614...44,371,837
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
increases cleavage multiple interactions increases expression
|
ISO
|
Betulinic Acid results in increased cleavage of PARP1 protein [Betulinic Acid co-treated with Oxygen] results in increased cleavage of PARP1 protein; Betulinic Acid promotes the reaction [Gefitinib results in increased cleavage of PARP1 protein] Betulinic Acid results in increased expression of PARP1 protein modified form
|
CTD |
PMID:26540049 PMID:30136359 PMID:33181113 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Pcna
|
proliferating cell nuclear antigen
|
multiple interactions decreases expression
|
EXP ISO
|
Betulinic Acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of PCNA protein] Betulinic Acid analog results in decreased expression of PCNA protein
|
CTD |
PMID:28254521 PMID:34541749 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901
|
|
G
|
Pla2g2a
|
phospholipase A2 group IIA
|
affects binding
|
ISO
|
Betulinic Acid binds to PLA2G2A protein
|
CTD |
PMID:29391000 |
|
NCBI chr 5:156,359,725...156,362,302
Ensembl chr 5:156,359,725...156,362,297
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
multiple interactions
|
ISO
|
[Betulinic Acid co-treated with regorafenib] results in increased expression of PPARA protein
|
CTD |
PMID:39067772 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
EXP
|
Betulinic Acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of PTGS2 protein]
|
CTD |
PMID:34541749 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Pthlh
|
parathyroid hormone-like hormone
|
multiple interactions decreases response to substance decreases secretion decreases expression
|
ISO
|
Betulinic Acid inhibits the reaction [PTHLH protein results in increased expression of TNFSF11 protein] Betulinic Acid results in decreased susceptibility to PTHLH protein Betulinic Acid results in decreased secretion of PTHLH protein Betulinic Acid results in decreased expression of PTHLH mRNA
|
CTD |
PMID:24463094 |
|
NCBI chr 4:181,919,400...181,930,454
Ensembl chr 4:181,919,400...181,930,454
|
|
G
|
Rb1
|
RB transcriptional corepressor 1
|
decreases expression multiple interactions
|
ISO
|
Betulinic Acid results in decreased expression of RB1 protein modified form Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of RB1 protein modified form]; Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of RB1 protein modified form]; Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in decreased expression of RB1 protein modified form]; Gefitinib promotes the reaction [Betulinic Acid results in decreased expression of RB1 protein modified form]
|
CTD |
PMID:30136359 |
|
NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
EXP
|
Betulinic Acid inhibits the reaction [Ethanol results in increased phosphorylation of RELA protein]
|
CTD |
PMID:21172400 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Rxra
|
retinoid X receptor alpha
|
multiple interactions
|
ISO
|
[Betulinic Acid co-treated with pirinixic acid] results in decreased expression of RXRA protein; [Betulinic Acid co-treated with regorafenib] results in decreased expression of RXRA protein
|
CTD |
PMID:39067772 |
|
NCBI chr 3:31,387,892...31,474,415
Ensembl chr 3:31,388,223...31,474,417
|
|
G
|
Slc10a1
|
solute carrier family 10 member 1
|
multiple interactions
|
ISO
|
Betulinic Acid inhibits the reaction [SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate]; Betulinic Acid inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; Betulinic Acid inhibits the reaction [SLC10A1 protein results in increased uptake of Taurolithocholic Acid]
|
CTD |
PMID:34079822 |
|
NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:106,344,319...106,357,944
|
|
G
|
Slc10a2
|
solute carrier family 10 member 2
|
multiple interactions
|
ISO
|
Betulinic Acid affects the reaction [SLC10A2 protein results in increased uptake of Taurolithocholic Acid]
|
CTD |
PMID:34079822 |
|
NCBI chr16:91,088,089...91,111,025
Ensembl chr16:91,076,423...91,111,025
|
|
G
|
Slc10a6
|
solute carrier family 10 member 6
|
multiple interactions
|
ISO
|
Betulinic Acid affects the reaction [SLC10A6 protein results in increased uptake of Taurolithocholic Acid]; Betulinic Acid inhibits the reaction [SLC10A6 protein results in increased uptake of Dehydroepiandrosterone Sulfate]
|
CTD |
PMID:34079822 |
|
NCBI chr14:6,385,348...6,407,532
Ensembl chr14:6,385,537...6,408,894
|
|
G
|
Smad3
|
SMAD family member 3
|
multiple interactions
|
EXP
|
Betulinic Acid inhibits the reaction [Ethanol results in increased phosphorylation of SMAD3 protein]
|
CTD |
PMID:21172400 |
|
NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324
|
|
G
|
Stat3
|
signal transducer and activator of transcription 3
|
multiple interactions
|
ISO
|
[Betulinic Acid co-treated with Erlotinib Hydrochloride] results in decreased expression of STAT3 protein modified form
|
CTD |
PMID:30136359 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
EXP ISO
|
Betulinic Acid inhibits the reaction [Ethanol results in increased expression of TGFB1 protein] Betulinic Acid affects the reaction [TGFB1 protein affects the expression of and affects the secretion of MMP2 protein]
|
CTD |
PMID:21172400 PMID:28578903 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
multiple interactions
|
EXP
|
Betulinic Acid inhibits the reaction [Ethanol results in increased expression of TIMP1 protein]
|
CTD |
PMID:21172400 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
G
|
Timp2
|
TIMP metallopeptidase inhibitor 2
|
multiple interactions
|
EXP
|
Betulinic Acid inhibits the reaction [Ethanol results in increased expression of TIMP2 protein]
|
CTD |
PMID:21172400 |
|
NCBI chr10:104,041,604...104,089,214
Ensembl chr10:104,041,604...104,089,214
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
EXP
|
Betulinic Acid inhibits the reaction [Dimethylnitrosamine results in increased expression of TNF protein]
|
CTD |
PMID:34472159 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tnfsf11
|
TNF superfamily member 11
|
multiple interactions decreases response to substance
|
ISO
|
Betulinic Acid inhibits the reaction [PTHLH protein results in increased expression of TNFSF11 protein] Betulinic Acid inhibits the reaction [TNFSF11 protein results in increased secretion of CTSK protein]; Betulinic Acid inhibits the reaction [TNFSF11 protein results in increased secretion of MMP2 protein]; Betulinic Acid inhibits the reaction [TNFSF11 protein results in increased secretion of MMP9 protein] Betulinic Acid results in decreased susceptibility to TNFSF11 protein
|
CTD |
PMID:24463094 |
|
NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479
|
|
G
|
Top1
|
DNA topoisomerase I
|
decreases activity
|
ISO
|
Betulinic Acid results in decreased activity of TOP1 protein
|
CTD |
PMID:10860928 |
|
NCBI chr 3:169,713,195...169,796,330
Ensembl chr 3:169,713,130...169,796,327
|
|
G
|
Top2a
|
DNA topoisomerase II alpha
|
decreases activity
|
ISO
|
Betulinic Acid results in decreased activity of TOP2A protein
|
CTD |
PMID:10860928 |
|
NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366
|
|
G
|
Tp53
|
tumor protein p53
|
increases expression multiple interactions
|
ISO
|
Betulinic Acid results in increased expression of TP53 protein [Betulinic Acid co-treated with Oxygen deficiency] results in increased expression of TP53 protein
|
CTD |
PMID:33181113 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Trib3
|
tribbles pseudokinase 3
|
multiple interactions
|
ISO
|
Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of TRIB3 protein]
|
CTD |
PMID:30482226 |
|
NCBI chr 3:161,269,939...161,275,533
Ensembl chr 3:161,269,955...161,274,802
|
|
G
|
Tyms
|
thymidylate synthetase
|
multiple interactions decreases expression
|
ISO
|
Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of TYMS protein]; Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of TYMS protein]; Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in decreased expression of TYMS protein]; Gefitinib promotes the reaction [Betulinic Acid results in decreased expression of TYMS protein]
|
CTD |
PMID:30136359 |
|
NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:120,763,386...120,776,097
|
|
G
|
Vdac1
|
voltage-dependent anion channel 1
|
decreases response to substance increases expression multiple interactions
|
ISO
|
VDAC1 protein results in decreased susceptibility to Betulinic Acid Betulinic Acid results in increased expression of VDAC1 protein [VDAC1 protein results in decreased susceptibility to Betulinic Acid] which results in increased expression of HK2 protein; VDAC1 protein inhibits the reaction [Betulinic Acid results in increased expression of CASP3 protein modified form]; VDAC1 protein inhibits the reaction [Betulinic Acid results in increased expression of CASP7 protein modified form]
|
CTD |
PMID:30136359 |
|
NCBI chr10:37,029,377...37,060,542
Ensembl chr10:37,023,145...37,060,541
|
|
|
G
|
Abcb11
|
ATP binding cassette subfamily B member 11
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; Enzymes and Coenzymes inhibits the reaction [celastrol inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]
|
CTD |
PMID:35101544 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein]; celastrol inhibits the reaction [Folic Acid results in increased expression of ACTA2 protein]; SR 144528 inhibits the reaction [celastrol inhibits the reaction [Folic Acid results in increased expression of ACTA2 protein]] celastrol inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]
|
CTD |
PMID:29789558 PMID:31901889 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Adgre1
|
adhesion G protein-coupled receptor E1
|
multiple interactions
|
ISO
|
[celastrol co-treated with coomassie Brilliant Blue] inhibits the reaction [Acetaminophen results in increased expression of ADGRE1 protein]; celastrol inhibits the reaction [Acetaminophen results in increased expression of ADGRE1 protein]
|
CTD |
PMID:28435131 |
|
NCBI chr 9:2,329,398...2,484,959
Ensembl chr 9:2,329,438...2,484,959
|
|
G
|
Ahsa1
|
activator of Hsp90 ATPase activity 1
|
increases expression
|
ISO
|
celastrol results in increased expression of AHSA1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 6:112,644,287...112,652,290
Ensembl chr 6:112,644,479...112,655,595
|
|
G
|
Akr1c1
|
aldo-keto reductase family 1, member C1
|
increases expression
|
ISO
|
celastrol results in increased expression of AKR1C1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr17:70,720,397...70,747,285
Ensembl chr17:70,720,398...70,747,247
|
|
G
|
Akr1c2
|
aldo-keto reductase family 1, member C2
|
increases expression
|
ISO
|
celastrol results in increased expression of AKR1C2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
decreases phosphorylation multiple interactions increases phosphorylation
|
ISO EXP
|
celastrol results in decreased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [celastrol results in decreased phosphorylation of AKT1 protein] celastrol results in increased phosphorylation of AKT1 protein celastrol inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; celastrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of AKT1 protein]; PTEN protein promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]]
|
CTD |
PMID:21466843 PMID:24111524 PMID:25903958 PMID:31715269 PMID:36827925 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Apc
|
APC regulator of WNT signaling pathway
|
multiple interactions
|
ISO
|
celastrol affects the reaction [APC protein mutant form affects the expression of CCND1 mRNA]; celastrol affects the reaction [APC protein mutant form affects the expression of CCND1 protein]; celastrol affects the reaction [APC protein mutant form affects the expression of CTNNB1 protein]; celastrol affects the reaction [APC protein mutant form affects the expression of MYC mRNA]; celastrol affects the reaction [APC protein mutant form affects the expression of MYC protein]; celastrol affects the reaction [APC protein mutant form affects the phosphorylation of GSK3B protein]
|
CTD |
PMID:31715269 |
|
NCBI chr18:26,138,382...26,196,021
Ensembl chr18:26,102,679...26,197,022
|
|
G
|
Ar
|
androgen receptor
|
multiple interactions decreases expression increases degradation
|
ISO
|
calpain inhibitor 2 inhibits the reaction [celastrol results in increased degradation of AR protein]; CAST inhibits the reaction [celastrol results in increased degradation of AR protein] celastrol results in decreased expression of AR protein
|
CTD |
PMID:17010675 PMID:18726991 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467
|
|
G
|
Arid5b
|
AT-rich interaction domain 5B
|
decreases expression
|
ISO
|
celastrol results in decreased expression of ARID5B mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr20:20,305,693...20,489,689
Ensembl chr20:20,306,712...20,489,686
|
|
G
|
Arrb2
|
arrestin, beta 2
|
multiple interactions
|
ISO
|
[celastrol co-treated with CNR2 protein] affects the localization of ARRB2 protein
|
CTD |
PMID:31901889 |
|
NCBI chr10:55,645,539...55,653,485
Ensembl chr10:55,645,357...55,653,487
|
|
G
|
Atf3
|
activating transcription factor 3
|
increases expression
|
ISO
|
celastrol results in increased expression of ATF3 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750
|
|
G
|
Atp5mc1
|
ATP synthase membrane subunit c locus 1
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [Dietary Fats results in decreased expression of ATP5MC1 mRNA]
|
CTD |
PMID:35679966 |
|
NCBI chr10:81,520,762...81,523,735
Ensembl chr10:81,520,765...81,523,363
|
|
G
|
Axin2
|
axin 2
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein]
|
CTD |
PMID:31715269 |
|
NCBI chr10:94,393,379...94,426,579
Ensembl chr10:94,395,909...94,426,575
|
|
G
|
Bag3
|
BAG cochaperone 3
|
increases expression
|
ISO
|
celastrol results in increased expression of BAG3 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 1:192,533,460...192,557,281
Ensembl chr 1:192,475,828...192,557,280
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression multiple interactions
|
ISO EXP
|
celastrol results in increased expression of BAX mRNA; celastrol results in increased expression of BAX protein celastrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of BAX mRNA] Uridine inhibits the reaction [celastrol results in increased expression of BAX protein] [celastrol co-treated with coomassie Brilliant Blue] inhibits the reaction [Acetaminophen results in increased expression of BAX protein]; celastrol inhibits the reaction [Acetaminophen results in increased expression of BAX protein]; celastrol inhibits the reaction [Plant Preparations results in increased expression of BAX mRNA]; celastrol inhibits the reaction [Plant Preparations results in increased expression of BAX protein]
|
CTD |
PMID:21466843 PMID:27374097 PMID:28435131 PMID:29643811 PMID:36827925 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression multiple interactions increases expression
|
ISO
|
celastrol results in decreased expression of BCL2 protein celastrol inhibits the reaction [Plant Preparations results in decreased expression of BCL2 protein] celastrol results in increased expression of BCL2 mRNA
|
CTD |
PMID:21466843 PMID:29643811 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bdnf
|
brain-derived neurotrophic factor
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [Dietary Fats results in increased expression of BDNF protein]
|
CTD |
PMID:35679966 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657
|
|
G
|
Becn1
|
beclin 1
|
increases expression
|
EXP
|
celastrol results in increased expression of BECN1 protein
|
CTD |
PMID:32470352 |
|
NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002
|
|
G
|
Birc5
|
baculoviral IAP repeat-containing 5
|
decreases expression
|
ISO
|
celastrol results in decreased expression of BIRC5 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155
|
|
G
|
Btg1
|
BTG anti-proliferation factor 1
|
decreases expression
|
ISO
|
celastrol results in decreased expression of BTG1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 7:33,228,149...33,230,406
Ensembl chr 7:33,227,833...33,230,406
|
|
G
|
Cacybp
|
calcyclin binding protein
|
increases expression
|
ISO
|
celastrol results in increased expression of CACYBP mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr13:74,970,917...74,981,298
Ensembl chr13:74,970,923...74,981,505
|
|
G
|
Casp1
|
caspase 1
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]]
|
CTD |
PMID:32470352 |
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275
|
|
G
|
Casp3
|
caspase 3
|
increases cleavage multiple interactions increases expression
|
ISO EXP
|
celastrol results in increased cleavage of CASP3 protein celastrol inhibits the reaction [Plant Preparations results in increased expression of CASP3 mRNA]; celastrol inhibits the reaction [Plant Preparations results in increased expression of CASP3 protein] celastrol results in increased expression of CASP3 mRNA celastrol inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]; celastrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CASP3 mRNA]; JUN mutant form promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]]; PTEN protein promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]]; pyrazolanthrone promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]] [TNFSF10 protein co-treated with celastrol] results in increased cleavage of CASP3 protein; Uridine inhibits the reaction [celastrol results in increased cleavage of CASP3 protein]
|
CTD |
PMID:20605676 PMID:21466843 PMID:24111524 PMID:27374097 PMID:29643811 PMID:36827925 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
increases cleavage decreases expression
|
ISO
|
celastrol results in increased cleavage of CASP8 protein celastrol results in decreased expression of CASP8 mRNA
|
CTD |
PMID:21466843 PMID:27374097 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
increases cleavage increases expression multiple interactions
|
ISO
|
celastrol results in increased cleavage of CASP9 protein celastrol results in increased expression of CASP9 mRNA Uridine inhibits the reaction [celastrol results in increased cleavage of CASP9 protein]
|
CTD |
PMID:21466843 PMID:27374097 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cast
|
calpastatin
|
multiple interactions
|
ISO
|
CAST inhibits the reaction [celastrol results in increased degradation of AR protein]
|
CTD |
PMID:18726991 |
|
NCBI chr 2:5,707,633...5,817,213
Ensembl chr 2:5,707,640...5,817,180
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
EXP ISO
|
celastrol inhibits the reaction [Bleomycin results in decreased activity of CAT protein]; celastrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of CAT protein] celastrol inhibits the reaction [Acetaminophen results in decreased activity of CAT protein]
|
CTD |
PMID:26768587 PMID:28984147 PMID:36827925 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Cbr3
|
carbonyl reductase 3
|
increases expression
|
ISO
|
celastrol results in increased expression of CBR3 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr11:46,478,295...46,486,555
Ensembl chr11:46,478,274...46,486,558
|
|
G
|
Ccl3
|
C-C motif chemokine ligand 3
|
increases expression
|
ISO
|
celastrol results in increased expression of CCL3 mRNA
|
CTD |
PMID:25477506 |
|
NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439
|
|
G
|
Ccn1
|
cellular communication network factor 1
|
decreases expression
|
ISO
|
celastrol results in decreased expression of CCN1 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:237,222,432...237,225,883
|
|
G
|
Ccnd1
|
cyclin D1
|
multiple interactions decreases expression
|
ISO
|
celastrol affects the reaction [APC protein mutant form affects the expression of CCND1 mRNA]; celastrol affects the reaction [APC protein mutant form affects the expression of CCND1 protein]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein] celastrol results in decreased expression of CCND1 mRNA; celastrol results in decreased expression of CCND1 protein
|
CTD |
PMID:31715269 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Cda
|
cytidine deaminase
|
increases expression
|
ISO
|
celastrol results in increased expression of CDA mRNA
|
CTD |
PMID:27374097 |
|
NCBI chr 5:155,839,929...155,866,541
Ensembl chr 5:155,839,929...155,866,541
|
|
G
|
Cdc7
|
cell division cycle 7
|
decreases expression
|
ISO
|
celastrol results in decreased expression of CDC7 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr14:2,949,538...2,969,656
Ensembl chr14:2,949,539...2,969,656
|
|
G
|
Cdk2
|
cyclin dependent kinase 2
|
decreases expression
|
ISO
|
celastrol results in decreased expression of CDK2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878
|
|
G
|
Cebpa
|
CCAAT/enhancer binding protein alpha
|
affects expression
|
ISO
|
celastrol affects the expression of CEBPA mRNA; celastrol affects the expression of CEBPA protein
|
CTD |
PMID:27085773 |
|
NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309
|
|
G
|
Cep78
|
centrosomal protein 78
|
increases expression
|
ISO
|
celastrol results in increased expression of CEP78 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 1:222,674,193...222,702,124
Ensembl chr 1:222,674,194...222,702,120
|
|
G
|
Chordc1
|
cysteine and histidine rich domain containing 1
|
increases expression
|
ISO
|
celastrol results in increased expression of CHORDC1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 8:23,650,721...23,674,786
Ensembl chr 8:23,650,865...23,677,696
|
|
G
|
Chrna3
|
cholinergic receptor nicotinic alpha 3 subunit
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; celastrol inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]
|
CTD |
PMID:39914504 |
|
NCBI chr 8:64,297,755...64,311,251
Ensembl chr 8:64,297,755...64,311,412
|
|
G
|
Chrnb2
|
cholinergic receptor nicotinic beta 2 subunit
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]
|
CTD |
PMID:39914504 |
|
NCBI chr 2:177,479,091...177,487,306
Ensembl chr 2:177,479,091...177,491,326
|
|
G
|
Chrnb4
|
cholinergic receptor nicotinic beta 4 subunit
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]
|
CTD |
PMID:39914504 |
|
NCBI chr 8:64,312,644...64,333,319
Ensembl chr 8:64,313,669...64,333,248
|
|
G
|
Chuk
|
component of inhibitor of nuclear factor kappa B kinase complex
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Doxorubicin results in increased phosphorylation of CHUK protein]
|
CTD |
PMID:30588110 |
|
NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273
|
|
G
|
Cited2
|
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2
|
decreases expression
|
ISO
|
celastrol results in decreased expression of CITED2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 1:14,132,303...14,134,746
Ensembl chr 1:14,103,457...14,134,782
|
|
G
|
Ckb
|
creatine kinase B
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Doxorubicin results in increased secretion of [CKM protein binds to CKB protein]]
|
CTD |
PMID:30588110 |
|
NCBI chr 6:136,550,583...136,553,464
Ensembl chr 6:136,549,844...136,553,478
|
|
G
|
Ckm
|
creatine kinase, M-type
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Doxorubicin results in increased secretion of [CKM protein binds to CKB protein]]
|
CTD |
PMID:30588110 |
|
NCBI chr 1:88,189,382...88,199,717
Ensembl chr 1:88,189,485...88,199,719
|
|
G
|
Cnr2
|
cannabinoid receptor 2
|
multiple interactions
|
ISO
|
[celastrol co-treated with CNR2 protein] affects the localization of ARRB2 protein; celastrol inhibits the reaction [TGFB1 protein results in decreased expression of CNR2 protein] 6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride inhibits the reaction [celastrol inhibits the reaction [Folic Acid results in decreased expression of CNR2 protein]]; celastrol inhibits the reaction [Folic Acid results in decreased expression of CNR2 protein]
|
CTD |
PMID:29789558 PMID:31901889 |
|
NCBI chr 5:153,408,968...153,435,092
Ensembl chr 5:153,409,147...153,435,961
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Doxorubicin results in increased expression of COL1A1 mRNA]
|
CTD |
PMID:30588110 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
G
|
Col6a1
|
collagen type VI alpha 1 chain
|
decreases expression
|
ISO
|
celastrol results in decreased expression of COL6A1 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr20:11,905,690...11,924,111
Ensembl chr20:11,905,457...11,924,107
|
|
G
|
Cryab
|
crystallin, alpha B
|
increases expression
|
ISO
|
celastrol results in increased expression of CRYAB mRNA
|
CTD |
PMID:25477506 |
|
NCBI chr 8:59,989,885...59,995,532
Ensembl chr 8:59,989,814...59,995,528
|
|
G
|
Cs
|
citrate synthase
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [Dietary Fats results in increased expression of CS mRNA]
|
CTD |
PMID:35679966 |
|
NCBI chr 7:1,348,389...1,374,624
Ensembl chr 7:1,342,942...1,375,938
|
|
G
|
Ctnnb1
|
catenin beta 1
|
decreases expression multiple interactions
|
ISO
|
celastrol results in decreased expression of CTNNB1 protein celastrol affects the reaction [APC protein mutant form affects the expression of CTNNB1 protein]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [celastrol results in decreased expression of CTNNB1 protein]; Chir 99021 inhibits the reaction [celastrol results in decreased expression of CTNNB1 protein]; GSK3B protein affects the reaction [celastrol results in decreased expression of CTNNB1 protein]; Lithium Chloride inhibits the reaction [celastrol results in decreased expression of CTNNB1 protein]; SB 216763 inhibits the reaction [celastrol results in decreased expression of CTNNB1 protein]
|
CTD |
PMID:31715269 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662
|
|
G
|
Cxcl10
|
C-X-C motif chemokine ligand 10
|
increases expression multiple interactions
|
ISO
|
celastrol results in increased expression of CXCL10 mRNA celastrol inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]
|
CTD |
PMID:25477506 PMID:31901889 |
|
NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261
|
|
G
|
Cxcr4
|
C-X-C motif chemokine receptor 4
|
decreases expression
|
ISO
|
Celastrol decreases expression of CXCR4 mRNA and protein in liver
|
RGD |
PMID:33574707 |
RGD:151665327 |
NCBI chr13:42,630,383...42,634,288
Ensembl chr13:42,630,104...42,634,459
|
|
G
|
Cycs
|
cytochrome c, somatic
|
multiple interactions increases expression
|
ISO
|
celastrol inhibits the reaction [Dietary Fats results in decreased expression of CYCS mRNA] celastrol results in increased expression of CYCS mRNA
|
CTD |
PMID:35679966 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816 Ensembl chr18:80,982,668...80,984,816
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
decreases expression
|
ISO
|
celastrol results in decreased expression of CYP1A1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyria
|
CYFIP related Rac1 interactor A
|
decreases expression
|
ISO
|
celastrol results in decreased expression of CYRIA mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 6:40,774,165...40,883,005
Ensembl chr 6:40,774,171...40,881,860
|
|
G
|
Dcdc2
|
doublecortin domain containing 2
|
increases expression
|
ISO
|
celastrol results in increased expression of DCDC2 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr17:40,274,009...40,459,757
Ensembl chr17:40,274,009...40,458,790
|
|
G
|
Ddit3
|
DNA-damage inducible transcript 3
|
increases expression
|
ISO
|
celastrol results in increased expression of DDIT3 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
G
|
Ddit4
|
DNA-damage-inducible transcript 4
|
increases expression
|
ISO
|
celastrol results in increased expression of DDIT4 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr20:28,434,938...28,437,037
Ensembl chr20:28,434,944...28,437,037
|
|
G
|
Dhodh
|
dihydroorotate dehydrogenase
|
decreases expression
|
ISO
|
celastrol results in decreased expression of DHODH mRNA; celastrol results in decreased expression of DHODH protein
|
CTD |
PMID:27374097 |
|
NCBI chr19:54,460,636...54,483,049
Ensembl chr19:54,468,690...54,514,496
|
|
G
|
Dkk2
|
dickkopf WNT signaling pathway inhibitor 2
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr 2:223,242,375...223,334,249
Ensembl chr 2:223,242,377...223,334,724
|
|
G
|
Dnaja1
|
DnaJ heat shock protein family (Hsp40) member A1
|
increases expression
|
ISO
|
celastrol results in increased expression of DNAJA1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 5:60,638,404...60,649,315
Ensembl chr 5:60,638,410...60,650,160
|
|
G
|
Dnajb4
|
DnaJ heat shock protein family (Hsp40) member B4
|
increases expression decreases expression
|
ISO
|
celastrol results in increased expression of DNAJB4 mRNA celastrol results in decreased expression of DNAJB4 mRNA
|
CTD |
PMID:17010675 PMID:39181414 |
|
NCBI chr 2:243,790,296...243,819,042
Ensembl chr 2:243,790,297...243,819,042
|
|
G
|
Efnb2
|
ephrin B2
|
decreases expression
|
ISO
|
celastrol results in decreased expression of EFNB2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr16:87,485,215...87,529,224
Ensembl chr16:87,485,198...87,529,208
|
|
G
|
Egfr
|
epidermal growth factor receptor
|
multiple interactions decreases expression
|
ISO
|
[Sulfasalazine co-treated with celastrol] affects the expression of EGFR protein; [Sulfasalazine co-treated with celastrol] results in decreased expression of EGFR protein celastrol results in decreased expression of EGFR protein
|
CTD |
PMID:17010675 PMID:20007406 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358
|
|
G
|
Eif4ebp1
|
eukaryotic translation initiation factor 4E binding protein 1
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EIF4EBP1 protein]
|
CTD |
PMID:24111524 |
|
NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874
|
|
G
|
Endog
|
endonuclease G
|
increases expression
|
ISO
|
celastrol results in increased expression of ENDOG mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 3:33,846,935...33,849,531
Ensembl chr 3:33,846,885...33,849,573
|
|
G
|
Erbb2
|
erb-b2 receptor tyrosine kinase 2
|
increases expression
|
ISO
|
celastrol results in increased expression of ERBB2 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481
|
|
G
|
Fabp4
|
fatty acid binding protein 4
|
affects expression
|
ISO
|
celastrol affects the expression of FABP4 mRNA
|
CTD |
PMID:27085773 |
|
NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972
|
|
G
|
Fam83d
|
family with sequence similarity 83, member D
|
decreases expression
|
ISO
|
celastrol results in decreased expression of FAM83D mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 3:167,841,748...167,861,062
Ensembl chr 3:167,841,791...167,861,061
|
|
G
|
Fas
|
Fas cell surface death receptor
|
increases expression
|
ISO
|
celastrol results in increased expression of FAS protein
|
CTD |
PMID:21466843 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104
|
|
G
|
Faslg
|
Fas ligand
|
increases expression
|
ISO
|
celastrol results in increased expression of FASLG protein
|
CTD |
PMID:21466843 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503
|
|
G
|
Fbxo32
|
F-box protein 32
|
multiple interactions decreases expression
|
EXP
|
HSPA1A protein affects the reaction [celastrol results in decreased expression of FBXO32 protein]
|
CTD |
PMID:25903958 |
|
NCBI chr 7:91,620,925...91,654,491
Ensembl chr 7:91,620,925...91,654,491
|
|
G
|
Ficd
|
FIC domain protein adenylyltransferase
|
increases expression
|
ISO
|
celastrol results in increased expression of FICD mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr12:48,549,737...48,554,626
Ensembl chr12:48,549,737...48,554,626
|
|
G
|
Flt3
|
Fms related receptor tyrosine kinase 3
|
decreases expression
|
ISO
|
celastrol results in decreased expression of FLT3 protein
|
CTD |
PMID:17010675 |
|
NCBI chr12:12,660,035...12,735,584
Ensembl chr12:12,659,946...12,735,581
|
|
G
|
Fn1
|
fibronectin 1
|
multiple interactions
|
ISO EXP
|
celastrol inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein] celastrol inhibits the reaction [Doxorubicin results in increased expression of FN1 mRNA] celastrol inhibits the reaction [Folic Acid results in increased expression of FN1 protein]; SR 144528 inhibits the reaction [celastrol inhibits the reaction [Folic Acid results in increased expression of FN1 protein]]
|
CTD |
PMID:29789558 PMID:30588110 |
|
NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137
|
|
G
|
Foxo3
|
forkhead box O3
|
increases phosphorylation
|
EXP
|
celastrol results in increased phosphorylation of FOXO3 protein
|
CTD |
PMID:25903958 |
|
NCBI chr20:47,251,968...47,348,254
Ensembl chr20:47,255,878...47,346,845
|
|
G
|
Fzd7
|
frizzled class receptor 7
|
increases expression
|
ISO
|
celastrol results in increased expression of FZD7 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 9:68,425,538...68,428,357
Ensembl chr 9:68,411,259...68,432,585
|
|
G
|
Gapdh
|
glyceraldehyde-3-phosphate dehydrogenase
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [Dietary Fats results in decreased expression of GAPDH mRNA]
|
CTD |
PMID:35679966 |
|
NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377
|
|
G
|
Gatd3a
|
glutamine amidotransferase class 1 domain containing 3A
|
decreases expression
|
ISO
|
celastrol results in decreased expression of GATD3 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr20:10,514,459...10,522,556
Ensembl chr20:10,514,443...10,522,555
|
|
G
|
Gclc
|
glutamate-cysteine ligase, catalytic subunit
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Doxorubicin results in decreased expression of GCLC mRNA]; celastrol inhibits the reaction [Doxorubicin results in decreased expression of GCLC protein]
|
CTD |
PMID:30588110 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893
|
|
G
|
Gclm
|
glutamate cysteine ligase, modifier subunit
|
increases expression multiple interactions
|
ISO EXP
|
celastrol results in increased expression of GCLM mRNA celastrol inhibits the reaction [Doxorubicin results in decreased expression of GCLM mRNA]
|
CTD |
PMID:17010675 PMID:30588110 |
|
NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003
|
|
G
|
Gdf15
|
growth differentiation factor 15
|
increases expression
|
ISO
|
celastrol results in increased expression of GDF15 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022
|
|
G
|
Ggcx
|
gamma-glutamyl carboxylase
|
increases expression
|
ISO
|
celastrol results in increased expression of GGCX mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 4:106,027,918...106,043,653
Ensembl chr 4:106,027,912...106,043,923
|
|
G
|
Gpd1
|
glycerol-3-phosphate dehydrogenase 1
|
affects activity
|
ISO
|
celastrol affects the activity of GPD1 protein
|
CTD |
PMID:27085773 |
|
NCBI chr 7:132,722,982...132,730,373
Ensembl chr 7:132,721,915...132,730,368
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
multiple interactions
|
ISO EXP
|
[coomassie Brilliant Blue co-treated with celastrol] inhibits the reaction [Acetaminophen results in increased activity of GPT protein]; celastrol inhibits the reaction [Acetaminophen results in increased activity of GPT protein]; celastrol inhibits the reaction [Dietary Fats results in increased expression of GPT protein] celastrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of GPT protein]
|
CTD |
PMID:28435131 PMID:35679966 PMID:36827925 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
G
|
Gsk3b
|
glycogen synthase kinase 3 beta
|
decreases phosphorylation multiple interactions
|
ISO
|
celastrol results in decreased phosphorylation of GSK3B protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [celastrol results in decreased phosphorylation of GSK3B protein]; GSK3B protein affects the reaction [celastrol results in decreased expression of CTNNB1 protein]; Lithium Chloride inhibits the reaction [celastrol results in decreased phosphorylation of GSK3B protein] celastrol affects the reaction [APC protein mutant form affects the phosphorylation of GSK3B protein]
|
CTD |
PMID:31715269 |
|
NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249
|
|
G
|
Gsr
|
glutathione-disulfide reductase
|
multiple interactions
|
EXP ISO
|
celastrol inhibits the reaction [Bleomycin results in decreased activity of GSR protein] celastrol inhibits the reaction [Acetaminophen results in decreased activity of GSR protein]
|
CTD |
PMID:26768587 PMID:28984147 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394
|
|
G
|
Gtf2i
|
general transcription factor II I
|
increases expression
|
ISO
|
celastrol results in increased expression of GTF2I mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr12:28,037,344...28,112,677
Ensembl chr12:28,037,853...28,112,677
|
|
G
|
Gtpbp2
|
GTP binding protein 2
|
increases expression
|
ISO
|
celastrol results in increased expression of GTPBP2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 9:22,311,532...22,321,405
Ensembl chr 9:22,311,158...22,321,441
|
|
G
|
Hilpda
|
hypoxia inducible lipid droplet-associated
|
decreases expression
|
ISO
|
celastrol results in decreased expression of HILPDA mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 4:58,836,463...58,839,423
Ensembl chr 4:58,836,463...58,839,423
|
|
G
|
Hk2
|
hexokinase 2
|
multiple interactions decreases expression
|
ISO
|
celastrol inhibits the reaction [Dietary Fats results in decreased expression of HK2 mRNA] celastrol results in decreased expression of HK2 mRNA
|
CTD |
PMID:35679966 PMID:39181414 |
|
NCBI chr 4:116,792,258...116,841,275
Ensembl chr 4:116,792,258...116,841,275
|
|
G
|
Hmga2
|
high mobility group AT-hook 2
|
decreases expression
|
ISO
|
celastrol results in decreased expression of HMGA2 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 7:57,762,710...57,884,555
Ensembl chr 7:57,765,675...57,880,341
|
|
G
|
Hmgcs1
|
3-hydroxy-3-methylglutaryl-CoA synthase 1
|
increases expression
|
ISO
|
celastrol results in increased expression of HMGCS1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 2:53,379,457...53,399,807
Ensembl chr 2:53,382,643...53,399,802
|
|
G
|
Hmox1
|
heme oxygenase 1
|
increases expression multiple interactions
|
ISO EXP
|
celastrol results in increased expression of HMOX1 mRNA celastrol inhibits the reaction [Plant Preparations results in decreased expression of HMOX1 mRNA]; celastrol inhibits the reaction [Plant Preparations results in decreased expression of HMOX1 protein] celastrol results in increased expression of HMOX1 protein celastrol inhibits the reaction [Bleomycin results in decreased expression of HMOX1 protein]; celastrol inhibits the reaction [Doxorubicin results in decreased expression of HMOX1 mRNA]; celastrol inhibits the reaction [Doxorubicin results in decreased expression of HMOX1 protein]; celastrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of HMOX1 mRNA]
|
CTD |
PMID:17010675 PMID:23942037 PMID:26768587 PMID:29643811 PMID:30588110 PMID:36827925 More...
|
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Hsf1
|
heat shock transcription factor 1
|
multiple interactions increases activity
|
EXP ISO
|
celastrol results in increased phosphorylation of and affects the localization of HSF1 protein celastrol results in increased activity of HSF1 protein
|
CTD |
PMID:25903958 PMID:34170685 |
|
NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665
|
|
G
|
Hsp90aa1
|
heat shock protein 90 alpha family class A member 1
|
decreases activity multiple interactions
|
ISO EXP
|
celastrol results in decreased activity of HSP90AA1 protein celastrol inhibits the reaction [Dextran Sulfate results in increased expression of HSP90AA1 mRNA]
|
CTD |
PMID:17010675 PMID:32470352 |
|
NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499
|
|
G
|
Hsp90ab1
|
heat shock protein 90 alpha family class B member 1
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of HSP90AB1 protein]
|
CTD |
PMID:32470352 |
|
NCBI chr 9:22,930,249...22,935,929
Ensembl chr 9:22,931,070...22,935,926
|
|
G
|
Hspa13
|
heat shock protein family A (Hsp70) member 13
|
increases expression
|
ISO
|
celastrol results in increased expression of HSPA13 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr11:27,862,717...27,876,898
Ensembl chr11:27,862,593...27,876,898
|
|
G
|
Hspa1a
|
heat shock protein family A (Hsp70) member 1A
|
increases expression multiple interactions
|
ISO EXP
|
celastrol results in increased expression of HSPA1A mRNA HSPA1A protein affects the reaction [celastrol results in decreased expression of FBXO32 protein]
|
CTD |
PMID:17010675 PMID:25477506 PMID:25903958 |
|
NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979
|
|
G
|
Hspa1b
|
heat shock protein family A (Hsp70) member 1B
|
increases expression
|
ISO
|
celastrol results in increased expression of HSPA1B mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr20:3,859,756...3,863,800
Ensembl chr20:3,855,780...3,877,979
|
|
G
|
Hspa5
|
heat shock protein family A (Hsp70) member 5
|
increases expression
|
ISO
|
celastrol results in increased expression of HSPA5 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790
|
|
G
|
Hspa6l-ps1
|
heat shock protein family A (Hsp70) member 6 like, pseudogene 1
|
increases expression
|
ISO
|
celastrol results in increased expression of HSPA6 mRNA
|
CTD |
PMID:25477506 |
|
NCBI chr13:85,805,911...85,807,052
|
|
G
|
Hsph1
|
heat shock protein family H (Hsp110) member 1
|
increases expression decreases expression
|
ISO
|
celastrol results in increased expression of HSPH1 mRNA celastrol results in decreased expression of HSPH1 mRNA
|
CTD |
PMID:17010675 PMID:39181414 |
|
NCBI chr12:10,427,368...10,446,602
Ensembl chr12:10,427,297...10,446,891
|
|
G
|
Icam1
|
intercellular adhesion molecule 1
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]; celastrol inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; celastrol inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; celastrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]
|
CTD |
PMID:16769766 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
G
|
Id1
|
inhibitor of DNA binding 1
|
increases expression
|
ISO
|
celastrol results in increased expression of ID1 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:161,671,538...161,672,685
|
|
G
|
Idh1
|
isocitrate dehydrogenase (NADP(+)) 1
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [Dietary Fats results in decreased expression of IDH1 mRNA]
|
CTD |
PMID:35679966 |
|
NCBI chr 9:74,027,887...74,057,442
Ensembl chr 9:74,027,892...74,049,555
|
|
G
|
Ifng
|
interferon gamma
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]; celastrol inhibits the reaction [IFNG protein results in increased expression of VCAM1 protein] celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]
|
CTD |
PMID:16769766 PMID:24384223 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
G
|
Il10
|
interleukin 10
|
multiple interactions
|
ISO
|
[celastrol co-treated with coomassie Brilliant Blue] inhibits the reaction [Acetaminophen results in increased expression of IL10 protein]; celastrol inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]
|
CTD |
PMID:24384223 PMID:28435131 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
G
|
Il17a
|
interleukin 17A
|
multiple interactions
|
ISO
|
[celastrol co-treated with coomassie Brilliant Blue] inhibits the reaction [Acetaminophen results in increased expression of IL17A protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]
|
CTD |
PMID:24384223 PMID:28435131 |
|
NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331
|
|
G
|
Il18
|
interleukin 18
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]]
|
CTD |
PMID:32470352 |
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions increases expression
|
ISO EXP
|
celastrol inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; celastrol inhibits the reaction [IL1B protein results in increased expression of SELE protein]; celastrol inhibits the reaction [IL1B protein results in increased expression of VCAM1 protein] celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; celastrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B mRNA]; celastrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]] celastrol results in increased expression of IL1B mRNA celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; celastrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; celastrol inhibits the reaction [Plant Preparations results in increased expression of IL1B protein]
|
CTD |
PMID:16769766 PMID:24384223 PMID:25477506 PMID:29643811 PMID:31715269 PMID:31901889 PMID:32470352 PMID:36827925 More...
|
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il1rn
|
interleukin 1 receptor antagonist
|
decreases expression
|
ISO
|
celastrol results in decreased expression of IL1RN mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732
|
|
G
|
Il23a
|
interleukin 23 subunit alpha
|
multiple interactions
|
ISO
|
[celastrol co-treated with coomassie Brilliant Blue] inhibits the reaction [Acetaminophen results in increased expression of IL23A protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL23A protein]
|
CTD |
PMID:24384223 PMID:28435131 |
|
NCBI chr 7:1,306,320...1,308,434
Ensembl chr 7:1,306,320...1,308,434
|
|
G
|
Il6
|
interleukin 6
|
increases expression decreases secretion multiple interactions
|
ISO EXP
|
celastrol results in increased expression of IL6 mRNA celastrol results in decreased secretion of IL6 protein celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; celastrol inhibits the reaction [Dietary Fats results in increased expression of IL6 protein]; celastrol inhibits the reaction [Plant Preparations results in increased expression of IL6 protein] celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; celastrol inhibits the reaction [Doxorubicin results in increased expression of IL6 protein]; celastrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 mRNA]; celastrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]]
|
CTD |
PMID:25477506 PMID:29643811 PMID:30588110 PMID:31715269 PMID:32470352 PMID:35679966 PMID:36827925 PMID:39181414 More...
|
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Ins1
|
insulin 1
|
multiple interactions
|
ISO
|
celastrol affects the reaction [[Dietary Fats affects the susceptibility to INS1 protein] which affects the oxidation of Glucose]; celastrol affects the reaction [[Dietary Fats affects the susceptibility to INS1 protein] which affects the uptake of Glucose]; celastrol inhibits the reaction [Dietary Fats results in increased expression of INS1 protein]
|
CTD |
PMID:35679966 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682
|
|
G
|
Insig1
|
insulin induced gene 1
|
increases expression
|
ISO
|
celastrol results in increased expression of INSIG1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:8,049,556...8,057,778
|
|
G
|
Jag1
|
jagged canonical Notch ligand 1
|
decreases expression
|
ISO
|
celastrol results in decreased expression of JAG1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 3:144,859,453...144,894,883
Ensembl chr 3:144,859,453...144,894,872
|
|
G
|
Jak2
|
Janus kinase 2
|
multiple interactions decreases expression
|
ISO
|
celastrol results in decreased expression of and results in decreased phosphorylation of JAK2 protein celastrol results in decreased expression of JAK2 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762
|
|
G
|
Jun
|
Jun proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions decreases expression
|
EXP ISO
|
celastrol inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased phosphorylation of JUN protein]; JUN mutant form promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]]; pyrazolanthrone promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased phosphorylation of JUN protein]] celastrol results in decreased expression of JUN mRNA
|
CTD |
PMID:24111524 PMID:39181414 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285
|
|
G
|
Kank2
|
KN motif and ankyrin repeat domains 2
|
increases expression
|
ISO
|
celastrol results in increased expression of KANK2 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 8:28,587,770...28,617,212
Ensembl chr 8:28,587,770...28,616,993
|
|
G
|
Kcnn2
|
potassium calcium-activated channel subfamily N member 2
|
decreases expression
|
ISO
|
celastrol results in decreased expression of KCNN2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr18:40,004,693...40,445,043
Ensembl chr18:40,155,939...40,445,045
|
|
G
|
Keap1
|
Kelch-like ECH-associated protein 1
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Bleomycin results in decreased expression of KEAP1 protein]
|
CTD |
PMID:26768587 |
|
NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042
|
|
G
|
Lamb3
|
laminin subunit beta 3
|
decreases expression
|
ISO
|
celastrol results in decreased expression of LAMB3 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr13:107,362,514...107,404,081
Ensembl chr13:107,322,526...107,404,081
|
|
G
|
Lamc2
|
laminin subunit gamma 2
|
decreases expression
|
ISO
|
celastrol results in decreased expression of LAMC2 mRNA; celastrol results in decreased expression of LAMC2 protein
|
CTD |
PMID:39181414 |
|
NCBI chr13:67,835,199...67,894,694
Ensembl chr13:67,835,199...67,895,102
|
|
G
|
Ldlr
|
low density lipoprotein receptor
|
increases expression
|
ISO
|
celastrol results in increased expression of LDLR mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:28,546,146...28,570,675
|
|
G
|
Lef1
|
lymphoid enhancer binding factor 1
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 protein]
|
CTD |
PMID:31715269 |
|
NCBI chr 2:222,340,541...222,453,931
Ensembl chr 2:222,340,704...222,453,929
|
|
G
|
Lpin1
|
lipin 1
|
increases expression
|
ISO
|
celastrol results in increased expression of LPIN1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 6:45,039,110...45,145,845
Ensembl chr 6:45,041,522...45,145,991
|
|
G
|
Lrp5
|
LDL receptor related protein 5
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LRP5 mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr 1:210,243,499...210,346,886
Ensembl chr 1:210,243,502...210,346,822
|
|
G
|
Ltn1
|
listerin E3 ubiquitin protein ligase 1
|
decreases expression
|
ISO
|
celastrol results in decreased expression of LTN1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr11:40,090,169...40,147,159
Ensembl chr11:40,090,169...40,147,303
|
|
G
|
Mafb
|
MAF bZIP transcription factor B
|
decreases expression
|
ISO
|
celastrol results in decreased expression of MAFB mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 3:169,417,890...169,419,810
Ensembl chr 3:169,416,945...169,419,975
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions increases phosphorylation
|
EXP
|
celastrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK1 protein]; celastrol promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein] celastrol results in increased phosphorylation of MAPK1 protein
|
CTD |
PMID:24111524 PMID:25903958 PMID:36827925 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions increases phosphorylation
|
EXP
|
celastrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK3 protein]; celastrol promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein] celastrol results in increased phosphorylation of MAPK3 protein
|
CTD |
PMID:24111524 PMID:25903958 PMID:36827925 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mapk8
|
mitogen-activated protein kinase 8
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK8 protein]
|
CTD |
PMID:36827925 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
G
|
Mcl1
|
MCL1 apoptosis regulator, BCL2 family member
|
decreases expression
|
ISO
|
celastrol results in decreased expression of MCL1 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782
|
|
G
|
Mdh2
|
malate dehydrogenase 2
|
decreases expression
|
ISO
|
celastrol results in decreased expression of MDH2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr12:26,530,886...26,543,841
Ensembl chr12:26,530,881...26,543,841
|
|
G
|
Me1
|
malic enzyme 1
|
increases expression
|
ISO
|
celastrol results in increased expression of ME1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 8:96,429,057...96,540,244
Ensembl chr 8:96,429,057...96,540,275
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Bleomycin results in increased expression of MMP2 protein]; celastrol inhibits the reaction [Doxorubicin results in increased expression of MMP2 mRNA]; celastrol inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]
|
CTD |
PMID:26768587 PMID:30588110 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
G
|
Mmp7
|
matrix metallopeptidase 7
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MMP7 mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr 8:13,133,043...13,140,761
Ensembl chr 8:13,133,043...13,140,755
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Bleomycin results in increased expression of MMP9 protein]; celastrol inhibits the reaction [Doxorubicin results in increased expression of MMP9 mRNA]; celastrol inhibits the reaction [Doxorubicin results in increased expression of MMP9 protein]
|
CTD |
PMID:26768587 PMID:30588110 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Mnt
|
MAX network transcriptional repressor
|
increases expression
|
ISO
|
celastrol results in increased expression of MNT mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr10:60,197,654...60,213,221
Ensembl chr10:60,197,948...60,213,209
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
ISO EXP
|
[celastrol co-treated with coomassie Brilliant Blue] inhibits the reaction [Acetaminophen results in increased activity of MPO protein]; celastrol inhibits the reaction [Acetaminophen results in increased activity of MPO protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein] celastrol inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]
|
CTD |
PMID:24384223 PMID:28435131 PMID:32470352 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Mrpl18
|
mitochondrial ribosomal protein L18
|
increases expression
|
ISO
|
celastrol results in increased expression of MRPL18 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 1:50,384,951...50,389,769
Ensembl chr 1:50,384,367...50,389,763
|
|
G
|
Msh6
|
mutS homolog 6
|
decreases expression
|
ISO
|
celastrol results in decreased expression of MSH6 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 6:12,316,190...12,333,505
Ensembl chr 6:12,316,198...12,333,844
|
|
G
|
Msmo1
|
methylsterol monooxygenase 1
|
increases expression
|
ISO
|
celastrol results in increased expression of MSMO1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr16:29,747,113...29,764,360
Ensembl chr16:29,747,137...29,764,445
|
|
G
|
Mtor
|
mechanistic target of rapamycin kinase
|
multiple interactions
|
EXP
|
[N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with celastrol] results in decreased expression of MTOR protein modified form; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of MTOR protein modified form]
|
CTD |
PMID:32470352 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435
|
|
G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
decreases expression multiple interactions
|
ISO
|
celastrol results in decreased expression of MYC mRNA; celastrol results in decreased expression of MYC protein celastrol affects the reaction [APC protein mutant form affects the expression of MYC mRNA]; celastrol affects the reaction [APC protein mutant form affects the expression of MYC protein]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC protein]
|
CTD |
PMID:26474287 PMID:31715269 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
G
|
Mycbp2
|
MYC binding protein 2
|
decreases expression
|
ISO
|
celastrol results in decreased expression of MYCBP2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr15:86,352,061...86,590,126
Ensembl chr15:86,352,061...86,590,325
|
|
G
|
Mynn
|
myoneurin
|
decreases expression
|
ISO
|
celastrol results in decreased expression of MYNN mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 2:114,708,150...114,726,450
Ensembl chr 2:114,708,156...114,725,452
|
|
G
|
Nbn
|
nibrin
|
decreases expression
|
ISO
|
celastrol results in decreased expression of NBN mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 5:34,256,678...34,291,163
Ensembl chr 5:34,256,627...34,291,162
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
increases expression increases activity multiple interactions
|
EXP ISO
|
celastrol results in increased expression of NFE2L2 protein celastrol results in increased expression of NFE2L2 mRNA celastrol results in increased activity of NFE2L2 protein celastrol inhibits the reaction [Bleomycin results in decreased expression of NFE2L2 protein]; celastrol inhibits the reaction [Doxorubicin results in decreased expression of and affects the localization of and results in decreased activity of NFE2L2 protein]; celastrol inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 mRNA]
|
CTD |
PMID:26768587 PMID:29643811 PMID:30588110 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Doxorubicin results in increased expression of NFKBIA protein modified form]
|
CTD |
PMID:30588110 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Nkd1
|
NKD inhibitor of WNT signaling pathway 1
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NKD1 mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr19:34,649,803...34,722,846
|
|
G
|
Nkx3-1
|
NK3 homeobox 1
|
decreases expression
|
ISO
|
celastrol results in decreased expression of NKX3-1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr15:50,883,661...50,886,253
Ensembl chr15:50,883,597...50,886,251
|
|
G
|
Nlrp3
|
NLR family, pyrin domain containing 3
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]]
|
CTD |
PMID:32470352 |
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]
|
CTD |
PMID:31901889 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Notum
|
NOTUM, palmitoleoyl-protein carboxylesterase
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NOTUM mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr10:105,933,245...105,940,327
Ensembl chr10:106,431,572...106,438,654
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Bleomycin results in decreased activity of NQO1 protein]; celastrol inhibits the reaction [Doxorubicin results in decreased expression of NQO1 mRNA]; celastrol inhibits the reaction [Doxorubicin results in decreased expression of NQO1 protein]; celastrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of NQO1 mRNA]
|
CTD |
PMID:26768587 PMID:30588110 PMID:36827925 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
G
|
Nrep
|
neuronal regeneration related protein
|
decreases expression
|
ISO
|
celastrol results in decreased expression of NREP mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr18:25,291,219...25,320,742
Ensembl chr18:25,291,219...25,320,742
|
|
G
|
Oas3
|
2'-5'-oligoadenylate synthetase 3
|
increases expression
|
ISO
|
celastrol results in increased expression of OAS3 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr12:41,439,645...41,463,392
Ensembl chr12:41,439,643...41,464,420
|
|
G
|
Ogdh
|
oxoglutarate dehydrogenase
|
multiple interactions increases expression
|
ISO
|
celastrol inhibits the reaction [Dietary Fats results in decreased expression of OGDH mRNA] celastrol results in increased expression of OGDH mRNA
|
CTD |
PMID:35679966 |
|
NCBI chr14:85,363,949...85,431,405
Ensembl chr14:85,364,014...85,432,271
|
|
G
|
Oprk1
|
opioid receptor, kappa 1
|
decreases expression
|
ISO
|
celastrol results in decreased expression of OPRK1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 5:18,657,866...18,675,671
Ensembl chr 5:18,657,871...18,675,671
|
|
G
|
Oser1
|
oxidative stress responsive serine-rich 1
|
increases expression
|
ISO
|
celastrol results in increased expression of OSER1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 3:172,486,417...172,504,607
Ensembl chr 3:172,486,440...172,504,597
|
|
G
|
Pakap
|
paralemmin A kinase anchor protein
|
decreases expression
|
ISO
|
celastrol results in decreased expression of PALM2AKAP2 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 5:76,976,906...77,443,656
Ensembl chr 5:76,977,112...77,443,656
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions increases cleavage
|
ISO
|
[TNFSF10 protein co-treated with celastrol] results in increased cleavage of PARP1 protein; TNFRSF10A protein promotes the reaction [[TNFSF10 protein co-treated with celastrol] results in increased cleavage of PARP1 protein]; TNFRSF10B protein promotes the reaction [[TNFSF10 protein co-treated with celastrol] results in increased cleavage of PARP1 protein] celastrol results in increased cleavage of PARP1 protein
|
CTD |
PMID:20605676 PMID:31715269 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Pcna
|
proliferating cell nuclear antigen
|
multiple interactions
|
ISO
|
celastrol promotes the reaction [[coomassie Brilliant Blue co-treated with Acetaminophen] results in increased expression of PCNA protein]
|
CTD |
PMID:28435131 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901
|
|
G
|
Pde9a
|
phosphodiesterase 9A
|
decreases expression
|
ISO
|
celastrol results in decreased expression of PDE9A mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr20:9,471,136...9,564,286
Ensembl chr20:9,471,167...9,564,286
|
|
G
|
Pdha1
|
pyruvate dehydrogenase E1 subunit alpha 1
|
decreases phosphorylation multiple interactions
|
ISO
|
celastrol results in decreased phosphorylation of PDHA1 protein celastrol inhibits the reaction [Dietary Fats results in increased phosphorylation of PDHA1 protein]
|
CTD |
PMID:35679966 |
|
NCBI chr X:38,509,158...38,522,986
Ensembl chr X:38,509,084...38,522,536
|
|
G
|
Pdhb
|
pyruvate dehydrogenase E1 subunit beta
|
multiple interactions increases expression
|
ISO
|
celastrol inhibits the reaction [Dietary Fats results in decreased expression of PDHB mRNA] celastrol results in increased expression of PDHB mRNA
|
CTD |
PMID:35679966 |
|
NCBI chr15:19,182,789...19,188,731
Ensembl chr15:19,181,208...19,188,976
|
|
G
|
Pdk4
|
pyruvate dehydrogenase kinase 4
|
decreases expression multiple interactions
|
ISO
|
celastrol results in decreased expression of PDK4 mRNA; celastrol results in decreased expression of PDK4 protein celastrol inhibits the reaction [Dietary Fats results in increased expression of PDK4 mRNA]; celastrol inhibits the reaction [Dietary Fats results in increased expression of PDK4 protein]
|
CTD |
PMID:35679966 |
|
NCBI chr 4:34,558,327...34,568,329
Ensembl chr 4:34,556,330...34,568,381
|
|
G
|
Pdp1
|
pyruvate dehydrogenase phosphatase catalytic subunit 1
|
multiple interactions increases expression
|
ISO
|
celastrol inhibits the reaction [Dietary Fats results in decreased expression of PDP1 mRNA]; celastrol inhibits the reaction [Dietary Fats results in decreased expression of PDP1 protein] celastrol results in increased expression of PDP1 mRNA; celastrol results in increased expression of PDP1 protein
|
CTD |
PMID:35679966 |
|
NCBI chr 5:30,245,699...30,252,494
Ensembl chr 5:30,242,704...30,253,960
|
|
G
|
Pfkm
|
phosphofructokinase, muscle
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [Dietary Fats results in decreased expression of PFKM mRNA]
|
CTD |
PMID:35679966 |
|
NCBI chr 7:131,100,684...131,138,250
Ensembl chr 7:131,100,753...131,138,248
|
|
G
|
Pgam1
|
phosphoglycerate mutase 1
|
increases expression multiple interactions
|
ISO
|
celastrol results in increased expression of PGAM1 mRNA celastrol inhibits the reaction [Dietary Fats results in decreased expression of PGAM1 mRNA]
|
CTD |
PMID:35679966 |
|
NCBI chr 1:250,673,152...250,680,762
Ensembl chr 1:250,673,049...250,690,203
|
|
G
|
Pgk1
|
phosphoglycerate kinase 1
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [Dietary Fats results in decreased expression of PGK1 mRNA]
|
CTD |
PMID:35679966 |
|
NCBI chr X:75,336,988...75,352,962
Ensembl chr X:75,336,687...75,352,959
|
|
G
|
Pik3c2a
|
phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha
|
increases expression
|
ISO
|
celastrol results in increased expression of PIK3C2A mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 1:180,012,248...180,117,786
Ensembl chr 1:180,012,248...180,117,773
|
|
G
|
Pik3cd
|
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
|
decreases expression
|
ISO
|
celastrol results in decreased expression of PIK3CD mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 5:165,377,994...165,426,620
Ensembl chr 5:165,377,994...165,403,968
|
|
G
|
Pik3r1
|
phosphoinositide-3-kinase regulatory subunit 1
|
decreases expression multiple interactions
|
ISO EXP
|
celastrol results in decreased expression of PIK3R1 mRNA celastrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of PIK3R1 protein]
|
CTD |
PMID:17010675 PMID:36827925 |
|
NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:34,612,946...34,626,347
|
|
G
|
Pisd
|
phosphatidylserine decarboxylase
|
increases expression
|
ISO
|
celastrol results in increased expression of PISD mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr14:82,166,401...82,215,479
Ensembl chr14:82,166,412...82,215,913
|
|
G
|
Pkm
|
pyruvate kinase M1/2
|
multiple interactions increases expression
|
ISO
|
[celastrol co-treated with Dietary Fats] results in increased expression of PKM mRNA celastrol results in increased expression of PKM mRNA
|
CTD |
PMID:35679966 |
|
NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:68,948,815...68,975,396
|
|
G
|
Pkp3
|
plakophilin 3
|
increases expression
|
ISO
|
celastrol results in increased expression of PKP3 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 1:205,617,511...205,628,441
Ensembl chr 1:205,617,511...205,628,440
|
|
G
|
Plaur
|
plasminogen activator, urokinase receptor
|
decreases expression
|
ISO
|
celastrol results in decreased expression of PLAUR mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:89,178,453...89,198,130
|
|
G
|
Plin1
|
perilipin 1
|
affects expression
|
ISO
|
celastrol affects the expression of PLIN1 mRNA
|
CTD |
PMID:27085773 |
|
NCBI chr 1:143,073,612...143,086,199
Ensembl chr 1:143,074,214...143,086,206
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
affects expression
|
ISO
|
celastrol affects the expression of PPARG mRNA; celastrol affects the expression of PPARG protein
|
CTD |
PMID:27085773 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
G
|
Ppif
|
peptidylprolyl isomerase F
|
decreases expression
|
ISO
|
celastrol results in decreased expression of PPIF mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr16:1,264,001...1,270,722
Ensembl chr16:1,263,541...1,316,954
|
|
G
|
Ptdss2
|
phosphatidylserine synthase 2
|
increases expression
|
ISO
|
celastrol results in increased expression of PTDSS2 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 1:205,671,024...205,695,556
Ensembl chr 1:205,671,041...205,695,553
|
|
G
|
Pten
|
phosphatase and tensin homolog
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Cadmium Chloride results in decreased expression of PTEN protein]; PTEN protein promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]]; PTEN protein promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]]; PTEN protein promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased phosphorylation of RPS6KB1 protein]]
|
CTD |
PMID:24111524 |
|
NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330
|
|
G
|
Ptgs1
|
prostaglandin-endoperoxide synthase 1
|
increases expression
|
ISO
|
celastrol results in increased expression of PTGS1 mRNA
|
CTD |
PMID:25477506 |
|
NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
decreases expression
|
ISO
|
celastrol results in decreased expression of PTGS2 mRNA; celastrol results in decreased expression of PTGS2 protein
|
CTD |
PMID:31715269 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Ptk7
|
protein tyrosine kinase 7
|
increases expression
|
ISO
|
celastrol results in increased expression of PTK7 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 9:21,849,756...21,916,077
Ensembl chr 9:21,849,801...21,916,078
|
|
G
|
Pura
|
purine rich element binding protein A
|
decreases expression
|
ISO
|
celastrol results in decreased expression of PURA mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr18:28,159,103...28,179,539
Ensembl chr18:28,125,126...28,211,111
|
|
G
|
Rac3
|
Rac family small GTPase 3
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of RAC3 mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr10:106,501,133...106,503,569
Ensembl chr10:106,501,135...106,503,569
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
ISO EXP
|
celastrol inhibits the reaction [TNF protein affects the localization of and results in increased activity of RELA protein] celastrol inhibits the reaction [Plant Preparations results in increased expression of RELA protein] celastrol inhibits the reaction [Doxorubicin results in increased expression of and results in increased phosphorylation of and results in increased activity of RELA protein]; celastrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of RELA protein]
|
CTD |
PMID:16769766 PMID:29643811 PMID:30588110 PMID:36827925 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Rps6kb1
|
ribosomal protein S6 kinase B1
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Cadmium Chloride results in increased phosphorylation of RPS6KB1 protein]; PTEN protein promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased phosphorylation of RPS6KB1 protein]]
|
CTD |
PMID:24111524 |
|
NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238
|
|
G
|
Rrm2
|
ribonucleotide reductase regulatory subunit M2
|
decreases expression
|
ISO
|
celastrol results in decreased expression of RRM2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370
|
|
G
|
S100a4
|
S100 calcium-binding protein A4
|
increases expression
|
ISO
|
celastrol results in increased expression of S100A4 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 2:178,388,529...178,390,838
Ensembl chr 2:178,388,526...178,390,837
|
|
G
|
Sdhb
|
succinate dehydrogenase complex iron sulfur subunit B
|
increases expression multiple interactions
|
ISO
|
celastrol results in increased expression of SDHB mRNA celastrol inhibits the reaction [Dietary Fats results in decreased expression of SDHB mRNA]; celastrol inhibits the reaction [Dietary Fats results in decreased expression of SDHB protein]
|
CTD |
PMID:35679966 |
|
NCBI chr 5:158,547,775...158,568,589
Ensembl chr 5:158,547,689...158,569,667
|
|
G
|
Sele
|
selectin E
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [IL1B protein results in increased expression of SELE protein]; celastrol inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; celastrol inhibits the reaction [TNF protein results in increased expression of SELE protein]
|
CTD |
PMID:16769766 |
|
NCBI chr13:78,935,997...78,945,905
Ensembl chr13:78,936,036...78,945,903
|
|
G
|
Serp1
|
stress-associated endoplasmic reticulum protein 1
|
increases expression
|
ISO
|
celastrol results in increased expression of SERP1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 2:144,907,204...144,911,187
Ensembl chr 2:144,907,205...144,911,187
|
|
G
|
Sesn1
|
sestrin 1
|
decreases expression
|
ISO
|
celastrol results in decreased expression of SESN1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr20:46,876,918...46,970,010
Ensembl chr20:46,876,895...46,970,010
|
|
G
|
Slc38a2
|
solute carrier family 38, member 2
|
decreases expression
|
ISO
|
celastrol results in decreased expression of SLC38A2 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 7:129,730,450...129,742,619
Ensembl chr 7:129,730,450...129,742,619
|
|
G
|
Slc3a2
|
solute carrier family 3 member 2
|
increases expression
|
ISO
|
celastrol results in increased expression of SLC3A2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 1:215,033,601...215,048,064
Ensembl chr 1:215,033,601...215,048,064
|
|
G
|
Slc7a11
|
solute carrier family 7 member 11
|
decreases response to substance increases expression
|
ISO
|
SLC7A11 protein results in decreased susceptibility to celastrol celastrol results in increased expression of SLC7A11 mRNA
|
CTD |
PMID:17010675 PMID:20007406 |
|
NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695
|
|
G
|
Sltm
|
SAFB-like, transcription modulator
|
decreases expression
|
ISO
|
celastrol results in decreased expression of SLTM mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 8:80,096,555...80,142,668
Ensembl chr 8:80,097,652...80,142,671
|
|
G
|
Smad3
|
SMAD family member 3
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]
|
CTD |
PMID:29789558 |
|
NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324
|
|
G
|
Sod2
|
superoxide dismutase 2
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Bleomycin results in decreased activity of SOD2 protein]
|
CTD |
PMID:26768587 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168
|
|
G
|
Sox4
|
SRY-box transcription factor 4
|
decreases expression
|
ISO
|
celastrol results in decreased expression of SOX4 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr17:35,876,298...35,881,004
Ensembl chr17:35,875,756...35,884,024
|
|
G
|
Sqstm1
|
sequestosome 1
|
decreases expression multiple interactions
|
EXP ISO
|
celastrol results in decreased expression of SQSTM1 protein celastrol results in decreased expression of SQSTM1 mRNA N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol results in decreased expression of SQSTM1 protein]
|
CTD |
PMID:32470352 PMID:39181414 |
|
NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750
|
|
G
|
Stat3
|
signal transducer and activator of transcription 3
|
decreases phosphorylation affects response to substance
|
ISO
|
celastrol results in decreased phosphorylation of STAT3 protein STAT3 protein affects the susceptibility to celastrol
|
CTD |
PMID:39181414 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359
|
|
G
|
Stip1
|
stress-induced phosphoprotein 1
|
increases expression
|
ISO
|
celastrol results in increased expression of STIP1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 1:213,638,641...213,657,654
Ensembl chr 1:213,638,641...213,657,654
|
|
G
|
Sugp2
|
SURP and G patch domain containing 2
|
increases expression
|
ISO
|
celastrol results in increased expression of SUGP2 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr16:19,193,910...19,225,364
Ensembl chr16:19,198,831...19,225,292
|
|
G
|
Taok3
|
TAO kinase 3
|
decreases expression
|
ISO
|
celastrol results in decreased expression of TAOK3 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr12:44,973,180...45,134,439
Ensembl chr12:44,973,180...45,134,439
|
|
G
|
Tap1
|
transporter 1, ATP binding cassette subfamily B member
|
increases expression
|
ISO
|
celastrol results in increased expression of TAP1 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr20:4,658,171...4,668,543
Ensembl chr20:4,658,172...4,668,810
|
|
G
|
Tcf7
|
transcription factor 7
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of TCF7 mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr10:36,924,363...36,954,279
Ensembl chr10:36,924,363...36,954,279
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
ISO EXP
|
celastrol inhibits the reaction [TGFB1 protein results in decreased expression of CNR2 protein]; celastrol inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; celastrol inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]; celastrol inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein] celastrol inhibits the reaction [Doxorubicin results in increased expression of TGFB1 mRNA]; celastrol inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]
|
CTD |
PMID:29789558 PMID:30588110 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 mRNA]; celastrol inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]
|
CTD |
PMID:30588110 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
G
|
Tmbim6
|
transmembrane BAX inhibitor motif containing 6
|
increases expression
|
ISO
|
celastrol results in increased expression of TMBIM6 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 7:132,405,217...132,422,492
Ensembl chr 7:132,386,134...132,422,492
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions increases expression
|
ISO EXP
|
celastrol inhibits the reaction [TNF protein affects the localization of and results in increased activity of RELA protein]; celastrol inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; celastrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; celastrol inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; celastrol inhibits the reaction [TNF protein results in increased expression of SELE protein]; celastrol inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; celastrol inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] celastrol inhibits the reaction [Bleomycin results in increased expression of TNF protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; celastrol inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]] celastrol results in increased expression of TNF mRNA celastrol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; celastrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; celastrol inhibits the reaction [Plant Preparations results in increased expression of TNF protein]; celastrol promotes the reaction [Dextran Sulfate results in increased expression of TNF protein]
|
CTD |
PMID:16769766 PMID:24384223 PMID:25477506 PMID:26768587 PMID:29643811 PMID:30588110 PMID:31715269 PMID:31901889 PMID:32470352 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tnfrsf10b
|
TNF receptor superfamily member 10b
|
increases expression multiple interactions
|
ISO
|
celastrol results in increased expression of TNFRSF10A mRNA celastrol results in increased expression of and results in increased localization of TNFRSF10A protein; TNFRSF10A protein promotes the reaction [[TNFSF10 protein co-treated with celastrol] results in increased cleavage of PARP1 protein]
|
CTD |
PMID:20605676 |
|
NCBI chr15:51,249,883...51,278,091
Ensembl chr15:51,250,112...51,278,082
|
|
G
|
Tnfsf10
|
TNF superfamily member 10
|
multiple interactions increases expression increases response to substance
|
ISO
|
[TNFSF10 protein co-treated with celastrol] results in increased cleavage of CASP3 protein; [TNFSF10 protein co-treated with celastrol] results in increased cleavage of PARP1 protein; TNFRSF10A protein promotes the reaction [[TNFSF10 protein co-treated with celastrol] results in increased cleavage of PARP1 protein]; TNFRSF10B protein promotes the reaction [[TNFSF10 protein co-treated with celastrol] results in increased cleavage of PARP1 protein] celastrol results in increased expression of TNFSF10 mRNA celastrol results in increased susceptibility to TNFSF10 protein
|
CTD |
PMID:20605676 PMID:25477506 |
|
NCBI chr 2:112,136,550...112,155,903
|
|
G
|
Tnni3
|
troponin I3, cardiac type
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Doxorubicin results in increased secretion of TNNI3 protein]
|
CTD |
PMID:30588110 |
|
NCBI chr 1:78,342,571...78,346,255
Ensembl chr 1:78,342,592...78,346,253
|
|
G
|
Tnnt2
|
troponin T2, cardiac type
|
multiple interactions
|
EXP
|
celastrol inhibits the reaction [Doxorubicin results in increased secretion of TNNT2 protein]
|
CTD |
PMID:30588110 |
|
NCBI chr13:49,819,123...49,837,125
Ensembl chr13:49,822,304...49,837,125
|
|
G
|
Tp53
|
tumor protein p53
|
increases expression multiple interactions
|
ISO
|
celastrol results in increased expression of TP53 protein Uridine inhibits the reaction [celastrol results in increased expression of TP53 protein]
|
CTD |
PMID:27374097 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Tspyl1
|
TSPY-like 1
|
decreases expression
|
ISO
|
celastrol results in decreased expression of TSPYL1 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr20:39,637,035...39,639,594
Ensembl chr20:39,635,135...39,695,333
|
|
G
|
Txnip
|
thioredoxin interacting protein
|
decreases expression
|
ISO
|
celastrol results in decreased expression of TXNIP mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:186,781,163...186,785,731
|
|
G
|
Txnrd1
|
thioredoxin reductase 1
|
increases expression
|
ISO
|
celastrol results in increased expression of TXNRD1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817
|
|
G
|
Ube2b
|
ubiquitin-conjugating enzyme E2B
|
increases expression
|
ISO
|
celastrol results in increased expression of UBE2B mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr10:36,749,365...36,764,335
Ensembl chr10:36,749,369...36,765,587
|
|
G
|
Ube2e1
|
ubiquitin-conjugating enzyme E2E 1
|
decreases expression
|
ISO
|
celastrol results in decreased expression of UBE2E1 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr15:9,870,528...9,924,194
Ensembl chr15:9,862,219...9,924,194
|
|
G
|
Ube2s
|
ubiquitin-conjugating enzyme E2S
|
decreases expression
|
ISO
|
celastrol results in decreased expression of UBE2S mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr 1:78,057,659...78,061,719
Ensembl chr 1:78,057,598...78,081,628
|
|
G
|
Uck1
|
uridine-cytidine kinase 1
|
increases expression
|
ISO
|
celastrol results in increased expression of UCK1 mRNA
|
CTD |
PMID:27374097 |
|
NCBI chr 3:35,936,328...35,942,213
Ensembl chr 3:35,936,339...35,954,311
|
|
G
|
Ugdh
|
UDP-glucose 6-dehydrogenase
|
increases expression
|
ISO
|
celastrol results in increased expression of UGDH mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr14:43,202,480...43,226,002
Ensembl chr14:43,202,356...43,226,629
|
|
G
|
Vcam1
|
vascular cell adhesion molecule 1
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [IFNG protein results in increased expression of VCAM1 protein]; celastrol inhibits the reaction [IL1B protein results in increased expression of VCAM1 protein]; celastrol inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; celastrol inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]
|
CTD |
PMID:16769766 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801
|
|
G
|
Wdr77
|
WD repeat domain 77
|
decreases expression
|
ISO
|
celastrol results in decreased expression of WDR77 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 2:196,123,882...196,133,853
Ensembl chr 2:196,123,848...196,134,567
|
|
G
|
Wif1
|
Wnt inhibitory factor 1
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WIF1 mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr 7:58,433,326...58,503,853
Ensembl chr 7:58,384,643...58,503,852
|
|
G
|
Wnt10a
|
Wnt family member 10A
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT10A mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr 9:83,798,594...83,811,060
Ensembl chr 9:83,798,594...83,811,067
|
|
G
|
Wnt3
|
Wnt family member 3
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT3 mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr10:89,180,224...89,224,195
Ensembl chr10:89,216,801...89,224,195
|
|
G
|
Wnt6
|
Wnt family member 6
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT6 mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr 9:83,778,552...83,792,186
Ensembl chr 9:83,778,552...83,792,186
|
|
G
|
Wnt7b
|
Wnt family member 7B
|
multiple interactions
|
ISO
|
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT7B mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr 7:118,514,684...118,559,316
Ensembl chr 7:118,514,684...118,559,316
|
|
G
|
Zbtb43
|
zinc finger and BTB domain containing 43
|
decreases expression
|
ISO
|
celastrol results in decreased expression of ZBTB43 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 3:37,142,210...37,161,524
Ensembl chr 3:37,141,354...37,162,238
|
|
G
|
Zc3h12a
|
zinc finger CCCH type containing 12A
|
decreases expression
|
ISO
|
celastrol results in decreased expression of ZC3H12A mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 5:142,661,193...142,670,051
Ensembl chr 5:142,661,199...142,669,985
|
|
G
|
Zeb1
|
zinc finger E-box binding homeobox 1
|
decreases expression
|
ISO
|
celastrol results in decreased expression of ZEB1 mRNA
|
CTD |
PMID:39181414 |
|
NCBI chr17:56,644,397...56,811,155
Ensembl chr17:56,644,397...56,810,745
|
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
ISO
|
cycloartenol inhibits the reaction [Benzoyl Peroxide results in decreased activity of CAT protein]
|
CTD |
PMID:12804013 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Cryz
|
crystallin zeta
|
multiple interactions
|
ISO
|
cycloartenol inhibits the reaction [Benzoyl Peroxide results in decreased activity of CRYZ protein]
|
CTD |
PMID:12804013 |
|
NCBI chr 2:246,211,707...246,239,472
Ensembl chr 2:246,211,156...246,239,470
|
|
G
|
G6pd
|
glucose-6-phosphate dehydrogenase
|
multiple interactions
|
ISO
|
cycloartenol inhibits the reaction [Benzoyl Peroxide results in decreased activity of G6PD protein]
|
CTD |
PMID:12804013 |
|
NCBI chr X:157,352,364...157,372,144
Ensembl chr X:157,352,373...157,372,144
|
|
G
|
Gsr
|
glutathione-disulfide reductase
|
multiple interactions
|
ISO
|
cycloartenol inhibits the reaction [Benzoyl Peroxide results in decreased activity of GSR protein]
|
CTD |
PMID:12804013 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394
|
|
G
|
Odc1
|
ornithine decarboxylase 1
|
multiple interactions
|
ISO
|
cycloartenol inhibits the reaction [Benzoyl Peroxide results in increased activity of ODC1 protein]
|
CTD |
PMID:12804013 |
|
NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:46,058,463...46,065,146
|
|
G
|
Xdh
|
xanthine dehydrogenase
|
multiple interactions
|
ISO
|
cycloartenol inhibits the reaction [Benzoyl Peroxide results in increased activity of XDH protein]
|
CTD |
PMID:12804013 |
|
NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:27,282,057...27,344,350
|
|
|
G
|
Aqp9
|
aquaporin 9
|
increases expression
|
ISO
|
cycloastragenol results in increased expression of AQP9 mRNA; cycloastragenol results in increased expression of AQP9 protein
|
CTD |
PMID:37918281 |
|
NCBI chr 8:80,678,027...80,718,273
Ensembl chr 8:80,678,030...80,717,240
|
|
G
|
Arhgap17
|
Rho GTPase activating protein 17
|
multiple interactions
|
EXP
|
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Arhgap17 protein in myocardium]
|
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 1:187,238,675...187,328,093
Ensembl chr 1:187,238,380...187,327,936
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
EXP
|
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Bax protein in myocardium]
|
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Ccnd1
|
cyclin D1
|
increases expression
|
ISO
|
cycloastragenol results in increased expression of CCND1 protein
|
CTD |
PMID:37918281 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Dsc2
|
desmocollin 2
|
multiple interactions
|
EXP
|
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Dsc2 protein in myocardium]
|
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr18:11,725,466...11,757,591
Ensembl chr18:11,725,466...11,757,466
|
|
G
|
Gsk3b
|
glycogen synthase kinase 3 beta
|
multiple interactions
|
EXP
|
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Gsk3b protein in myocardium]
|
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249
|
|
G
|
Ifng
|
interferon gamma
|
multiple interactions
|
EXP
|
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Ifng protein in spleen]
|
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
G
|
Ikbkg
|
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma
|
multiple interactions
|
EXP
|
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Ikbkg protein in myocardium]
|
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr X:157,358,279...157,397,563
Ensembl chr X:157,367,639...157,392,757
|
|
G
|
Il10
|
interleukin 10
|
multiple interactions
|
EXP
|
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Il10 protein in spleenocytes and peripheral blood]
|
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
G
|
Il17a
|
interleukin 17A
|
multiple interactions
|
EXP
|
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Il17 protein in spleenocytes and peripheral blood]
|
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
EXP
|
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Il1b protein in spleenocytes and peripheral blood]
|
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il4
|
interleukin 4
|
multiple interactions
|
EXP
|
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Il4 protein in spleen]
|
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
EXP ISO
|
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Il6 protein in spleenocytes and peripheral blood] cycloastragenol inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased secretion of IL6 protein]
|
CTD RGD |
PMID:37579952 PMID:32068187 |
RGD:267358468 |
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions
|
ISO
|
cycloastragenol inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased secretion of MMP9 protein]
|
CTD |
PMID:37579952 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Mt-co2
|
mitochondrially encoded cytochrome c oxidase II
|
multiple interactions
|
EXP
|
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Mt-co2 protein in myocardium]
|
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr MT:7,006...7,689
Ensembl chr MT:6,991...7,674
|
|
G
|
Pcna
|
proliferating cell nuclear antigen
|
increases expression
|
ISO
|
cycloastragenol results in increased expression of PCNA protein
|
CTD |
PMID:37918281 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901
|
|
G
|
Plcg1
|
phospholipase C, gamma 1
|
multiple interactions
|
EXP
|
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Plcg1 protein in myocardium]
|
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 3:169,805,299...169,836,040
Ensembl chr 3:169,804,846...169,836,050
|
|
G
|
Rhoa
|
ras homolog family member A
|
multiple interactions
|
EXP
|
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Rhoa protein in myocardium]
|
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:117,870,270...117,904,302
|
|
G
|
Rit2
|
Ras-like without CAAX 2
|
multiple interactions
|
EXP
|
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Rit2 protein in myocardium]
|
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr18:22,839,914...23,196,137
Ensembl chr18:22,839,915...23,269,823
|
|
G
|
Tert
|
telomerase reverse transcriptase
|
multiple interactions
|
ISO
|
cycloastragenol inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of TERT protein]; cycloastragenol inhibits the reaction [Benzo(a)pyrene results in decreased expression of TERT protein]
|
CTD |
PMID:37579952 |
|
NCBI chr 1:31,465,766...31,488,650
Ensembl chr 1:31,466,056...31,488,111
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
EXP
|
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Tnf protein in spleen]
|
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Zeb1
|
zinc finger E-box binding homeobox 1
|
multiple interactions
|
EXP
|
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Zeb1 protein in myocardium]
|
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr17:56,644,397...56,811,155
Ensembl chr17:56,644,397...56,810,745
|
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
ISO
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [euscaphic acid inhibits the reaction [Oxygen deficiency results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [euscaphic acid inhibits the reaction [Oxygen deficiency results in increased phosphorylation of AKT1 protein]]; euscaphic acid inhibits the reaction [Oxygen deficiency results in increased phosphorylation of AKT1 protein]
|
CTD |
PMID:32298737 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
ISO
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [euscaphic acid inhibits the reaction [Oxygen deficiency results in increased cleavage of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [euscaphic acid inhibits the reaction [Oxygen deficiency results in increased cleavage of CASP3 protein]]; euscaphic acid inhibits the reaction [Oxygen deficiency results in increased cleavage of CASP3 protein]
|
CTD |
PMID:32298737 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp9
|
caspase 9
|
multiple interactions
|
ISO
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [euscaphic acid inhibits the reaction [Oxygen deficiency results in increased cleavage of CASP9 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [euscaphic acid inhibits the reaction [Oxygen deficiency results in increased cleavage of CASP9 protein]]; euscaphic acid inhibits the reaction [Oxygen deficiency results in increased cleavage of CASP9 protein]
|
CTD |
PMID:32298737 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cycs
|
cytochrome c, somatic
|
multiple interactions
|
ISO
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [euscaphic acid inhibits the reaction [Oxygen deficiency results in increased expression of CYCS protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [euscaphic acid inhibits the reaction [Oxygen deficiency results in increased expression of CYCS protein]]; euscaphic acid inhibits the reaction [Oxygen deficiency results in increased expression of CYCS protein]
|
CTD |
PMID:32298737 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816 Ensembl chr18:80,982,668...80,984,816
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
ISO
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [euscaphic acid promotes the reaction [Oxygen deficiency results in increased phosphorylation of MAPK1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [euscaphic acid promotes the reaction [Oxygen deficiency results in increased phosphorylation of MAPK1 protein]]; euscaphic acid promotes the reaction [Oxygen deficiency results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:32298737 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
ISO
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [euscaphic acid promotes the reaction [Oxygen deficiency results in increased phosphorylation of MAPK3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [euscaphic acid promotes the reaction [Oxygen deficiency results in increased phosphorylation of MAPK3 protein]]; euscaphic acid promotes the reaction [Oxygen deficiency results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:32298737 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
ISO
|
friedelin inhibits the reaction [Ethanol results in increased expression of CASP3 protein]
|
CTD |
PMID:37939858 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions
|
ISO
|
friedelin inhibits the reaction [Ethanol results in increased expression of PARP1 protein]
|
CTD |
PMID:37939858 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
ISO
|
friedelin inhibits the reaction [Ethanol results in increased expression of RELA protein]
|
CTD |
PMID:37939858 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
|
G
|
Ahsa1
|
activator of Hsp90 ATPase activity 1
|
increases expression
|
ISO
|
gedunin results in increased expression of AHSA1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 6:112,644,287...112,652,290
Ensembl chr 6:112,644,479...112,655,595
|
|
G
|
Akr1c1
|
aldo-keto reductase family 1, member C1
|
increases expression
|
ISO
|
gedunin results in increased expression of AKR1C1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr17:70,720,397...70,747,285
Ensembl chr17:70,720,398...70,747,247
|
|
G
|
Akr1c2
|
aldo-keto reductase family 1, member C2
|
increases expression
|
ISO
|
gedunin results in increased expression of AKR1C2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686
|
|
G
|
Ar
|
androgen receptor
|
decreases expression
|
ISO
|
gedunin results in decreased expression of AR protein
|
CTD |
PMID:17010675 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467
|
|
G
|
Arid5b
|
AT-rich interaction domain 5B
|
decreases expression
|
ISO
|
gedunin results in decreased expression of ARID5B mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr20:20,305,693...20,489,689
Ensembl chr20:20,306,712...20,489,686
|
|
G
|
Atf3
|
activating transcription factor 3
|
increases expression
|
ISO
|
gedunin results in increased expression of ATF3 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750
|
|
G
|
Bag3
|
BAG cochaperone 3
|
increases expression
|
ISO
|
gedunin results in increased expression of BAG3 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 1:192,533,460...192,557,281
Ensembl chr 1:192,475,828...192,557,280
|
|
G
|
Birc5
|
baculoviral IAP repeat-containing 5
|
decreases expression
|
ISO
|
gedunin results in decreased expression of BIRC5 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155
|
|
G
|
Btg1
|
BTG anti-proliferation factor 1
|
decreases expression
|
ISO
|
gedunin results in decreased expression of BTG1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 7:33,228,149...33,230,406
Ensembl chr 7:33,227,833...33,230,406
|
|
G
|
Cacybp
|
calcyclin binding protein
|
increases expression
|
ISO
|
gedunin results in increased expression of CACYBP mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr13:74,970,917...74,981,298
Ensembl chr13:74,970,923...74,981,505
|
|
G
|
Casp3
|
caspase 3
|
increases activity
|
ISO
|
gedunin results in increased activity of CASP3 protein
|
CTD |
PMID:21381696 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
increases activity
|
ISO
|
gedunin results in increased activity of CASP8 protein
|
CTD |
PMID:21381696 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
increases activity
|
ISO
|
gedunin results in increased activity of CASP9 protein
|
CTD |
PMID:21381696 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cbr3
|
carbonyl reductase 3
|
increases expression
|
ISO
|
gedunin results in increased expression of CBR3 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr11:46,478,295...46,486,555
Ensembl chr11:46,478,274...46,486,558
|
|
G
|
Cdc7
|
cell division cycle 7
|
decreases expression
|
ISO
|
gedunin results in decreased expression of CDC7 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr14:2,949,538...2,969,656
Ensembl chr14:2,949,539...2,969,656
|
|
G
|
Cdk2
|
cyclin dependent kinase 2
|
decreases expression
|
ISO
|
gedunin results in decreased expression of CDK2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878
|
|
G
|
Chordc1
|
cysteine and histidine rich domain containing 1
|
increases expression
|
ISO
|
gedunin results in increased expression of CHORDC1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 8:23,650,721...23,674,786
Ensembl chr 8:23,650,865...23,677,696
|
|
G
|
Cited2
|
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2
|
decreases expression
|
ISO
|
gedunin results in decreased expression of CITED2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 1:14,132,303...14,134,746
Ensembl chr 1:14,103,457...14,134,782
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
decreases expression
|
ISO
|
gedunin results in decreased expression of CYP1A1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Ddit3
|
DNA-damage inducible transcript 3
|
increases expression
|
ISO
|
gedunin results in increased expression of DDIT3 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
G
|
Ddit4
|
DNA-damage-inducible transcript 4
|
increases expression
|
ISO
|
gedunin results in increased expression of DDIT4 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr20:28,434,938...28,437,037
Ensembl chr20:28,434,944...28,437,037
|
|
G
|
Dnaja1
|
DnaJ heat shock protein family (Hsp40) member A1
|
increases expression
|
ISO
|
gedunin results in increased expression of DNAJA1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 5:60,638,404...60,649,315
Ensembl chr 5:60,638,410...60,650,160
|
|
G
|
Dnajb4
|
DnaJ heat shock protein family (Hsp40) member B4
|
increases expression
|
ISO
|
gedunin results in increased expression of DNAJB4 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 2:243,790,296...243,819,042
Ensembl chr 2:243,790,297...243,819,042
|
|
G
|
Efnb2
|
ephrin B2
|
decreases expression
|
ISO
|
gedunin results in decreased expression of EFNB2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr16:87,485,215...87,529,224
Ensembl chr16:87,485,198...87,529,208
|
|
G
|
Egfr
|
epidermal growth factor receptor
|
decreases expression
|
ISO
|
gedunin results in decreased expression of EGFR protein
|
CTD |
PMID:17010675 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358
|
|
G
|
Ficd
|
FIC domain protein adenylyltransferase
|
increases expression
|
ISO
|
gedunin results in increased expression of FICD mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr12:48,549,737...48,554,626
Ensembl chr12:48,549,737...48,554,626
|
|
G
|
Flt3
|
Fms related receptor tyrosine kinase 3
|
decreases expression
|
ISO
|
gedunin results in decreased expression of FLT3 protein
|
CTD |
PMID:17010675 |
|
NCBI chr12:12,660,035...12,735,584
Ensembl chr12:12,659,946...12,735,581
|
|
G
|
Gatd3a
|
glutamine amidotransferase class 1 domain containing 3A
|
decreases expression
|
ISO
|
gedunin results in decreased expression of GATD3 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr20:10,514,459...10,522,556
Ensembl chr20:10,514,443...10,522,555
|
|
G
|
Gclm
|
glutamate cysteine ligase, modifier subunit
|
increases expression
|
ISO
|
gedunin results in increased expression of GCLM mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003
|
|
G
|
Gdf15
|
growth differentiation factor 15
|
increases expression
|
ISO
|
gedunin results in increased expression of GDF15 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022
|
|
G
|
Gtpbp2
|
GTP binding protein 2
|
increases expression
|
ISO
|
gedunin results in increased expression of GTPBP2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 9:22,311,532...22,321,405
Ensembl chr 9:22,311,158...22,321,441
|
|
G
|
Hilpda
|
hypoxia inducible lipid droplet-associated
|
decreases expression
|
ISO
|
gedunin results in decreased expression of HILPDA mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 4:58,836,463...58,839,423
Ensembl chr 4:58,836,463...58,839,423
|
|
G
|
Hmgcs1
|
3-hydroxy-3-methylglutaryl-CoA synthase 1
|
increases expression
|
ISO
|
gedunin results in increased expression of HMGCS1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 2:53,379,457...53,399,807
Ensembl chr 2:53,382,643...53,399,802
|
|
G
|
Hmox1
|
heme oxygenase 1
|
increases expression
|
ISO
|
gedunin results in increased expression of HMOX1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Hsp90aa1
|
heat shock protein 90 alpha family class A member 1
|
decreases activity
|
ISO
|
gedunin results in decreased activity of HSP90AA1 protein
|
CTD |
PMID:17010675 |
|
NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499
|
|
G
|
Hspa13
|
heat shock protein family A (Hsp70) member 13
|
increases expression
|
ISO
|
gedunin results in increased expression of HSPA13 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr11:27,862,717...27,876,898
Ensembl chr11:27,862,593...27,876,898
|
|
G
|
Hspa1a
|
heat shock protein family A (Hsp70) member 1A
|
increases expression
|
ISO
|
gedunin results in increased expression of HSPA1A mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979
|
|
G
|
Hspa1b
|
heat shock protein family A (Hsp70) member 1B
|
increases expression
|
ISO
|
gedunin results in increased expression of HSPA1B mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr20:3,859,756...3,863,800
Ensembl chr20:3,855,780...3,877,979
|
|
G
|
Hspa5
|
heat shock protein family A (Hsp70) member 5
|
increases expression
|
ISO
|
gedunin results in increased expression of HSPA5 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790
|
|
G
|
Hsph1
|
heat shock protein family H (Hsp110) member 1
|
increases expression
|
ISO
|
gedunin results in increased expression of HSPH1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr12:10,427,368...10,446,602
Ensembl chr12:10,427,297...10,446,891
|
|
G
|
Il1rn
|
interleukin 1 receptor antagonist
|
decreases expression
|
ISO
|
gedunin results in decreased expression of IL1RN mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732
|
|
G
|
Insig1
|
insulin induced gene 1
|
increases expression
|
ISO
|
gedunin results in increased expression of INSIG1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:8,049,556...8,057,778
|
|
G
|
Jag1
|
jagged canonical Notch ligand 1
|
decreases expression
|
ISO
|
gedunin results in decreased expression of JAG1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 3:144,859,453...144,894,883
Ensembl chr 3:144,859,453...144,894,872
|
|
G
|
Kcnn2
|
potassium calcium-activated channel subfamily N member 2
|
decreases expression
|
ISO
|
gedunin results in decreased expression of KCNN2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr18:40,004,693...40,445,043
Ensembl chr18:40,155,939...40,445,045
|
|
G
|
Ldlr
|
low density lipoprotein receptor
|
increases expression
|
ISO
|
gedunin results in increased expression of LDLR mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:28,546,146...28,570,675
|
|
G
|
Lpin1
|
lipin 1
|
increases expression
|
ISO
|
gedunin results in increased expression of LPIN1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 6:45,039,110...45,145,845
Ensembl chr 6:45,041,522...45,145,991
|
|
G
|
Ltn1
|
listerin E3 ubiquitin protein ligase 1
|
decreases expression
|
ISO
|
gedunin results in decreased expression of LTN1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr11:40,090,169...40,147,159
Ensembl chr11:40,090,169...40,147,303
|
|
G
|
Mafb
|
MAF bZIP transcription factor B
|
decreases expression
|
ISO
|
gedunin results in decreased expression of MAFB mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 3:169,417,890...169,419,810
Ensembl chr 3:169,416,945...169,419,975
|
|
G
|
Mdh2
|
malate dehydrogenase 2
|
decreases expression
|
ISO
|
gedunin results in decreased expression of MDH2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr12:26,530,886...26,543,841
Ensembl chr12:26,530,881...26,543,841
|
|
G
|
Me1
|
malic enzyme 1
|
increases expression
|
ISO
|
gedunin results in increased expression of ME1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 8:96,429,057...96,540,244
Ensembl chr 8:96,429,057...96,540,275
|
|
G
|
Mnt
|
MAX network transcriptional repressor
|
increases expression
|
ISO
|
gedunin results in increased expression of MNT mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr10:60,197,654...60,213,221
Ensembl chr10:60,197,948...60,213,209
|
|
G
|
Mrpl18
|
mitochondrial ribosomal protein L18
|
increases expression
|
ISO
|
gedunin results in increased expression of MRPL18 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 1:50,384,951...50,389,769
Ensembl chr 1:50,384,367...50,389,763
|
|
G
|
Msh6
|
mutS homolog 6
|
decreases expression
|
ISO
|
gedunin results in decreased expression of MSH6 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 6:12,316,190...12,333,505
Ensembl chr 6:12,316,198...12,333,844
|
|
G
|
Msmo1
|
methylsterol monooxygenase 1
|
increases expression
|
ISO
|
gedunin results in increased expression of MSMO1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr16:29,747,113...29,764,360
Ensembl chr16:29,747,137...29,764,445
|
|
G
|
Mycbp2
|
MYC binding protein 2
|
decreases expression
|
ISO
|
gedunin results in decreased expression of MYCBP2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr15:86,352,061...86,590,126
Ensembl chr15:86,352,061...86,590,325
|
|
G
|
Mynn
|
myoneurin
|
decreases expression
|
ISO
|
gedunin results in decreased expression of MYNN mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 2:114,708,150...114,726,450
Ensembl chr 2:114,708,156...114,725,452
|
|
G
|
Nbn
|
nibrin
|
decreases expression
|
ISO
|
gedunin results in decreased expression of NBN mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 5:34,256,678...34,291,163
Ensembl chr 5:34,256,627...34,291,162
|
|
G
|
Nkx3-1
|
NK3 homeobox 1
|
decreases expression
|
ISO
|
gedunin results in decreased expression of NKX3-1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr15:50,883,661...50,886,253
Ensembl chr15:50,883,597...50,886,251
|
|
G
|
Nrep
|
neuronal regeneration related protein
|
decreases expression
|
ISO
|
gedunin results in decreased expression of NREP mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr18:25,291,219...25,320,742
Ensembl chr18:25,291,219...25,320,742
|
|
G
|
Oprk1
|
opioid receptor, kappa 1
|
decreases expression
|
ISO
|
gedunin results in decreased expression of OPRK1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 5:18,657,866...18,675,671
Ensembl chr 5:18,657,871...18,675,671
|
|
G
|
Oser1
|
oxidative stress responsive serine-rich 1
|
increases expression
|
ISO
|
gedunin results in increased expression of OSER1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 3:172,486,417...172,504,607
Ensembl chr 3:172,486,440...172,504,597
|
|
G
|
Pde9a
|
phosphodiesterase 9A
|
decreases expression
|
ISO
|
gedunin results in decreased expression of PDE9A mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr20:9,471,136...9,564,286
Ensembl chr20:9,471,167...9,564,286
|
|
G
|
Pik3cd
|
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
|
decreases expression
|
ISO
|
gedunin results in decreased expression of PIK3CD mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 5:165,377,994...165,426,620
Ensembl chr 5:165,377,994...165,403,968
|
|
G
|
Pik3r1
|
phosphoinositide-3-kinase regulatory subunit 1
|
decreases expression
|
ISO
|
gedunin results in decreased expression of PIK3R1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:34,612,946...34,626,347
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
multiple interactions
|
ISO
|
[gedunin co-treated with Glucose] binds to PPARA protein; gedunin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]
|
CTD |
PMID:18812576 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
G
|
Ppif
|
peptidylprolyl isomerase F
|
decreases expression
|
ISO
|
gedunin results in decreased expression of PPIF mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr16:1,264,001...1,270,722
Ensembl chr16:1,263,541...1,316,954
|
|
G
|
Pura
|
purine rich element binding protein A
|
decreases expression
|
ISO
|
gedunin results in decreased expression of PURA mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr18:28,159,103...28,179,539
Ensembl chr18:28,125,126...28,211,111
|
|
G
|
Rrm2
|
ribonucleotide reductase regulatory subunit M2
|
decreases expression
|
ISO
|
gedunin results in decreased expression of RRM2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370
|
|
G
|
Serp1
|
stress-associated endoplasmic reticulum protein 1
|
increases expression
|
ISO
|
gedunin results in increased expression of SERP1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 2:144,907,204...144,911,187
Ensembl chr 2:144,907,205...144,911,187
|
|
G
|
Sesn1
|
sestrin 1
|
decreases expression
|
ISO
|
gedunin results in decreased expression of SESN1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr20:46,876,918...46,970,010
Ensembl chr20:46,876,895...46,970,010
|
|
G
|
Slc3a2
|
solute carrier family 3 member 2
|
increases expression
|
ISO
|
gedunin results in increased expression of SLC3A2 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 1:215,033,601...215,048,064
Ensembl chr 1:215,033,601...215,048,064
|
|
G
|
Slc7a11
|
solute carrier family 7 member 11
|
increases expression
|
ISO
|
gedunin results in increased expression of SLC7A11 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695
|
|
G
|
Sltm
|
SAFB-like, transcription modulator
|
decreases expression
|
ISO
|
gedunin results in decreased expression of SLTM mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 8:80,096,555...80,142,668
Ensembl chr 8:80,097,652...80,142,671
|
|
G
|
Sox4
|
SRY-box transcription factor 4
|
decreases expression
|
ISO
|
gedunin results in decreased expression of SOX4 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr17:35,876,298...35,881,004
Ensembl chr17:35,875,756...35,884,024
|
|
G
|
Stip1
|
stress-induced phosphoprotein 1
|
increases expression
|
ISO
|
gedunin results in increased expression of STIP1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 1:213,638,641...213,657,654
Ensembl chr 1:213,638,641...213,657,654
|
|
G
|
Taok3
|
TAO kinase 3
|
decreases expression
|
ISO
|
gedunin results in decreased expression of TAOK3 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr12:44,973,180...45,134,439
Ensembl chr12:44,973,180...45,134,439
|
|
G
|
Txnip
|
thioredoxin interacting protein
|
decreases expression
|
ISO
|
gedunin results in decreased expression of TXNIP mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:186,781,163...186,785,731
|
|
G
|
Txnrd1
|
thioredoxin reductase 1
|
increases expression
|
ISO
|
gedunin results in increased expression of TXNRD1 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817
|
|
G
|
Ube2b
|
ubiquitin-conjugating enzyme E2B
|
increases expression
|
ISO
|
gedunin results in increased expression of UBE2B mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr10:36,749,365...36,764,335
Ensembl chr10:36,749,369...36,765,587
|
|
G
|
Ugdh
|
UDP-glucose 6-dehydrogenase
|
increases expression
|
ISO
|
gedunin results in increased expression of UGDH mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr14:43,202,480...43,226,002
Ensembl chr14:43,202,356...43,226,629
|
|
G
|
Wdr77
|
WD repeat domain 77
|
decreases expression
|
ISO
|
gedunin results in decreased expression of WDR77 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 2:196,123,882...196,133,853
Ensembl chr 2:196,123,848...196,134,567
|
|
G
|
Zbtb43
|
zinc finger and BTB domain containing 43
|
decreases expression
|
ISO
|
gedunin results in decreased expression of ZBTB43 mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 3:37,142,210...37,161,524
Ensembl chr 3:37,141,354...37,162,238
|
|
G
|
Zc3h12a
|
zinc finger CCCH type containing 12A
|
decreases expression
|
ISO
|
gedunin results in decreased expression of ZC3H12A mRNA
|
CTD |
PMID:17010675 |
|
NCBI chr 5:142,661,193...142,670,051
Ensembl chr 5:142,661,199...142,669,985
|
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
ISO
|
glutinol inhibits the reaction [Ethanol results in decreased phosphorylation of AKT protein]
|
CTD |
PMID:37939858 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
ISO
|
glutinol inhibits the reaction [Ethanol results in increased expression of CASP3 protein]
|
CTD |
PMID:37939858 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions
|
ISO
|
glutinol inhibits the reaction [Ethanol results in increased expression of PARP1 protein]
|
CTD |
PMID:37939858 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO
|
glutinol inhibits the reaction [Ethanol results in increased expression of TNF protein]
|
CTD |
PMID:37939858 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
|
G
|
Abcb11
|
ATP binding cassette subfamily B member 11
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; [Glycyrrhetinic Acid affects the activity of ABCB1 protein] which affects the susceptibility to Vinblastine; [Glycyrrhetinic Acid affects the activity of ABCB1 protein] which results in increased abundance of Daunorubicin; Glycyrrhetinic Acid inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; Glycyrrhetinic Acid inhibits the reaction [Verapamil results in increased activity of ABCB1 protein]
|
CTD |
PMID:16904803 PMID:18204840 PMID:24380838 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Abcb4
|
ATP binding cassette subfamily B member 4
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB4 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 4:26,106,895...26,164,440
|
|
G
|
Abcc1
|
ATP binding cassette subfamily C member 1
|
multiple interactions increases activity
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC1 mRNA] Glycyrrhetinic Acid results in increased activity of ABCC1 protein [Glycyrrhetinic Acid affects the activity of ABCC1 protein] which affects the susceptibility to Doxorubicin; [Glycyrrhetinic Acid affects the activity of ABCC1 protein] which results in increased abundance of fluorexon
|
CTD |
PMID:18204840 PMID:28549656 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404
|
|
G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
multiple interactions
|
EXP
|
Glycyrrhetinic Acid inhibits the reaction [ABCC2 protein results in increased transport of estradiol-17 beta-glucuronide]
|
CTD |
PMID:18436619 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471
|
|
G
|
Abcc3
|
ATP binding cassette subfamily C member 3
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ABCC3 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494
|
|
G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [ABCG2 protein results in increased transport of estradiol-17 beta-glucuronide]
|
CTD |
PMID:18436619 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493
|
|
G
|
Abcg5
|
ATP binding cassette subfamily G member 5
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCG5 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 6:15,717,936...15,743,376
Ensembl chr 6:15,717,936...15,743,376
|
|
G
|
Acat2
|
acetyl-CoA acetyltransferase 2
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ACAT2 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 1:50,100,840...50,118,886
Ensembl chr 1:50,100,817...50,135,095
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
multiple interactions
|
EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [Monocrotaline results in increased expression of ACTA2 protein]
|
CTD |
PMID:31325423 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Akr1c1
|
aldo-keto reductase family 1, member C1
|
decreases activity
|
ISO
|
Glycyrrhetinic Acid results in decreased activity of AKR1C1 protein
|
CTD |
PMID:12604236 |
|
NCBI chr17:70,720,397...70,747,285
Ensembl chr17:70,720,398...70,747,247
|
|
G
|
Akr1c2
|
aldo-keto reductase family 1, member C2
|
decreases activity
|
ISO
|
Glycyrrhetinic Acid results in decreased activity of AKR1C2 protein
|
CTD |
PMID:12604236 |
|
NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686
|
|
G
|
Akr1c3
|
aldo-keto reductase family 1, member C3
|
affects activity decreases activity
|
ISO
|
18alpha-glycyrrhetinic acid affects the activity of AKR1C3 protein Glycyrrhetinic Acid results in decreased activity of AKR1C3 protein
|
CTD |
PMID:11165023 PMID:12604236 |
|
NCBI chr17:71,020,884...71,037,779
Ensembl chr17:70,970,900...71,048,438
|
|
G
|
Alb
|
albumin
|
multiple interactions
|
ISO
|
ALB protein binds to and affects the transport of Glycyrrhetinic Acid
|
CTD |
PMID:8831264 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
G
|
Alpl
|
alkaline phosphatase, biomineralization associated
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Ethinyl Estradiol results in increased expression of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]
|
CTD |
PMID:21910061 PMID:38244730 |
|
NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167
|
|
G
|
Atf6
|
activating transcription factor 6
|
multiple interactions
|
EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of ATF6 mRNA]
|
CTD |
PMID:35699857 |
|
NCBI chr13:85,460,312...85,639,959
Ensembl chr13:85,462,840...85,640,033
|
|
G
|
Atp8b1
|
ATPase phospholipid transporting 8B1
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ATP8B1 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr18:60,286,605...60,427,862
Ensembl chr18:60,288,464...60,427,027
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions decreases expression
|
EXP ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of BAX]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of BAX protein]; Glycyrrhetinic Acid promotes the reaction [bisphenol A results in increased expression of BAX protein] Glycyrrhetinic Acid results in decreased expression of BAX protein 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in decreased expression of BAX protein]
|
CTD |
PMID:28414158 PMID:31325423 PMID:35699857 PMID:38348715 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions decreases expression
|
EXP ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in decreased expression of BCL2]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein]; Glycyrrhetinic Acid inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein] Glycyrrhetinic Acid results in decreased expression of BCL2 protein 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of BCL2 protein]
|
CTD |
PMID:28414158 PMID:31325423 PMID:35699857 PMID:38348715 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bglap
|
bone gamma-carboxyglutamate protein
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA]
|
CTD |
PMID:21910061 |
|
NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318
|
|
G
|
Bmp2
|
bone morphogenetic protein 2
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA]
|
CTD |
PMID:21910061 |
|
NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:141,264,646...141,274,760
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of CASP3]
|
CTD |
PMID:35699857 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
ISO EXP
|
Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of CAT mRNA] Glycyrrhetinic Acid inhibits the reaction [bisphenol A results in decreased activity of CAT protein]
|
CTD |
PMID:23341968 PMID:38348715 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Cdkn1b
|
cyclin-dependent kinase inhibitor 1B
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in decreased expression of CDKN1B protein]
|
CTD |
PMID:31325423 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA]
|
CTD |
PMID:21910061 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
G
|
Csf2
|
colony stimulating factor 2
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]
|
CTD |
PMID:10460758 |
|
NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031
|
|
G
|
Cxcr3
|
C-X-C motif chemokine receptor 3
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [Ethinyl Estradiol results in increased expression of CXCR3 mRNA]
|
CTD |
PMID:38244730 |
|
NCBI chr X:70,884,293...70,886,944
Ensembl chr X:70,883,958...70,886,871
|
|
G
|
Cycs
|
cytochrome c, somatic
|
multiple interactions decreases expression
|
EXP
|
Glycyrrhetinic Acid inhibits the reaction [bisphenol A results in increased expression of CYCS protein] Glycyrrhetinic Acid results in decreased expression of CYCS protein
|
CTD |
PMID:38348715 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816 Ensembl chr18:80,982,668...80,984,816
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
multiple interactions
|
EXP
|
[brucine co-treated with Glycyrrhetinic Acid] results in decreased activity of CYP1A2 protein
|
CTD |
PMID:21800547 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
multiple interactions
|
EXP
|
[brucine co-treated with Glycyrrhetinic Acid] results in decreased activity of CYP2E1 protein
|
CTD |
PMID:21800547 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495
|
|
G
|
Cyp7a1
|
cytochrome P450 family 7 subfamily A member 1
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP7A1 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202
|
|
G
|
Eif2ak3
|
eukaryotic translation initiation factor 2 alpha kinase 3
|
multiple interactions
|
EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of EIF2AK3 mRNA]
|
CTD |
PMID:35699857 |
|
NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:104,363,833...104,425,268
|
|
G
|
Ern1
|
endoplasmic reticulum to nucleus signaling 1
|
multiple interactions
|
ISO EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of ERN1 protein] 18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of ERN1 mRNA]
|
CTD |
PMID:29444456 PMID:35699857 |
|
NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791
|
|
G
|
Ggt1
|
gamma-glutamyltransferase 1
|
multiple interactions
|
EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased activity of GGT1 protein]
|
CTD |
PMID:28414158 |
|
NCBI chr20:13,074,141...13,103,551
Ensembl chr20:13,074,141...13,088,050
|
|
G
|
Got1
|
glutamic-oxaloacetic transaminase 1
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [Ethinyl Estradiol results in increased expression of GOT1 protein]
|
CTD |
PMID:38244730 |
|
NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
multiple interactions
|
EXP ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased activity of GPT protein] 18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [Ethinyl Estradiol results in increased expression of GPT protein]; Glycyrrhetinic Acid inhibits the reaction [diosbulbin B results in increased activity of GPT protein]
|
CTD |
PMID:28414158 PMID:28549656 PMID:36807597 PMID:38244730 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
G
|
Gpx2
|
glutathione peroxidase 2
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of GPX2 mRNA]
|
CTD |
PMID:23341968 |
|
NCBI chr 6:101,226,745...101,230,033
Ensembl chr 6:101,226,745...101,230,862
|
|
G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions
|
EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of HMOX1 mRNA]
|
CTD |
PMID:28414158 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Hras
|
HRas proto-oncogene, GTPase
|
decreases expression
|
ISO
|
Glycyrrhetinic Acid results in decreased expression of HRAS protein
|
CTD |
PMID:19958823 |
|
NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:205,725,975...205,729,590
|
|
G
|
Hsd11b1
|
hydroxysteroid 11-beta dehydrogenase 1
|
decreases activity
|
ISO
|
18alpha-glycyrrhetinic acid results in decreased activity of HSD11B1 protein
|
CTD |
PMID:24135201 |
|
NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432
|
|
G
|
Hsd11b2
|
hydroxysteroid 11-beta dehydrogenase 2
|
decreases activity multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid results in decreased activity of HSD11B2 protein Glycyrrhetinic Acid inhibits the reaction [tributyltin results in increased activity of HSD11B2 protein]; Glycyrrhetinic Acid inhibits the reaction [triphenyltin chloride results in increased activity of HSD11B2 protein]
|
CTD |
PMID:24135201 PMID:31927052 |
|
NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812
|
|
G
|
Hsd3b1
|
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1
|
multiple interactions
|
ISO
|
[Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein
|
CTD |
PMID:25526675 |
|
NCBI chr 2:188,858,574...188,864,694
|
|
G
|
Hspa5
|
heat shock protein family A (Hsp70) member 5
|
multiple interactions
|
EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of HSPA5 mRNA]
|
CTD |
PMID:35699857 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
ISO EXP
|
Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]] Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B mRNA] 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of IL1B protein]
|
CTD |
PMID:10460758 PMID:23373965 PMID:28414158 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA]
|
CTD |
PMID:21644799 PMID:23373965 PMID:24849676 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Irak1
|
interleukin-1 receptor-associated kinase 1
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]]
|
CTD |
PMID:28213090 |
|
NCBI chr X:156,919,927...156,929,825
Ensembl chr X:156,920,081...156,929,825
|
|
G
|
Irak3
|
interleukin-1 receptor-associated kinase 3
|
multiple interactions increases expression
|
ISO
|
[Glycyrrhetinic Acid co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IRAK3 mRNA; IRAK3 protein promotes the reaction [Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]] Glycyrrhetinic Acid results in increased expression of IRAK3 protein
|
CTD |
PMID:28213090 |
|
NCBI chr 7:57,538,522...57,600,166
Ensembl chr 7:57,539,557...57,598,706
|
|
G
|
Ly96
|
lymphocyte antigen 96
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [TLR4 protein binds to LY96 protein]]
|
CTD |
PMID:28213090 |
|
NCBI chr 5:7,365,536...7,397,864
Ensembl chr 5:7,365,557...7,395,816
|
|
G
|
Map3k5
|
mitogen-activated protein kinase kinase kinase 5
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of MAP3K5 protein]
|
CTD |
PMID:29444456 |
|
NCBI chr 1:16,505,387...16,723,899
Ensembl chr 1:16,505,596...16,723,898
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:23373965 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:23373965 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]
|
CTD |
PMID:24613819 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [diosbulbin B results in increased activity of MPO protein]
|
CTD |
PMID:36807597 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Mttp
|
microsomal triglyceride transfer protein
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of MTTP mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 2:229,286,501...229,327,650
Ensembl chr 2:229,286,501...229,327,650
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions increases expression
|
ISO EXP
|
[Glycyrrhetinic Acid results in increased expression of NFE2L2] which results in decreased susceptibility to Carbon Tetrachloride; Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride affects the localization of NFE2L2 protein] 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 protein]
|
CTD |
PMID:23341968 PMID:28414158 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of NFKB1 protein]
|
CTD |
PMID:24613819 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein] Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of NFKBIA protein]
|
CTD |
PMID:23373965 PMID:24613819 PMID:28213090 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]
|
CTD |
PMID:21644799 PMID:23373965 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Npc1l1
|
NPC1 like intracellular cholesterol transporter 1
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of NPC1L1 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr14:85,285,387...85,305,050
Ensembl chr14:85,285,390...85,305,050
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
multiple interactions
|
EXP
|
glycyrrhetinic acid inhibits the reaction [1-naphthyl isothiocyanate decreases expression of Nr1h4 mRNA in liver]
|
RGD |
PMID:30061734 |
RGD:15092071 |
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389
|
|
G
|
Pdgfb
|
platelet derived growth factor subunit B
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in decreased expression of BAX protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in decreased expression of CDKN1B protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of BCL2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RHOA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RHOA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK1 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of PPP1R12A protein]
|
CTD |
PMID:31325423 |
|
NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:113,420,710...113,438,343
|
|
G
|
Pik3cd
|
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
|
decreases activity
|
ISO
|
18alpha-glycyrrhetinic acid results in decreased activity of PIK3CD protein
|
CTD |
PMID:21644799 |
|
NCBI chr 5:165,377,994...165,426,620
Ensembl chr 5:165,377,994...165,403,968
|
|
G
|
Pik3cg
|
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma
|
decreases activity
|
ISO
|
18alpha-glycyrrhetinic acid results in decreased activity of PIK3CG protein
|
CTD |
PMID:21644799 |
|
NCBI chr 6:54,494,247...54,529,563
Ensembl chr 6:54,478,603...54,529,509
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
multiple interactions
|
EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of PPARG mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of PPARG protein]
|
CTD |
PMID:28414158 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
G
|
Ppp1r12a
|
protein phosphatase 1, regulatory subunit 12A
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of PPP1R12A protein]
|
CTD |
PMID:31325423 |
|
NCBI chr 7:45,368,922...45,480,158
Ensembl chr 7:45,369,315...45,480,157
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein]
|
CTD |
PMID:21644799 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of RELA protein] Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein]
|
CTD |
PMID:23373965 PMID:24613819 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Ren
|
renin
|
decreases activity
|
ISO
|
Glycyrrhetinic Acid results in decreased activity of REN protein
|
CTD |
PMID:20460744 |
|
NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543
|
|
G
|
Rhoa
|
ras homolog family member A
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RHOA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RHOA protein]
|
CTD |
PMID:31325423 |
|
NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:117,870,270...117,904,302
|
|
G
|
Rock1
|
Rho-associated coiled-coil containing protein kinase 1
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK1 protein]
|
CTD |
PMID:31325423 |
|
NCBI chr18:1,387,360...1,509,218
Ensembl chr18:1,387,360...1,509,147
|
|
G
|
Rock2
|
Rho-associated coiled-coil containing protein kinase 2
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK2 protein]
|
CTD |
PMID:31325423 |
|
NCBI chr 6:45,407,823...45,502,773
Ensembl chr 6:45,407,965...45,502,771
|
|
G
|
Rorc
|
RAR-related orphan receptor C
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [Ethinyl Estradiol results in increased expression of RORC mRNA]
|
CTD |
PMID:38244730 |
|
NCBI chr 2:184,698,779...184,723,942
Ensembl chr 2:184,698,818...184,724,566
|
|
G
|
Runx2
|
RUNX family transcription factor 2
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA]
|
CTD |
PMID:21910061 |
|
NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027
|
|
G
|
Slc51b
|
SLC51 subunit beta
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLC51B mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 8:74,827,047...74,835,109
Ensembl chr 8:74,827,047...74,835,109
|
|
G
|
Slco1a4
|
solute carrier organic anion transporter family, member 1a4
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLCO1A4 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 4:176,441,104...176,495,846
Ensembl chr 4:176,441,104...176,495,816
|
|
G
|
Sod3
|
superoxide dismutase 3
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of SOD3 mRNA]
|
CTD |
PMID:23341968 |
|
NCBI chr14:62,822,865...62,828,602
Ensembl chr14:62,811,177...62,829,125
|
|
G
|
Sp7
|
Sp7 transcription factor
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA]
|
CTD |
PMID:21910061 |
|
NCBI chr 7:135,363,193...135,373,376
Ensembl chr 7:135,363,199...135,373,559
|
|
G
|
Tlr4
|
toll-like receptor 4
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [TLR4 protein binds to LY96 protein]]
|
CTD |
PMID:28213090 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; IRAK3 protein promotes the reaction [Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]] 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of TNF protein] 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of NFKB1 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of RELA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of VEGFA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
|
CTD |
PMID:21644799 PMID:24613819 PMID:28213090 PMID:28414158 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tp53
|
tumor protein p53
|
decreases expression
|
EXP
|
Glycyrrhetinic Acid results in decreased expression of TP53 protein
|
CTD |
PMID:38348715 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Traf6
|
TNF receptor associated factor 6
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]]
|
CTD |
PMID:28213090 |
|
NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:108,418,513...108,443,328
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of VEGFA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]
|
CTD |
PMID:24613819 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
G
|
Xbp1
|
X-box binding protein 1
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of XBP1 protein alternative form]
|
CTD |
PMID:29444456 |
|
NCBI chr14:84,604,623...84,609,707
Ensembl chr14:84,604,107...84,609,706
|
|
|
G
|
Abcb11
|
ATP binding cassette subfamily B member 11
|
multiple interactions decreases activity
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Glycyrrhizic Acid results in decreased activity of ABCB11 protein
|
CTD |
PMID:24014644 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
increases expression
|
EXP
|
Glycyrrhizic Acid results in increased expression of ABCB1A mRNA; Glycyrrhizic Acid results in increased expression of ABCB1A protein
|
CTD |
PMID:38448046 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Abcb1b
|
ATP-binding cassette, sub-family B member 1B
|
increases expression
|
EXP
|
Glycyrrhizic Acid results in increased expression of ABCB1B mRNA; Glycyrrhizic Acid results in increased expression of ABCB1B protein
|
CTD |
PMID:38448046 |
|
NCBI chr 4:26,197,706...26,280,156
Ensembl chr 4:26,106,903...26,279,567
|
|
G
|
Abcc3
|
ATP binding cassette subfamily C member 3
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ABCC3 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494
|
|
G
|
Acaca
|
acetyl-CoA carboxylase alpha
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of ACACA mRNA]
|
CTD |
PMID:31918260 |
|
NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888
|
|
G
|
Acat2
|
acetyl-CoA acetyltransferase 2
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ACAT2 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 1:50,100,840...50,118,886
Ensembl chr 1:50,100,817...50,135,095
|
|
G
|
Ache
|
acetylcholinesterase
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Fusaric Acid results in decreased expression of ACHE protein]
|
CTD |
PMID:31150628 |
|
NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
decreases expression multiple interactions
|
ISO EXP
|
Glycyrrhizic Acid results in decreased expression of ACTA2 protein Glycyrrhizic Acid inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 mRNA]; Glycyrrhizic Acid inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein] Glycyrrhizic Acid inhibits the reaction [Sodium Nitrite results in increased expression of ACTA2 protein]; Glycyrrhizic Acid inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]
|
CTD |
PMID:33030083 PMID:33522686 PMID:39800143 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased phosphorylation of AKT1 protein]
|
CTD |
PMID:32525084 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Alb
|
albumin
|
multiple interactions
|
ISO EXP
|
ALB protein binds to and affects the transport of Glycyrrhizic Acid Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased expression of and results in increased secretion of ALB protein]
|
CTD |
PMID:8831264 PMID:19558898 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
G
|
Aqp2
|
aquaporin 2
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Gentamicins results in decreased expression of AQP2 protein]
|
CTD |
PMID:12969435 |
|
NCBI chr 7:132,590,286...132,595,321
Ensembl chr 7:132,590,225...132,595,319
|
|
G
|
Aqp5
|
aquaporin 5
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [Histamine results in decreased expression of AQP5 protein]
|
CTD |
PMID:29452068 |
|
NCBI chr 7:132,601,528...132,605,060
Ensembl chr 7:132,601,059...132,605,062
|
|
G
|
Ar
|
androgen receptor
|
multiple interactions affects localization
|
ISO
|
Glycyrrhizic Acid binds to and results in increased activity of AR protein Glycyrrhizic Acid affects the localization of AR protein
|
CTD |
PMID:28478275 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467
|
|
G
|
Bad
|
BCL2-associated agonist of cell death
|
increases expression
|
ISO
|
Glycyrrhizic Acid results in increased expression of BAD mRNA
|
CTD |
PMID:35844403 |
|
NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression
|
ISO
|
Glycyrrhizic Acid results in increased expression of BAX mRNA
|
CTD |
PMID:35844403 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression multiple interactions
|
ISO
|
Glycyrrhizic Acid results in decreased expression of BCL2 mRNA [Glycyrrhizic Acid co-treated with Cisplatin] results in decreased expression of BCL2 mRNA
|
CTD |
PMID:35844403 PMID:37659683 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bdnf
|
brain-derived neurotrophic factor
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Fusaric Acid results in decreased expression of BDNF protein]
|
CTD |
PMID:31150628 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657
|
|
G
|
Casp2
|
caspase 2
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in increased activity of CASP2 protein]
|
CTD |
PMID:22051199 |
|
NCBI chr 4:72,116,265...72,134,023
Ensembl chr 4:72,116,246...72,134,022
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions increases activity
|
EXP ISO
|
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in increased activity of CASP3 protein]; Glycyrrhizic Acid inhibits the reaction [Fusaric Acid results in decreased expression of CASP3 protein] [Glycyrrhizic Acid co-treated with Cisplatin] results in increased expression of CASP3 mRNA Glycyrrhizic Acid results in increased activity of CASP3 protein
|
CTD |
PMID:22051199 PMID:31150628 PMID:35844403 PMID:37659683 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp6
|
caspase 6
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in increased activity of CASP6 protein]
|
CTD |
PMID:22051199 |
|
NCBI chr 2:221,140,287...221,152,727
Ensembl chr 2:221,140,256...221,152,726
|
|
G
|
Casp8
|
caspase 8
|
multiple interactions increases activity
|
EXP ISO
|
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in increased activity of CASP8 protein] [Glycyrrhizic Acid co-treated with Cisplatin] results in increased expression of CASP8 mRNA Glycyrrhizic Acid results in increased activity of CASP8 protein
|
CTD |
PMID:22051199 PMID:35844403 PMID:37659683 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
multiple interactions increases activity
|
EXP ISO
|
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in increased activity of CASP9 protein] [Glycyrrhizic Acid co-treated with Cisplatin] results in increased expression of CASP9 mRNA Glycyrrhizic Acid results in increased activity of CASP9 protein
|
CTD |
PMID:22051199 PMID:35844403 PMID:37659683 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Ccl2
|
C-C motif chemokine ligand 2
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [Cyclosporine results in increased expression of CCL2 mRNA]
|
CTD |
PMID:27585667 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
G
|
Ccn2
|
cellular communication network factor 2
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased expression of and results in increased secretion of CCN2 protein]; Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased expression of CCN2 mRNA]; Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased expression of CCN2 protein]
|
CTD |
PMID:19558898 |
|
NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976
|
|
G
|
Ccnd1
|
cyclin D1
|
decreases expression
|
ISO
|
Glycyrrhizic Acid results in decreased expression of CCND1 mRNA
|
CTD |
PMID:35844403 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Cd68
|
Cd68 molecule
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Sodium Nitrite results in increased expression of CD68 protein]
|
CTD |
PMID:33030083 |
|
NCBI chr10:54,880,562...54,882,441
Ensembl chr10:54,880,563...54,882,540
|
|
G
|
Cdh1
|
cadherin 1
|
increases expression multiple interactions
|
ISO
|
Glycyrrhizic Acid results in increased expression of CDH1 protein Glycyrrhizic Acid inhibits the reaction [Silicon Dioxide results in decreased expression of CDH1 mRNA]
|
CTD |
PMID:33522686 PMID:39800143 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565
|
|
G
|
Cdh2
|
cadherin 2
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [Silicon Dioxide results in increased expression of CDH2 protein]
|
CTD |
PMID:39800143 |
|
NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288
|
|
G
|
Cdk4
|
cyclin-dependent kinase 4
|
decreases expression
|
ISO
|
Glycyrrhizic Acid results in decreased expression of CDK4 mRNA
|
CTD |
PMID:35844403 |
|
NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression
|
ISO
|
Glycyrrhizic Acid results in increased expression of CDKN1A mRNA
|
CTD |
PMID:35844403 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Cebpa
|
CCAAT/enhancer binding protein alpha
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA]
|
CTD |
PMID:34302803 |
|
NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309
|
|
G
|
Cebpb
|
CCAAT/enhancer binding protein beta
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPB mRNA]
|
CTD |
PMID:34302803 |
|
NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072
|
|
G
|
Cebpd
|
CCAAT/enhancer binding protein delta
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPD mRNA]
|
CTD |
PMID:34302803 |
|
NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824
|
|
G
|
Col4a1
|
collagen type IV alpha 1 chain
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased expression of and results in increased secretion of COL4A1 protein]; Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased expression of COL4A1 protein]
|
CTD |
PMID:19558898 |
|
NCBI chr16:84,885,597...84,996,482
Ensembl chr16:84,885,597...84,996,482
|
|
G
|
Cpt1a
|
carnitine palmitoyltransferase 1A
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of CPT1A mRNA]
|
CTD |
PMID:31918260 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326
|
|
G
|
Creb1
|
cAMP responsive element binding protein 1
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [Histamine results in decreased phosphorylation of CREB1 protein]
|
CTD |
PMID:29452068 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339
|
|
G
|
Ctnnb1
|
catenin beta 1
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [Silicon Dioxide results in increased expression of CTNNB1 protein]
|
CTD |
PMID:39800143 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662
|
|
G
|
Cyp11b3
|
cytochrome P450, family 11, subfamily b, polypeptide 3
|
decreases expression
|
EXP
|
Glycyrrhizic Acid results in decreased expression of CYP11B2 mRNA
|
CTD |
PMID:10474021 PMID:11798659 |
|
NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:108,689,165...108,694,921
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
multiple interactions increases expression
|
ISO EXP
|
NR1I2 protein affects the reaction [Glycyrrhizic Acid results in increased expression of CYP3A4 mRNA] Glycyrrhizic Acid results in increased expression of CYP3A2 mRNA; Glycyrrhizic Acid results in increased expression of CYP3A2 protein Glycyrrhizic Acid results in increased expression of CYP3A4 mRNA; Glycyrrhizic Acid results in increased expression of CYP3A4 protein
|
CTD |
PMID:22982774 PMID:38448046 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Cyp3a23-3a1
|
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1
|
increases expression
|
EXP
|
Glycyrrhizic Acid results in increased expression of CYP3A23-3A1 mRNA; Glycyrrhizic Acid results in increased expression of CYP3A23-3A1 protein
|
CTD |
PMID:38448046 |
|
NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813
|
|
G
|
Cyp7a1
|
cytochrome P450 family 7 subfamily A member 1
|
decreases expression multiple interactions
|
ISO
|
Glycyrrhizic Acid results in decreased expression of CYP7A1 mRNA Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP7A1 mRNA]
|
CTD |
PMID:22982774 PMID:28549656 |
|
NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202
|
|
G
|
Ephx2
|
epoxide hydrolase 2
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in decreased activity of EPHX2 protein]
|
CTD |
PMID:22051199 |
|
NCBI chr15:44,465,447...44,503,157
Ensembl chr15:44,465,448...44,503,160
|
|
G
|
Fabp4
|
fatty acid binding protein 4
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]
|
CTD |
PMID:34302803 |
|
NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972
|
|
G
|
Fn1
|
fibronectin 1
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased expression of and results in increased secretion of FN1 protein]
|
CTD |
PMID:19558898 |
|
NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137
|
|
G
|
Got1
|
glutamic-oxaloacetic transaminase 1
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased secretion of GOT1 protein]
|
CTD |
PMID:31918260 |
|
NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
multiple interactions
|
EXP ISO
|
Glycyrrhizic Acid inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with BCG Vaccine] results in increased activity of GPT protein]; Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased secretion of GPT protein] Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein]; Glycyrrhizic Acid inhibits the reaction [diosbulbin B results in increased activity of GPT protein]
|
CTD |
PMID:19196740 PMID:28549656 PMID:31918260 PMID:37794747 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
G
|
Hes1
|
hes family bHLH transcription factor 1
|
decreases expression
|
ISO
|
Glycyrrhizic Acid results in decreased expression of HES1 mRNA
|
CTD |
PMID:35844403 |
|
NCBI chr11:84,210,632...84,213,045
Ensembl chr11:84,210,633...84,213,061
|
|
G
|
Hmgb1
|
high mobility group box 1
|
decreases secretion multiple interactions decreases activity
|
ISO EXP
|
Glycyrrhizic Acid results in decreased secretion of HMGB1 protein Glycyrrhizic Acid inhibits the reaction [Silicon Dioxide results in increased expression of HMGB1 protein] Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased expression of HMGB1 protein] Glycyrrhizic Acid results in decreased activity of HMGB1 protein
|
CTD |
PMID:27585667 PMID:27689324 PMID:27783111 PMID:32525084 PMID:39800143 |
|
NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327 Ensembl chr12:39,039,050...39,041,327
|
|
G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 mRNA]; Glycyrrhizic Acid promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 protein]
|
CTD |
PMID:17917259 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Hsd11b2
|
hydroxysteroid 11-beta dehydrogenase 2
|
decreases expression
|
EXP
|
Glycyrrhizic Acid results in decreased expression of HSD11B2 mRNA
|
CTD |
PMID:10474021 PMID:11798659 |
|
NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812
|
|
G
|
Ifng
|
interferon gamma
|
affects expression
|
ISO
|
Glycyrrhizic Acid affects the expression of IFNG mRNA
|
CTD |
PMID:16945185 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
G
|
Il12a
|
interleukin 12A
|
multiple interactions
|
ISO
|
[Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of [IL12A protein binds to IL12B protein]; [Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of IL12A mRNA
|
CTD |
PMID:11412311 |
|
NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:155,275,625...155,282,997
|
|
G
|
Il12b
|
interleukin 12B
|
multiple interactions
|
ISO
|
[Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of [IL12A protein binds to IL12B protein]; [Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of IL12B mRNA; [Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of IL12B protein
|
CTD |
PMID:11412311 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Sodium Nitrite results in increased expression of IL1B protein]
|
CTD |
PMID:33030083 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
ISO EXP
|
Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein] Glycyrrhizic Acid inhibits the reaction [Histamine results in increased expression of IL6 mRNA]; Glycyrrhizic Acid inhibits the reaction [Histamine results in increased secretion of IL6 protein] Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased expression of IL6 mRNA]; Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased expression of IL6 protein]
|
CTD |
PMID:21644799 PMID:26524701 PMID:29452068 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Ins1
|
insulin 1
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPB mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPD mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of LPL mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of SCD1 mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of SLC2A4 mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased phosphorylation of MAPK1 protein]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:34302803 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682
|
|
G
|
Jag1
|
jagged canonical Notch ligand 1
|
decreases expression
|
ISO
|
Glycyrrhizic Acid results in decreased expression of JAG1 mRNA
|
CTD |
PMID:35844403 |
|
NCBI chr 3:144,859,453...144,894,883
Ensembl chr 3:144,859,453...144,894,872
|
|
G
|
Lpl
|
lipoprotein lipase
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of LPL mRNA]
|
CTD |
PMID:34302803 |
|
NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107
|
|
G
|
Map1lc3b
|
microtubule-associated protein 1 light chain 3 beta
|
multiple interactions
|
EXP
|
[Glycyrrhizic Acid co-treated with bafilomycin A1] results in increased lipidation of MAP1LC3B protein; Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased lipidation of MAP1LC3B protein]
|
CTD |
PMID:32525084 |
|
NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358 Ensembl chr16:66,574,407...66,584,358
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:34302803 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:34302803 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [Picryl Chloride results in increased secretion of MMP2 protein] [Glycyrrhizic Acid co-treated with Cisplatin] results in decreased expression of MMP2 mRNA
|
CTD |
PMID:16945185 PMID:37659683 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions
|
ISO
|
[Glycyrrhizic Acid co-treated with Cisplatin] results in decreased expression of MMP9 mRNA
|
CTD |
PMID:37659683 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [diosbulbin B results in increased activity of MPO protein]
|
CTD |
PMID:37794747 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Mtor
|
mechanistic target of rapamycin kinase
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased phosphorylation of MTOR protein]
|
CTD |
PMID:32525084 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435
|
|
G
|
Mttp
|
microsomal triglyceride transfer protein
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of MTTP mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 2:229,286,501...229,327,650
Ensembl chr 2:229,286,501...229,327,650
|
|
G
|
Muc5ac
|
mucin 5AC, oligomeric mucus/gel-forming
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [Histamine results in increased expression of MUC5AC mRNA]; Glycyrrhizic Acid inhibits the reaction [Histamine results in increased secretion of MUC5AC protein]
|
CTD |
PMID:29452068 |
|
NCBI chr 1:206,293,717...206,326,006
Ensembl chr 1:206,293,869...206,326,006
|
|
G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
multiple interactions
|
ISO
|
[Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased activity of [NFKB1 protein binds to RELA protein]
|
CTD |
PMID:11412311 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [Histamine results in increased phosphorylation of NFKBIA protein]
|
CTD |
PMID:29452068 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 mRNA]; Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]
|
CTD |
PMID:17917259 PMID:21644799 PMID:23373965 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Notch1
|
notch receptor 1
|
decreases expression
|
ISO
|
Glycyrrhizic Acid results in decreased expression of NOTCH1 mRNA
|
CTD |
PMID:35844403 |
|
NCBI chr 3:29,676,040...29,721,613
Ensembl chr 3:29,676,171...29,721,613
|
|
G
|
Npc1l1
|
NPC1 like intracellular cholesterol transporter 1
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of NPC1L1 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr14:85,285,387...85,305,050
Ensembl chr14:85,285,390...85,305,050
|
|
G
|
Nr0b2
|
nuclear receptor subfamily 0, group B, member 2
|
increases expression
|
ISO
|
Glycyrrhizic Acid results in increased expression of NR0B2 mRNA
|
CTD |
PMID:22982774 |
|
NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475
|
|
G
|
Nr1i2
|
nuclear receptor subfamily 1, group I, member 2
|
increases activity multiple interactions
|
ISO
|
Glycyrrhizic Acid results in increased activity of NR1I2 protein NR1I2 protein affects the reaction [Glycyrrhizic Acid results in increased expression of CYP3A4 mRNA]
|
CTD |
PMID:22982774 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380
|
|
G
|
Pik3cd
|
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
|
decreases activity
|
ISO
|
Glycyrrhizic Acid results in decreased activity of PIK3CD protein
|
CTD |
PMID:21644799 |
|
NCBI chr 5:165,377,994...165,426,620
Ensembl chr 5:165,377,994...165,403,968
|
|
G
|
Pik3cg
|
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma
|
decreases activity
|
ISO
|
Glycyrrhizic Acid results in decreased activity of PIK3CG protein
|
CTD |
PMID:21644799 |
|
NCBI chr 6:54,494,247...54,529,563
Ensembl chr 6:54,478,603...54,529,509
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of PPARA mRNA]
|
CTD |
PMID:31918260 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]
|
CTD |
PMID:34302803 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 mRNA]; Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein]
|
CTD |
PMID:17917259 PMID:21644799 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Rad21
|
RAD21 cohesin complex component
|
decreases binding
|
ISO
|
Glycyrrhizinic acid decreases binding of RAD21 protein to SMC3 protein in lymphoma cells
|
RGD |
PMID:21880767 |
RGD:243065267 |
NCBI chr 7:85,177,715...85,204,657
Ensembl chr 7:85,177,716...85,204,657
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
ISO EXP
|
[Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased activity of [NFKB1 protein binds to RELA protein] Glycyrrhizic Acid inhibits the reaction [Histamine results in increased phosphorylation of RELA protein] Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene affects the localization of RELA protein]; Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased phosphorylation of RELA protein]
|
CTD |
PMID:11412311 PMID:22051199 PMID:26524701 PMID:29452068 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Ren
|
renin
|
decreases activity
|
ISO
|
Glycyrrhizic Acid results in decreased activity of REN protein
|
CTD |
PMID:20460744 |
|
NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543
|
|
G
|
Scd
|
stearoyl-CoA desaturase
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of SCD1 mRNA]
|
CTD |
PMID:34302803 |
|
NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785
|
|
G
|
Sirt1
|
sirtuin 1
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]
|
CTD |
PMID:25162824 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000
|
|
G
|
Slc22a2
|
solute carrier family 22 member 2
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
|
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019
|
|
G
|
Slc2a4
|
solute carrier family 2 member 4
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of SLC2A4 mRNA]
|
CTD |
PMID:34302803 |
|
NCBI chr10:55,164,721...55,170,289
Ensembl chr10:55,164,721...55,170,270
|
|
G
|
Slc51b
|
SLC51 subunit beta
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLC51B mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 8:74,827,047...74,835,109
Ensembl chr 8:74,827,047...74,835,109
|
|
G
|
Slco1a4
|
solute carrier organic anion transporter family, member 1a4
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLCO1A4 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 4:176,441,104...176,495,846
Ensembl chr 4:176,441,104...176,495,816
|
|
G
|
Smad4
|
SMAD family member 4
|
decreases expression
|
ISO
|
Glycyrrhizic Acid results in decreased expression of SMAD4 protein
|
CTD |
PMID:33522686 |
|
NCBI chr18:69,518,988...69,549,684
Ensembl chr18:69,518,988...69,549,684
|
|
G
|
Smad7
|
SMAD family member 7
|
increases expression
|
ISO
|
Glycyrrhizic Acid results in increased expression of SMAD7 protein
|
CTD |
PMID:33522686 |
|
NCBI chr18:71,263,508...71,291,849
Ensembl chr18:71,263,508...71,291,849
|
|
G
|
Sod1
|
superoxide dismutase 1
|
increases activity
|
ISO
|
Glycyrrhizic Acid results in increased activity of SOD1 protein
|
CTD |
PMID:37659683 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
G
|
Sod2
|
superoxide dismutase 2
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Glucose results in decreased expression of SOD2 protein]
|
CTD |
PMID:25162824 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168
|
|
G
|
Sqstm1
|
sequestosome 1
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid affects the reaction [Doxorubicin results in increased expression of SQSTM1 protein]
|
CTD |
PMID:32525084 |
|
NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750
|
|
G
|
Srebf1
|
sterol regulatory element binding transcription factor 1
|
multiple interactions
|
EXP
|
Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of SREBF1 mRNA]
|
CTD |
PMID:31918260 |
|
NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
EXP ISO
|
Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased expression of and results in increased secretion of TGFB1 protein]; Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased expression of TGFB1 mRNA]; Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]; Glycyrrhizic Acid inhibits the reaction [Glucose results in increased expression of TGFB1 protein]; Glycyrrhizic Acid inhibits the reaction [Sodium Nitrite results in increased expression of TGFB1 protein]; Glycyrrhizic Acid inhibits the reaction [TGFB1 protein results in decreased expression of TJP1 protein]; Glycyrrhizic Acid inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] Glycyrrhizic Acid inhibits the reaction [Silicon Dioxide results in increased secretion of TGFB1 protein]
|
CTD |
PMID:19558898 PMID:25162824 PMID:33030083 PMID:39800143 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Tgfbr1
|
transforming growth factor, beta receptor 1
|
decreases expression
|
ISO
|
Glycyrrhizic Acid results in decreased expression of TGFBR1 protein
|
CTD |
PMID:33522686 |
|
NCBI chr 5:66,449,348...66,506,371
Ensembl chr 5:66,449,293...66,527,260
|
|
G
|
Tgfbr2
|
transforming growth factor, beta receptor 2
|
decreases expression
|
ISO
|
Glycyrrhizic Acid results in decreased expression of TGFBR2 protein
|
CTD |
PMID:33522686 |
|
NCBI chr 8:124,672,677...124,761,741
Ensembl chr 8:124,674,986...124,761,469
|
|
G
|
Tjp1
|
tight junction protein 1
|
multiple interactions
|
ISO EXP
|
Glycyrrhizic Acid inhibits the reaction [Glucose results in decreased expression of TJP1 protein]; Glycyrrhizic Acid inhibits the reaction [Palmitic Acid results in decreased expression of TJP1 protein]; Glycyrrhizic Acid inhibits the reaction [Silicon Dioxide results in decreased expression of TJP1 mRNA] Glycyrrhizic Acid inhibits the reaction [TGFB1 protein results in decreased expression of TJP1 protein]
|
CTD |
PMID:27689324 PMID:27783111 PMID:39800143 |
|
NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158
|
|
G
|
Tjp2
|
tight junction protein 2
|
multiple interactions
|
ISO
|
Glycyrrhizic Acid inhibits the reaction [Glucose results in decreased expression of TJP2 protein]; Glycyrrhizic Acid inhibits the reaction [Palmitic Acid results in decreased expression of TJP2 protein]
|
CTD |
PMID:27689324 PMID:27783111 |
|
NCBI chr 1:231,136,218...231,264,750
Ensembl chr 1:231,136,243...231,264,750
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO EXP
|
Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA]; Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein] Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased expression of TNF mRNA]; Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased expression of TNF protein]; Glycyrrhizic Acid inhibits the reaction [Sodium Nitrite results in increased expression of TNF protein]
|
CTD |
PMID:17917259 PMID:21644799 PMID:26524701 PMID:33030083 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tp53
|
tumor protein p53
|
increases expression
|
ISO
|
Glycyrrhizic Acid results in increased expression of TP53 mRNA
|
CTD |
PMID:35844403 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
|
G
|
Slco1b2
|
solute carrier organic anion transporter family member 1B2
|
decreases activity
|
ISO
|
cauloside A results in decreased activity of SLCO1B3 protein
|
CTD |
PMID:38761881 |
|
NCBI chr 4:176,282,577...176,355,557
Ensembl chr 4:176,282,584...176,351,083
|
|
|
G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
decreases expression
|
ISO
|
lupeol results in decreased expression of ABCG2 protein
|
CTD |
PMID:20979057 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
EXP ISO
|
lupeol inhibits the reaction [COL2A1 results in increased expression of AKT1 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lupeol inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased phosphorylation of AKT1 protein]]; lupeol inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased phosphorylation of AKT1 protein]
|
CTD |
PMID:35446470 PMID:39067743 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Alox5
|
arachidonate 5-lipoxygenase
|
multiple interactions
|
EXP
|
lupeol inhibits the reaction [COL2A1 results in increased activity of ALOX5 protein]
|
CTD |
PMID:35446470 |
|
NCBI chr 4:151,203,948...151,251,126
Ensembl chr 4:151,203,949...151,251,126
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions increases expression
|
ISO EXP
|
lupeol inhibits the reaction [mancozeb results in increased expression of BAX mRNA] lupeol inhibits the reaction [COL2A1 results in decreased expression of BAX protein] lupeol results in increased expression of BAX mRNA; lupeol results in increased expression of BAX protein
|
CTD |
PMID:27235710 PMID:30506710 PMID:31112703 PMID:35446470 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions decreases expression
|
ISO EXP
|
lupeol inhibits the reaction [mancozeb results in decreased expression of BCL2 mRNA] lupeol inhibits the reaction [COL2A1 results in increased expression of BCL2 protein] lupeol results in decreased expression of BCL2 mRNA; lupeol results in decreased expression of BCL2 protein
|
CTD |
PMID:27235710 PMID:30506710 PMID:31112703 PMID:35446470 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Becn1
|
beclin 1
|
multiple interactions
|
ISO
|
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lupeol inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased expression of BECN1 protein]]; lupeol inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased expression of BECN1 protein]
|
CTD |
PMID:39067743 |
|
NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002
|
|
G
|
Casp3
|
caspase 3
|
increases expression multiple interactions
|
ISO EXP
|
lupeol results in increased expression of CASP3 mRNA; lupeol results in increased expression of CASP3 protein lupeol inhibits the reaction [COL2A1 results in decreased expression of CASP3 protein]
|
CTD |
PMID:30506710 PMID:35446470 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
increases expression
|
ISO
|
lupeol results in increased expression of CASP8 mRNA; lupeol results in increased expression of CASP8 protein
|
CTD |
PMID:30506710 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
increases expression multiple interactions
|
ISO EXP
|
lupeol results in increased expression of CASP9 mRNA; lupeol results in increased expression of CASP9 protein lupeol inhibits the reaction [COL2A1 results in decreased expression of CASP9 protein]
|
CTD |
PMID:30506710 PMID:35446470 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
EXP ISO
|
lupeol inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein]; lupeol inhibits the reaction [Sodium Selenite results in decreased activity of CAT protein] lupeol inhibits the reaction [mancozeb results in decreased activity of CAT protein]
|
CTD |
PMID:16933029 PMID:26697995 PMID:27235710 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ccnd1
|
cyclin D1
|
decreases expression
|
ISO
|
lupeol results in decreased expression of CCND1 mRNA
|
CTD |
PMID:20732907 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Cdh1
|
cadherin 1
|
increases expression
|
ISO
|
lupeol results in increased expression of CDH1 mRNA; lupeol results in increased expression of CDH1 protein
|
CTD |
PMID:31112703 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
multiple interactions
|
ISO
|
lupeol inhibits the reaction [mancozeb results in increased expression of CDKN1A mRNA]
|
CTD |
PMID:27235710 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Cflar
|
CASP8 and FADD-like apoptosis regulator
|
decreases activity multiple interactions
|
ISO
|
lupeol results in decreased activity of CFLAR protein enzalutamide promotes the reaction [lupeol results in decreased activity of CFLAR protein]; lupeol promotes the reaction [enzalutamide results in decreased activity of CFLAR protein]
|
CTD |
PMID:37777120 |
|
NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434
|
|
G
|
Col2a1
|
collagen type II alpha 1 chain
|
multiple interactions
|
EXP
|
lupeol inhibits the reaction [COL2A1 protein results in increased secretion of Dinoprostone]; lupeol inhibits the reaction [COL2A1 protein results in increased secretion of IL6 protein]; lupeol inhibits the reaction [COL2A1 protein results in increased secretion of TNF protein]; lupeol inhibits the reaction [COL2A1 results in decreased expression of BAX protein]; lupeol inhibits the reaction [COL2A1 results in decreased expression of CASP3 protein]; lupeol inhibits the reaction [COL2A1 results in decreased expression of CASP9 protein]; lupeol inhibits the reaction [COL2A1 results in increased activity of ALOX5 protein]; lupeol inhibits the reaction [COL2A1 results in increased activity of MPO protein]; lupeol inhibits the reaction [COL2A1 results in increased activity of PTGS2 protein]; lupeol inhibits the reaction [COL2A1 results in increased expression of AKT1 protein]; lupeol inhibits the reaction [COL2A1 results in increased expression of BCL2 protein]; lupeol inhibits the reaction [COL2A1 results in increased secretion of CP protein]; lupeol inhibits the reaction [COL2A1 results in increased secretion of CRP protein]
|
CTD |
PMID:35446470 |
|
NCBI chr 7:130,977,561...131,006,627
Ensembl chr 7:130,977,561...131,006,627
|
|
G
|
Cp
|
ceruloplasmin
|
multiple interactions
|
EXP
|
lupeol inhibits the reaction [COL2A1 results in increased secretion of CP protein]
|
CTD |
PMID:35446470 |
|
NCBI chr 2:104,368,336...104,427,119
Ensembl chr 2:104,368,456...104,427,087
|
|
G
|
Crp
|
C-reactive protein
|
multiple interactions
|
EXP
|
lupeol inhibits the reaction [COL2A1 results in increased secretion of CRP protein]
|
CTD |
PMID:35446470 |
|
NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514
|
|
G
|
Cryz
|
crystallin zeta
|
multiple interactions
|
ISO
|
lupeol inhibits the reaction [Benzoyl Peroxide affects the activity of CRYZ protein]
|
CTD |
PMID:15248479 |
|
NCBI chr 2:246,211,707...246,239,472
Ensembl chr 2:246,211,156...246,239,470
|
|
G
|
Ctnnb1
|
catenin beta 1
|
decreases expression multiple interactions
|
ISO
|
lupeol results in decreased expression of CTNNB1 protein lupeol results in decreased localization of and results in decreased activity of CTNNB1 protein
|
CTD |
PMID:20732907 PMID:20979057 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662
|
|
G
|
Gadd45a
|
growth arrest and DNA-damage-inducible, alpha
|
multiple interactions
|
ISO
|
lupeol inhibits the reaction [mancozeb results in increased expression of GADD45A mRNA]
|
CTD |
PMID:27235710 |
|
NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807
|
|
G
|
Gsk3b
|
glycogen synthase kinase 3 beta
|
affects binding
|
EXP
|
lupeol binds to GSK3B protein
|
CTD |
PMID:18222664 |
|
NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249
|
|
G
|
Gsr
|
glutathione-disulfide reductase
|
multiple interactions
|
EXP
|
lupeol inhibits the reaction [Sodium Selenite results in decreased activity of GSR protein]
|
CTD |
PMID:26697995 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394
|
|
G
|
Il10
|
interleukin 10
|
decreases expression increases expression
|
ISO
|
lupeol results in decreased expression of IL10 mRNA lupeol results in increased expression of IL10 protein
|
CTD |
PMID:31112703 PMID:39067743 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
G
|
Il1b
|
interleukin 1 beta
|
decreases expression multiple interactions
|
ISO
|
lupeol results in decreased expression of IL1B mRNA lupeol inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased expression of IL1B protein]
|
CTD |
PMID:31112703 PMID:39067743 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
decreases expression multiple interactions
|
ISO EXP
|
lupeol results in decreased expression of IL6 mRNA lupeol inhibits the reaction [COL2A1 protein results in increased secretion of IL6 protein]
|
CTD |
PMID:31112703 PMID:35446470 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Mdm2
|
MDM2 proto-oncogene
|
multiple interactions
|
ISO
|
lupeol inhibits the reaction [mancozeb results in increased expression of MDM2 mRNA]
|
CTD |
PMID:27235710 |
|
NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791
|
|
G
|
Mki67
|
marker of proliferation Ki-67
|
decreases expression
|
ISO
|
lupeol results in decreased expression of MKI67 mRNA
|
CTD |
PMID:20732907 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
ISO EXP
|
[lupeol binds to stearic acid] inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased expression of MPO protein]; lupeol inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased activity of MPO protein] lupeol inhibits the reaction [COL2A1 results in increased activity of MPO protein]
|
CTD |
PMID:32006539 PMID:35446470 PMID:39067743 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Mtor
|
mechanistic target of rapamycin kinase
|
multiple interactions
|
ISO
|
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lupeol inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased phosphorylation of MTOR protein]]; lupeol inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased phosphorylation of MTOR protein]
|
CTD |
PMID:39067743 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435
|
|
G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
decreases expression decreases activity multiple interactions
|
ISO
|
lupeol results in decreased expression of MYC mRNA lupeol results in decreased activity of MYC protein enzalutamide promotes the reaction [lupeol results in decreased activity of MYC protein]; lupeol promotes the reaction [enzalutamide results in decreased activity of MYC protein]
|
CTD |
PMID:20732907 PMID:37777120 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
G
|
Nanog
|
Nanog homeobox
|
decreases expression
|
ISO
|
lupeol results in decreased expression of NANOG protein
|
CTD |
PMID:20979057 |
|
NCBI chr 4:157,615,687...157,623,061
Ensembl chr 4:157,615,687...157,623,061
|
|
G
|
Nes
|
nestin
|
decreases expression
|
ISO
|
lupeol results in decreased expression of NES protein
|
CTD |
PMID:20979057 |
|
NCBI chr 2:175,735,715...175,745,631
Ensembl chr 2:175,736,551...175,746,228
|
|
G
|
Numa1
|
nuclear mitotic apparatus protein 1
|
multiple interactions
|
EXP
|
lupeol inhibits the reaction [[Butylhydroxybutylnitrosamine co-treated with Cacodylic Acid] results in increased expression of NUMA1 protein]
|
CTD |
PMID:26251508 |
|
NCBI chr 1:165,709,893...165,784,848
Ensembl chr 1:165,709,905...165,784,848
|
|
G
|
Ogg1
|
8-oxoguanine DNA glycosylase
|
multiple interactions
|
ISO
|
lupeol inhibits the reaction [mancozeb results in decreased expression of OGG1 mRNA]
|
CTD |
PMID:27235710 |
|
NCBI chr 4:148,030,237...148,037,599
Ensembl chr 4:148,030,349...148,037,604
|
|
G
|
Pcna
|
proliferating cell nuclear antigen
|
decreases expression
|
ISO
|
lupeol results in decreased expression of PCNA mRNA
|
CTD |
PMID:20732907 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901
|
|
G
|
Pou5f1
|
POU class 5 homeobox 1
|
decreases expression
|
ISO
|
lupeol results in decreased expression of POU5F1 protein
|
CTD |
PMID:20979057 |
|
NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,227,837...3,232,598
|
|
G
|
Prom1
|
prominin 1
|
decreases expression
|
ISO
|
lupeol results in decreased expression of PROM1 protein
|
CTD |
PMID:20979057 |
|
NCBI chr14:71,202,303...71,307,008
Ensembl chr14:71,202,336...71,307,002
|
|
G
|
Pten
|
phosphatase and tensin homolog
|
increases expression multiple interactions increases response to substance
|
ISO EXP
|
lupeol results in increased expression of PTEN protein lupeol inhibits the reaction [[Butylhydroxybutylnitrosamine co-treated with Cacodylic Acid] results in decreased expression of PTEN protein] PTEN protein results in increased susceptibility to lupeol
|
CTD |
PMID:20979057 PMID:26251508 |
|
NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330
|
|
G
|
Ptges
|
prostaglandin E synthase
|
multiple interactions
|
ISO
|
lupeol inhibits the reaction [mancozeb results in increased expression of PTGES mRNA]
|
CTD |
PMID:27235710 |
|
NCBI chr 3:34,575,643...34,586,987
Ensembl chr 3:34,575,639...34,586,995
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
EXP
|
lupeol inhibits the reaction [[Butylhydroxybutylnitrosamine co-treated with Cacodylic Acid] results in increased expression of PTGS2 protein]; lupeol inhibits the reaction [COL2A1 results in increased activity of PTGS2 protein]
|
CTD |
PMID:26251508 PMID:35446470 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
ISO EXP
|
lupeol inhibits the reaction [mancozeb affects the localization of RELA protein] lupeol inhibits the reaction [[Butylhydroxybutylnitrosamine co-treated with Cacodylic Acid] results in increased phosphorylation of RELA protein]
|
CTD |
PMID:26251508 PMID:27235710 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Sox2
|
SRY-box transcription factor 2
|
decreases expression
|
ISO
|
lupeol results in decreased expression of SOX2 protein
|
CTD |
PMID:20979057 |
|
NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:119,454,541...119,496,350
|
|
G
|
Tlr4
|
toll-like receptor 4
|
multiple interactions
|
ISO
|
lupeol inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased expression of TLR4 protein]
|
CTD |
PMID:39067743 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
G
|
Tnf
|
tumor necrosis factor
|
decreases expression multiple interactions
|
ISO EXP
|
lupeol results in decreased expression of TNF mRNA lupeol inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased expression of TNF protein] lupeol inhibits the reaction [[Butylhydroxybutylnitrosamine co-treated with Cacodylic Acid] results in increased expression of TNF protein]; lupeol inhibits the reaction [COL2A1 protein results in increased secretion of TNF protein]
|
CTD |
PMID:26251508 PMID:31112703 PMID:35446470 PMID:39067743 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tp53
|
tumor protein p53
|
multiple interactions
|
ISO
|
lupeol inhibits the reaction [mancozeb results in increased expression of TP53 mRNA]
|
CTD |
PMID:27235710 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Xdh
|
xanthine dehydrogenase
|
multiple interactions
|
ISO
|
lupeol inhibits the reaction [Benzoyl Peroxide affects the activity of XDH protein]
|
CTD |
PMID:15248479 |
|
NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:27,282,057...27,344,350
|
|
G
|
Xrcc1
|
X-ray repair cross complementing 1
|
multiple interactions
|
ISO
|
lupeol inhibits the reaction [mancozeb results in decreased expression of XRCC1 mRNA]
|
CTD |
PMID:27235710 |
|
NCBI chr 1:89,268,721...89,296,619
Ensembl chr 1:89,268,644...89,296,613
|
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
increases expression
|
EXP
|
madecassic acid results in increased expression of BCL2 mRNA
|
CTD |
PMID:38527925 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
ISO
|
madecassoside inhibits the reaction [Cisplatin results in increased expression of BAX mRNA] madecassoside inhibits the reaction [Cisplatin results in increased expression of BAX mRNA]; madecassoside inhibits the reaction [Cisplatin results in increased expression of BAX protein]
|
CTD |
PMID:37087747 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions
|
ISO
|
madecassoside inhibits the reaction [Cisplatin results in decreased expression of BCL2 mRNA]
|
CTD |
PMID:37087747 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
ISO
|
madecassoside inhibits the reaction [Cisplatin results in increased expression of and results in increased cleavage of CASP3 protein]
|
CTD |
PMID:37087747 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Cyp2c6
|
cytochrome P450, family 2, subfamily C, polypeptide 6
|
decreases activity
|
ISO
|
madecassoside results in decreased activity of CYP2C19 protein
|
CTD |
PMID:21349323 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
decreases activity
|
ISO
|
madecassoside results in decreased activity of CYP3A4 protein
|
CTD |
PMID:21349323 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Havcr1
|
hepatitis A virus cellular receptor 1
|
multiple interactions
|
ISO
|
madecassoside inhibits the reaction [Cisplatin results in increased expression of HAVCR1 mRNA]
|
CTD |
PMID:37087747 |
|
NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,619,897...31,653,268
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
ISO
|
madecassoside inhibits the reaction [Cisplatin results in increased expression of IL1B mRNA]
|
CTD |
PMID:37087747 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
ISO
|
madecassoside inhibits the reaction [Cisplatin results in increased expression of IL6 mRNA]
|
CTD |
PMID:37087747 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Lcn2
|
lipocalin 2
|
multiple interactions
|
ISO
|
madecassoside inhibits the reaction [Cisplatin results in increased expression of LCN2 mRNA]; madecassoside inhibits the reaction [Cisplatin results in increased expression of LCN2 protein]
|
CTD |
PMID:37087747 |
|
NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:36,078,436...36,081,842
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
ISO
|
madecassoside inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:37087747 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk14
|
mitogen activated protein kinase 14
|
multiple interactions
|
ISO
|
madecassoside inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK14 protein]
|
CTD |
PMID:37087747 |
|
NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO
|
madecassoside inhibits the reaction [Cisplatin results in increased expression of TNF mRNA]
|
CTD |
PMID:37087747 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
|
G
|
Cxcl2
|
C-X-C motif chemokine ligand 2
|
multiple interactions
|
ISO
|
maslinic acid analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CXCL2 mRNA]; maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CXCL2 mRNA]
|
CTD |
PMID:26513295 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255
|
|
G
|
Cxcl3
|
C-X-C motif chemokine ligand 3
|
multiple interactions
|
ISO
|
maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CXCL1 mRNA]
|
CTD |
PMID:26513295 |
|
NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624
|
|
G
|
Igf1r
|
insulin-like growth factor 1 receptor
|
multiple interactions
|
ISO
|
maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of IGF1R protein]
|
CTD |
PMID:26513295 |
|
NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:130,959,997...131,248,664
|
|
G
|
Il17a
|
interleukin 17A
|
multiple interactions
|
ISO
|
maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL17A mRNA]
|
CTD |
PMID:26513295 |
|
NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331
|
|
G
|
Jun
|
Jun proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions
|
ISO
|
maslinic acid analog inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of JUN protein]; maslinic acid analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of JUN protein]; maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of JUN protein]
|
CTD |
PMID:26513295 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285
|
|
G
|
Pdcd4
|
programmed cell death 4
|
multiple interactions
|
ISO
|
maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of PDCD4 protein]
|
CTD |
PMID:26513295 |
|
NCBI chr 1:262,912,659...262,949,581
Ensembl chr 1:262,926,656...262,950,189
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
ISO
|
maslinic acid analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]; maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]; maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]
|
CTD |
PMID:26513295 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Src
|
SRC proto-oncogene, non-receptor tyrosine kinase
|
multiple interactions
|
ISO
|
maslinic acid analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of SRC protein]; maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of SRC protein]
|
CTD |
PMID:26513295 |
|
NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462
|
|
G
|
Stat3
|
signal transducer and activator of transcription 3
|
multiple interactions
|
ISO
|
maslinic acid analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of STAT3 protein]; maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of STAT3 protein]
|
CTD |
PMID:26513295 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359
|
|
G
|
Stk11
|
serine/threonine kinase 11
|
multiple interactions
|
ISO
|
maslinic acid analog inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased phosphorylation of STK11 protein]; maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased phosphorylation of STK11 protein]
|
CTD |
PMID:26513295 |
|
NCBI chr 7:10,225,204...10,241,965
Ensembl chr 7:10,225,204...10,241,965
|
|
G
|
Ulk1
|
unc-51 like autophagy activating kinase 1
|
multiple interactions
|
ISO
|
[maslinic acid analog co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of ULK1 protein
|
CTD |
PMID:26513295 |
|
NCBI chr12:51,511,492...51,537,746
Ensembl chr12:51,511,492...51,537,746
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
multiple interactions
|
ISO
|
maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of VEGFA mRNA]
|
CTD |
PMID:26513295 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
|
G
|
Ephx2
|
epoxide hydrolase 2
|
multiple interactions
|
ISO
|
nomilin inhibits the reaction [EPHX2 protein results in increased metabolism of stilbene oxide analog]
|
CTD |
PMID:2043152 |
|
NCBI chr15:44,465,447...44,503,157
Ensembl chr15:44,465,448...44,503,160
|
|
|
G
|
Abcb11
|
ATP binding cassette subfamily B member 11
|
decreases expression multiple interactions
|
ISO
|
Oleanolic Acid results in decreased expression of ABCB11 mRNA; Oleanolic Acid results in decreased expression of ABCB11 protein dorsomorphin inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 mRNA]; dorsomorphin inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 protein]; GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 mRNA]; GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 protein]; HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 protein]]; NR1H4 protein inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 mRNA]; pregna-4,17-diene-3,16-dione promotes the reaction [Oleanolic Acid results in decreased expression of ABCB11 mRNA]; PRKAA1 protein affects the reaction [Oleanolic Acid results in decreased expression of ABCB11 mRNA]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 mRNA]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 protein]; U 0126 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 mRNA]
|
CTD |
PMID:23948738 PMID:36846903 PMID:37028458 PMID:39030772 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581
|
|
G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
decreases expression multiple interactions
|
ISO
|
Oleanolic Acid results in decreased expression of ABCC2 mRNA; Oleanolic Acid results in decreased expression of ABCC2 protein dorsomorphin inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 mRNA]; dorsomorphin inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 protein]; GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 mRNA]; GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 protein]; HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 protein]]; NR1H4 protein inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 mRNA]; pregna-4,17-diene-3,16-dione promotes the reaction [Oleanolic Acid results in decreased expression of ABCC2 mRNA]; PRKAA1 protein affects the reaction [Oleanolic Acid results in decreased expression of ABCC2 mRNA]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 mRNA]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 protein]; U 0126 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 mRNA]
|
CTD |
PMID:36846903 PMID:37028458 PMID:39030772 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471
|
|
G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
increases expression
|
ISO
|
Oleanolic Acid results in increased expression of ABCG2 mRNA
|
CTD |
PMID:23948738 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
multiple interactions
|
EXP ISO
|
Oleanolic Acid analog inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA]
|
CTD |
PMID:17922224 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Adh1c
|
alcohol dehydrogenase 1C (class I), gamma polypeptide
|
multiple interactions
|
EXP
|
Oleanolic Acid inhibits the reaction [Ethanol results in increased expression of and results in increased activity of ADH1 protein]
|
CTD |
PMID:25111957 |
|
NCBI chr 2:229,470,703...229,482,291
Ensembl chr 2:229,470,703...229,482,291
|
|
G
|
Ager
|
advanced glycosylation end product-specific receptor
|
multiple interactions
|
ISO
|
Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of AGER protein]
|
CTD |
PMID:22386814 |
|
NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685
|
|
G
|
Akr1b10
|
aldo-keto reductase family 1 member B10
|
multiple interactions
|
ISO
|
Oleanolic Acid inhibits the reaction [[AKR1B10 protein results in decreased susceptibility to Doxorubicin] which results in increased expression of MMP2 mRNA]; Oleanolic Acid inhibits the reaction [[AKR1B10 protein results in decreased susceptibility to Doxorubicin] which results in increased secretion of MMP2 protein]; Oleanolic Acid inhibits the reaction [AKR1B10 protein results in decreased susceptibility to Doxorubicin]; Oleanolic Acid inhibits the reaction [AKR1B10 protein results in increased metabolism of 4-hydroxy-2-nonenal]; Oleanolic Acid inhibits the reaction [AKR1B10 protein results in increased metabolism of 4-oxo-2-nonenal]
|
CTD |
PMID:25686905 PMID:27417252 |
|
NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:64,007,420...64,020,847
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions decreases phosphorylation increases phosphorylation
|
EXP ISO
|
[Fructose co-treated with Oleanolic Acid] results in increased expression of AKT1 mRNA Oleanolic Acid results in decreased phosphorylation of AKT1 protein Oleanolic Acid analog results in increased phosphorylation of AKT1 protein
|
CTD |
PMID:24704288 PMID:26612655 PMID:35690101 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Alpl
|
alkaline phosphatase, biomineralization associated
|
increases activity
|
ISO
|
Oleanolic Acid results in increased activity of ALPL protein
|
CTD |
PMID:39984133 |
|
NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167
|
|
G
|
Alpp
|
alkaline phosphatase, placental
|
increases expression multiple interactions
|
ISO
|
Oleanolic Acid results in increased expression of AKP3 protein GW 4064 inhibits the reaction [Oleanolic Acid results in increased expression of AKP3 protein]; sulfanitran inhibits the reaction [Oleanolic Acid results in increased expression of AKP3 protein]; verlukast promotes the reaction [Oleanolic Acid results in increased expression of AKP3 protein]
|
CTD |
PMID:39030772 |
|
NCBI chr 9:95,213,763...95,216,509
Ensembl chr 9:95,213,374...95,219,451
|
|
G
|
Atg5
|
autophagy related 5
|
increases expression multiple interactions
|
ISO
|
Oleanolic Acid analog results in increased expression of ATG5 protein; Oleanolic Acid results in increased expression of ATG5 protein Oleanolic Acid inhibits the reaction [Cisplatin results in increased expression of ATG5 protein]
|
CTD |
PMID:26612655 PMID:31306688 PMID:35690101 |
|
NCBI chr20:49,380,835...49,471,826
Ensembl chr20:49,380,813...49,471,821
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression multiple interactions
|
ISO
|
Oleanolic Acid analog results in increased expression of BAX protein; Oleanolic Acid results in increased expression of BAX protein [Oleanolic Acid analog binds to Succinic Acid] which results in increased expression of BAX mRNA; [Oleanolic Acid analog binds to Succinic Acid] which results in increased expression of BAX protein; [Oleanolic Acid results in increased susceptibility to Doxorubicin] which affects the expression of BAX mRNA; Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of BAX protein]; TRAP1 protein affects the reaction [Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of BAX protein]]
|
CTD |
PMID:26612655 PMID:31401087 PMID:33465424 PMID:34364837 PMID:37345903 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression multiple interactions
|
ISO
|
Oleanolic Acid analog results in decreased expression of BCL2 protein; Oleanolic Acid results in decreased expression of BCL2 protein [Oleanolic Acid results in increased susceptibility to Doxorubicin] which affects the expression of BCL2 mRNA; Cisplatin promotes the reaction [Oleanolic Acid results in decreased expression of BCL2 protein]; Oleanolic Acid inhibits the reaction [ochratoxin A results in decreased expression of BCL2 protein]; Oleanolic Acid promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]; TRAP1 protein affects the reaction [Oleanolic Acid inhibits the reaction [ochratoxin A results in decreased expression of BCL2 protein]]
|
CTD |
PMID:22678527 PMID:26612655 PMID:31306688 PMID:33465424 PMID:34364837 PMID:37345903 More...
|
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bcl2l1
|
Bcl2-like 1
|
multiple interactions
|
ISO
|
[Oleanolic Acid analog binds to Succinic Acid] which results in decreased expression of BCL2L1 mRNA; [Oleanolic Acid analog binds to Succinic Acid] which results in decreased expression of BCL2L1 protein
|
CTD |
PMID:31401087 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907 Ensembl chr 1:161,745,540...161,764,907
|
|
G
|
Becn1
|
beclin 1
|
affects expression increases expression
|
ISO
|
Oleanolic Acid analog affects the expression of BECN1 protein Oleanolic Acid results in increased expression of BECN1 protein
|
CTD |
PMID:26612655 PMID:35690101 |
|
NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002
|
|
G
|
Birc5
|
baculoviral IAP repeat-containing 5
|
decreases expression multiple interactions
|
ISO
|
Oleanolic Acid results in decreased expression of BIRC5 protein [Oleanolic Acid results in increased susceptibility to Doxorubicin] which affects the expression of BIRC5 mRNA
|
CTD |
PMID:22678527 PMID:37345903 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155
|
|
G
|
Casp3
|
caspase 3
|
increases activity multiple interactions increases cleavage decreases expression increases expression
|
ISO
|
Oleanolic Acid results in increased activity of CASP3 protein Oleanolic Acid inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein] [Oleanolic Acid results in increased susceptibility to Doxorubicin] which affects the expression of CASP3 mRNA; Ascorbic Acid inhibits the reaction [Oleanolic Acid results in increased cleavage of CASP3 protein]; Cisplatin inhibits the reaction [Oleanolic Acid results in increased cleavage of CASP3 protein]; Oleanolic Acid inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Oleanolic Acid inhibits the reaction [ochratoxin A results in increased cleavage of CASP3 protein] Oleanolic Acid analog results in decreased expression of CASP3 protein Oleanolic Acid results in increased expression of CASP3 protein
|
CTD |
PMID:20005942 PMID:20726234 PMID:22678527 PMID:26612655 PMID:31306688 PMID:33465424 PMID:35690101 PMID:37345903 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
increases activity multiple interactions
|
ISO
|
Oleanolic Acid results in increased activity of CASP8 protein [Oleanolic Acid results in increased susceptibility to Doxorubicin] which affects the expression of CASP8 mRNA
|
CTD |
PMID:20005942 PMID:37345903 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
decreases expression multiple interactions increases cleavage
|
ISO
|
Oleanolic Acid analog results in decreased expression of CASP9 protein Oleanolic Acid inhibits the reaction [ochratoxin A results in increased cleavage of CASP9 protein] Oleanolic Acid inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein] Oleanolic Acid results in increased cleavage of CASP9 protein
|
CTD |
PMID:22678527 PMID:26612655 PMID:31306688 PMID:33465424 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cat
|
catalase
|
increases expression multiple interactions
|
EXP ISO
|
Oleanolic Acid results in increased expression of CAT mRNA Oleanolic Acid inhibits the reaction [Paraquat results in increased activity of CAT protein] Oleanolic Acid inhibits the reaction [Ethanol results in increased activity of CAT protein] Oleanolic Acid inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CAT protein]
|
CTD |
PMID:18706400 PMID:20100471 PMID:21801858 PMID:25111957 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ccnd1
|
cyclin D1
|
increases expression multiple interactions decreases expression
|
ISO EXP
|
Oleanolic Acid results in increased expression of CCND1 mRNA; Oleanolic Acid results in increased expression of CCND1 protein [Oleanolic Acid affects the localization of NR1I2 protein] which results in increased expression of CCND1 protein Oleanolic Acid results in decreased expression of CCND1 protein
|
CTD |
PMID:18706400 PMID:20726234 PMID:35690101 PMID:38513930 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Ccne1
|
cyclin E1
|
increases expression multiple interactions
|
ISO
|
Oleanolic Acid results in increased expression of CCNE1 protein [Oleanolic Acid affects the localization of NR1I2 protein] which results in increased expression of CCNE1 protein
|
CTD |
PMID:38513930 |
|
NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822
|
|
G
|
Ccng1
|
cyclin G1
|
decreases expression
|
ISO
|
oleanolic acid decreases expression of CCNG1 protein in human lung carcinoma xenografts in mouse
|
RGD |
PMID:25472877 |
RGD:151361106 |
NCBI chr10:25,678,503...25,684,876
Ensembl chr10:25,677,885...25,683,766
|
|
G
|
Cd274
|
CD274 molecule
|
multiple interactions
|
ISO
|
[Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; [Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 protein]; Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]; TET3 protein inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; TET3 protein inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]]
|
CTD |
PMID:32894642 |
|
NCBI chr 1:236,526,215...236,549,956
Ensembl chr 1:236,496,463...236,549,951
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression multiple interactions decreases expression
|
EXP ISO
|
Oleanolic Acid results in increased expression of CDKN1A mRNA Oleanolic Acid results in increased expression of CDKN1A protein Oleanolic Acid inhibits the reaction [Cisplatin results in increased expression of CDKN1A protein] Oleanolic Acid results in decreased expression of CDKN1A protein
|
CTD |
PMID:18706400 PMID:22678527 PMID:31306688 PMID:35690101 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Cdkn1b
|
cyclin-dependent kinase inhibitor 1B
|
multiple interactions decreases expression
|
ISO
|
[Oleanolic Acid affects the localization of NR1I2 protein] which results in decreased expression of CDKN1B protein Oleanolic Acid results in decreased expression of CDKN1B protein
|
CTD |
PMID:38513930 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498
|
|
G
|
Chuk
|
component of inhibitor of nuclear factor kappa B kinase complex
|
multiple interactions
|
ISO
|
Oleanolic Acid inhibits the reaction [IL1B protein results in increased phosphorylation of CHUK protein]
|
CTD |
PMID:32894642 |
|
NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
decreases expression
|
EXP
|
Oleanolic Acid analog results in decreased expression of COL1A1 mRNA
|
CTD |
PMID:17922224 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
G
|
Cxcl2
|
C-X-C motif chemokine ligand 2
|
increases expression multiple interactions
|
ISO
|
Oleanolic Acid results in increased expression of CXCL2 protein Oleanolic Acid inhibits the reaction [Phalloidine results in increased expression of CXCL2 mRNA]; Oleanolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CXCL2 mRNA]
|
CTD |
PMID:25280775 PMID:26513295 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255
|
|
G
|
Cxcl3
|
C-X-C motif chemokine ligand 3
|
multiple interactions
|
ISO
|
Oleanolic Acid inhibits the reaction [Phalloidine results in increased expression of CXCL1 mRNA]
|
CTD |
PMID:25280775 |
|
NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624
|
|
G
|
Cxcl6
|
C-X-C motif chemokine ligand 6
|
increases expression
|
EXP
|
Oleanolic Acid results in increased expression of CXCL5 mRNA
|
CTD |
PMID:18706400 |
|
NCBI chr14:17,594,959...17,596,417
Ensembl chr14:17,594,959...17,596,417
|
|
G
|
Cycs
|
cytochrome c, somatic
|
multiple interactions
|
ISO
|
Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of CYCS protein]
|
CTD |
PMID:33465424 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816 Ensembl chr18:80,982,668...80,984,816
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
multiple interactions decreases expression decreases activity
|
ISO EXP
|
Oleanolic Acid inhibits the reaction [CYP1A2 protein results in increased metabolism of Phenacetin] Oleanolic Acid results in decreased expression of CYP1A2 mRNA Oleanolic Acid results in decreased activity of CYP1A2 protein
|
CTD |
PMID:15043991 PMID:18706400 PMID:23948738 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp27a1
|
cytochrome P450, family 27, subfamily a, polypeptide 1
|
decreases expression
|
ISO
|
Oleanolic Acid results in decreased expression of CYP27A1 mRNA
|
CTD |
PMID:23948738 PMID:39984133 |
|
NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:83,713,293...83,743,215
|
|
G
|
Cyp2b3
|
cytochrome P450, family 2, subfamily b, polypeptide 3
|
decreases expression
|
ISO
|
Oleanolic Acid results in decreased expression of CYP2B10 mRNA
|
CTD |
PMID:23948738 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
multiple interactions decreases expression
|
ISO EXP
|
Oleanolic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of and results in increased activity of CYP2E1 protein] Oleanolic Acid inhibits the reaction [Ethanol results in increased expression of and results in increased activity of CYP2E1 protein] Oleanolic Acid results in decreased expression of CYP2E1 mRNA
|
CTD |
PMID:10355542 PMID:18706400 PMID:25111957 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495
|
|
G
|
Cyp2f4
|
cytochrome P450, family 2, subfamily f, polypeptide 4
|
decreases expression
|
ISO
|
Oleanolic Acid results in decreased expression of CYP2F2 mRNA
|
CTD |
PMID:18706400 |
|
NCBI chr 1:91,543,768...91,557,553
Ensembl chr 1:91,543,768...91,557,553
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
multiple interactions increases expression decreases activity
|
ISO
|
Oleanolic Acid inhibits the reaction [CYP3A4 protein results in increased metabolism of Midazolam] Oleanolic Acid results in increased expression of CYP3A4 protein Oleanolic Acid results in decreased activity of CYP3A4 protein
|
CTD |
PMID:15043991 PMID:38513930 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Cyp7a1
|
cytochrome P450 family 7 subfamily A member 1
|
decreases expression multiple interactions
|
ISO
|
Oleanolic Acid results in decreased expression of CYP7A1 mRNA; Oleanolic Acid results in decreased expression of CYP7A1 protein GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP7A1 mRNA]; GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP7A1 protein]; HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP7A1 protein]]; NR1H4 protein inhibits the reaction [Oleanolic Acid results in decreased expression of CYP7A1 mRNA]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP7A1 mRNA]
|
CTD |
PMID:23948738 PMID:37028458 PMID:39030772 |
|
NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202
|
|
G
|
Cyp7b1
|
cytochrome P450 family 7 subfamily B member 1
|
decreases expression
|
ISO
|
Oleanolic Acid results in decreased expression of CYP7B1 mRNA
|
CTD |
PMID:23948738 |
|
NCBI chr 2:102,419,011...102,586,047
Ensembl chr 2:102,419,011...102,451,804
|
|
G
|
Cyp8b1
|
cytochrome P450 family 8 subfamily B member 1
|
decreases expression multiple interactions
|
ISO
|
Oleanolic Acid results in decreased expression of CYP8B1 mRNA; Oleanolic Acid results in decreased expression of CYP8B1 protein GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP8B1 mRNA]; GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP8B1 protein]; HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP8B1 protein]]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP8B1 mRNA]
|
CTD |
PMID:23948738 PMID:37028458 PMID:39030772 |
|
NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:130,442,503...130,457,689
|
|
G
|
Ddit3
|
DNA-damage inducible transcript 3
|
multiple interactions
|
ISO
|
Oleanolic Acid inhibits the reaction [Phalloidine results in increased expression of DDIT3 mRNA] Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of DDIT3 protein]; TRAP1 protein affects the reaction [Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of DDIT3 protein]]
|
CTD |
PMID:25280775 PMID:33465424 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
G
|
Diablo
|
diablo, IAP-binding mitochondrial protein
|
multiple interactions
|
ISO
|
[Oleanolic Acid results in increased susceptibility to Doxorubicin] which affects the expression of DIABLO mRNA
|
CTD |
PMID:37345903 |
|
NCBI chr12:38,716,668...38,731,285
Ensembl chr12:38,716,668...38,731,265
|
|
G
|
Foxo1
|
forkhead box O1
|
decreases expression multiple interactions
|
ISO
|
Oleanolic Acid results in decreased expression of FOXO1 protein [Oleanolic Acid affects the localization of NR1I2 protein] which results in decreased expression of FOXO1 protein
|
CTD |
PMID:38513930 |
|
NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419
|
|
G
|
Foxo3
|
forkhead box O3
|
affects localization multiple interactions
|
ISO
|
Oleanolic Acid affects the localization of FOXO3 protein Oleanolic Acid results in increased expression of and results in increased phosphorylation of FOXO3 protein
|
CTD |
PMID:35690101 |
|
NCBI chr20:47,251,968...47,348,254
Ensembl chr20:47,255,878...47,346,845
|
|
G
|
Gadd45a
|
growth arrest and DNA-damage-inducible, alpha
|
multiple interactions
|
ISO
|
Oleanolic Acid inhibits the reaction [Phalloidine results in increased expression of GADD45A mRNA]
|
CTD |
PMID:25280775 |
|
NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807
|
|
G
|
Gclc
|
glutamate-cysteine ligase, catalytic subunit
|
increases expression
|
EXP ISO
|
Oleanolic Acid results in increased expression of GCLC mRNA Oleanolic Acid results in increased expression of GCLC mRNA; Oleanolic Acid results in increased expression of GCLC protein
|
CTD |
PMID:18706400 PMID:19283895 PMID:25280775 PMID:39984133 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893
|
|
G
|
Gclm
|
glutamate cysteine ligase, modifier subunit
|
increases expression
|
ISO
|
Oleanolic Acid results in increased expression of GCLM mRNA
|
CTD |
PMID:18706400 |
|
NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003
|
|
G
|
Ghrl
|
ghrelin and obestatin prepropeptide
|
decreases expression
|
ISO
|
Oleanolic Acid results in decreased expression of GHRL protein
|
CTD |
PMID:20188082 |
|
NCBI chr 4:148,421,315...148,431,128
Ensembl chr 4:148,421,315...148,425,969
|
|
G
|
Gnas
|
GNAS complex locus
|
multiple interactions
|
ISO
|
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [[[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased hydrolysis of Phosphatidylinositols]; 4,4,',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakis(benzene-1,3-disulfonate) inhibits the reaction [[[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased hydrolysis of Phosphatidylinositols]; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Calcium; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased hydrolysis of Phosphatidylinositols; [Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein
|
CTD |
PMID:23022524 |
|
NCBI chr 3:183,489,648...183,554,570
Ensembl chr 3:183,503,243...183,554,536
|
|
G
|
Got1
|
glutamic-oxaloacetic transaminase 1
|
multiple interactions increases expression
|
ISO
|
GW 4064 inhibits the reaction [Oleanolic Acid results in increased expression of GOT1 protein]; sulfanitran inhibits the reaction [Oleanolic Acid results in increased expression of GOT1 protein]; verlukast promotes the reaction [Oleanolic Acid results in increased expression of GOT1 protein]
|
CTD |
PMID:39030772 |
|
NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871
|
|
G
|
Gpbar1
|
G protein-coupled bile acid receptor 1
|
multiple interactions increases response to substance
|
ISO
|
[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Calcium; Oleanolic Acid binds to and results in increased activity of GPBAR1 protein 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [[[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased hydrolysis of Phosphatidylinositols]; 4,4,',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakis(benzene-1,3-disulfonate) inhibits the reaction [[[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased hydrolysis of Phosphatidylinositols]; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Calcium; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased hydrolysis of Phosphatidylinositols; [Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein; Oleanolic Acid binds to and results in increased activity of GPBAR1 protein GPBAR1 protein results in increased susceptibility to Oleanolic Acid
|
CTD |
PMID:23022524 PMID:23041323 |
|
NCBI chr 9:83,309,895...83,312,397
Ensembl chr 9:83,311,246...83,315,608
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
multiple interactions increases expression increases activity
|
ISO
|
dorsomorphin inhibits the reaction [Oleanolic Acid results in increased expression of GPT protein]; GW 4064 inhibits the reaction [Oleanolic Acid results in increased activity of GPT protein]; GW 4064 inhibits the reaction [Oleanolic Acid results in increased expression of GPT protein]; Oleanolic Acid inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]; SRT1720 inhibits the reaction [Oleanolic Acid results in increased activity of GPT protein]; sulfanitran inhibits the reaction [Oleanolic Acid results in increased expression of GPT protein]; verlukast promotes the reaction [Oleanolic Acid results in increased expression of GPT protein]
|
CTD |
PMID:10355542 PMID:15720792 PMID:36846903 PMID:37028458 PMID:39030772 PMID:39984133 More...
|
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
G
|
Gpx1
|
glutathione peroxidase 1
|
increases expression
|
ISO
|
Oleanolic Acid results in increased expression of GPX1 mRNA
|
CTD |
PMID:18706400 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581
|
|
G
|
Gsr
|
glutathione-disulfide reductase
|
multiple interactions
|
EXP
|
Oleanolic Acid inhibits the reaction [Ethanol results in decreased expression of and results in decreased activity of GSR protein]
|
CTD |
PMID:25111957 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394
|
|
G
|
Gstm2
|
glutathione S-transferase mu 2
|
multiple interactions increases expression
|
ISO
|
[Oleanolic Acid affects the localization of NR1I2 protein] which results in increased expression of GSTM2 protein Oleanolic Acid results in increased expression of GSTM2 protein
|
CTD |
PMID:38513930 |
|
NCBI chr 2:198,312,179...198,316,962
|
|
G
|
Hdac1
|
histone deacetylase 1
|
decreases expression
|
ISO
|
Oleanolic Acid results in decreased expression of HDAC1 protein
|
CTD |
PMID:20726234 |
|
NCBI chr 5:147,138,328...147,165,387
Ensembl chr 5:147,138,156...147,165,387
|
|
G
|
Hmgb1
|
high mobility group box 1
|
multiple interactions decreases response to substance decreases expression
|
ISO
|
Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of AGER protein]; Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of ICAM1 protein]; Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of SELE protein]; Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of TNF protein]; Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of VCAM1 protein]; Oleanolic Acid inhibits the reaction [Lipopolysaccharides results in increased secretion of HMGB1 protein] Oleanolic Acid results in decreased susceptibility to HMGB1 protein Oleanolic Acid results in decreased expression of HMGB1 protein
|
CTD |
PMID:22386814 |
|
NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327 Ensembl chr12:39,039,050...39,041,327
|
|
G
|
Hmox1
|
heme oxygenase 1
|
increases expression multiple interactions
|
ISO EXP
|
Oleanolic Acid results in increased expression of HMOX1 mRNA Oleanolic Acid results in increased expression of HMOX1 protein Oleanolic Acid inhibits the reaction [Phalloidine results in increased expression of HMOX1 mRNA] Oleanolic Acid inhibits the reaction [Ethanol results in decreased expression of HMOX1 protein]
|
CTD |
PMID:18706400 PMID:19283895 PMID:25111957 PMID:25280775 PMID:35690101 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Hnf1a
|
HNF1 homeobox A
|
multiple interactions
|
ISO
|
HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 protein]]; HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 protein]]; HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP7A1 protein]]; HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP8B1 protein]]; HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of NR1H4 protein]]
|
CTD |
PMID:37028458 |
|
NCBI chr12:47,299,171...47,333,457
Ensembl chr12:47,306,245...47,332,755
|
|
G
|
Hspa1b
|
heat shock protein family A (Hsp70) member 1B
|
increases expression
|
ISO
|
Oleanolic Acid results in increased expression of HSPA1B mRNA
|
CTD |
PMID:18706400 |
|
NCBI chr20:3,859,756...3,863,800
Ensembl chr20:3,855,780...3,877,979
|
|
G
|
Hspa5
|
heat shock protein family A (Hsp70) member 5
|
multiple interactions
|
ISO
|
Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of HSPA5 protein]; TRAP1 protein affects the reaction [Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of HSPA5 protein]]
|
CTD |
PMID:33465424 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790
|
|
G
|
Icam1
|
intercellular adhesion molecule 1
|
decreases expression multiple interactions
|
ISO
|
Oleanolic Acid results in decreased expression of ICAM1 protein Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of ICAM1 protein]
|
CTD |
PMID:20005942 PMID:22386814 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
G
|
Ifng
|
interferon gamma
|
multiple interactions
|
ISO
|
Oleanolic Acid inhibits the reaction [Paraquat results in increased expression of IFNG mRNA]
|
CTD |
PMID:21801858 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
ISO
|
[Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; [Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 protein]; Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of RELA protein]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of TET3 mRNA]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of TET3 protein]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased phosphorylation of CHUK protein]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein]; TET3 protein inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; TET3 protein inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]]
|
CTD |
PMID:32894642 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
ISO
|
Oleanolic Acid inhibits the reaction [Paraquat results in increased expression of IL6 mRNA]
|
CTD |
PMID:21801858 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Ins1
|
insulin 1
|
multiple interactions
|
EXP
|
Oleanolic Acid inhibits the reaction [Fructose results in increased expression of INS1 protein]
|
CTD |
PMID:24704288 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682
|
|
G
|
Ins2
|
insulin 2
|
multiple interactions
|
ISO
|
[Oleanolic Acid co-treated with Glucose] results in increased secretion of INS protein
|
CTD |
PMID:23022524 |
|
NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805
|
|
G
|
Insr
|
insulin receptor
|
multiple interactions
|
EXP
|
[Fructose co-treated with Oleanolic Acid] results in increased expression of INSR mRNA
|
CTD |
PMID:24704288 |
|
NCBI chr12:5,991,135...6,129,275
Ensembl chr12:5,981,835...6,128,803
|
|
G
|
Irs1
|
insulin receptor substrate 1
|
multiple interactions
|
EXP
|
[Fructose co-treated with Oleanolic Acid] results in increased expression of IRS1 mRNA; [Fructose co-treated with Oleanolic Acid] results in increased expression of IRS1 protein; Oleanolic Acid inhibits the reaction [Fructose results in increased phosphorylation of IRS1 protein]
|
CTD |
PMID:24704288 |
|
NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:90,993,519...91,054,538
|
|
G
|
Lep
|
leptin
|
increases expression
|
ISO
|
Oleanolic Acid results in increased expression of LEP protein
|
CTD |
PMID:20188082 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661
|
|
G
|
Map1lc3b
|
microtubule-associated protein 1 light chain 3 beta
|
multiple interactions increases expression
|
ISO
|
Cisplatin promotes the reaction [Oleanolic Acid results in increased expression of MAP1LC3B protein]; Oleanolic Acid promotes the reaction [Cisplatin results in increased expression of MAP1LC3B protein]; Oleanolic Acid results in increased expression of and results in increased lipidation of MAP1LC3B protein Oleanolic Acid inhibits the reaction [Cisplatin results in increased expression of MAP1LC3B protein]
|
CTD |
PMID:31306688 PMID:35690101 |
|
NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358 Ensembl chr16:66,574,407...66,584,358
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions increases phosphorylation decreases phosphorylation
|
ISO
|
Oleanolic Acid inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of MAPK1 protein modified form] Oleanolic Acid results in increased phosphorylation of MAPK1 protein Oleanolic Acid inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Oleanolic Acid results in increased phosphorylation of MAPK1 protein] Oleanolic Acid analog results in decreased phosphorylation of MAPK1 protein; Oleanolic Acid results in decreased phosphorylation of MAPK1 protein
|
CTD |
PMID:20100471 PMID:26612655 PMID:31306688 PMID:35690101 PMID:36846903 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk14
|
mitogen activated protein kinase 14
|
decreases phosphorylation
|
ISO
|
Oleanolic Acid analog results in decreased phosphorylation of MAPK14 protein
|
CTD |
PMID:26612655 |
|
NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions increases phosphorylation decreases phosphorylation
|
ISO
|
Oleanolic Acid inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of MAPK3 protein modified form] Oleanolic Acid results in increased phosphorylation of MAPK3 protein Oleanolic Acid inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Oleanolic Acid results in increased phosphorylation of MAPK3 protein] Oleanolic Acid analog results in decreased phosphorylation of MAPK3 protein; Oleanolic Acid results in decreased phosphorylation of MAPK3 protein
|
CTD |
PMID:20100471 PMID:26612655 PMID:31306688 PMID:35690101 PMID:36846903 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mapk8
|
mitogen-activated protein kinase 8
|
decreases phosphorylation
|
ISO
|
Oleanolic Acid analog results in decreased phosphorylation of MAPK8 protein
|
CTD |
PMID:26612655 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
G
|
Mef2d
|
myocyte enhancer factor 2D
|
decreases expression
|
ISO
|
oleanolic acid decreases expression of MEF2D protein in human lung carcinoma xenografts in mouse
|
RGD |
PMID:25472877 |
RGD:151361106 |
NCBI chr 2:175,904,332...175,933,451
Ensembl chr 2:175,903,959...175,930,760
|
|
G
|
Met
|
MET proto-oncogene, receptor tyrosine kinase
|
decreases expression
|
ISO
|
Oleanolic Acid results in decreased expression of MET protein
|
CTD |
PMID:20726234 |
|
NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:46,756,506...46,870,821
|
|
G
|
Mgst1
|
microsomal glutathione S-transferase 1
|
increases expression
|
ISO
|
Oleanolic Acid results in increased expression of MGST1 mRNA
|
CTD |
PMID:39984133 |
|
NCBI chr 4:172,760,930...172,776,157
Ensembl chr 4:172,760,886...172,776,875
|
|
G
|
Mif
|
macrophage migration inhibitory factor
|
multiple interactions
|
ISO
|
Oleanolic Acid inhibits the reaction [Paraquat results in increased expression of MIF mRNA]
|
CTD |
PMID:21801858 |
|
NCBI chr20:12,767,138...12,791,222
Ensembl chr 4:134,041,774...134,042,121 Ensembl chr20:134,041,774...134,042,121
|
|
G
|
Mir122
|
microRNA 122
|
increases expression
|
ISO
|
oleanolic acid increases expression of MIR122 protein in human lung carcinoma xenografts in mouse
|
RGD |
PMID:25472877 |
RGD:151361106 |
NCBI chr18:61,028,817...61,028,901
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
multiple interactions
|
ISO
|
[Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; [Ursolic Acid co-treated with Oleanolic Acid] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; Oleanolic Acid inhibits the reaction [[AKR1B10 protein results in decreased susceptibility to Doxorubicin] which results in increased expression of MMP2 mRNA]; Oleanolic Acid inhibits the reaction [[AKR1B10 protein results in decreased susceptibility to Doxorubicin] which results in increased secretion of MMP2 protein]; Oleanolic Acid results in decreased secretion of and results in decreased activity of and affects the expression of MMP2 protein
|
CTD |
PMID:25686905 PMID:36191607 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions
|
ISO
|
[Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP9 protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased expression of MMP9 protein; [Ursolic Acid co-treated with Oleanolic Acid] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP9 protein; Oleanolic Acid results in decreased secretion of and results in decreased activity of and affects the expression of MMP9 protein
|
CTD |
PMID:36191607 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Mt1a
|
metallothionein 1A
|
increases expression multiple interactions
|
EXP ISO
|
Oleanolic Acid results in increased expression of MT1 mRNA; Oleanolic Acid results in increased expression of MT1A mRNA; Oleanolic Acid results in increased expression of MT1A protein Oleanolic Acid promotes the reaction [Phalloidine results in increased expression of MT1 mRNA]
|
CTD |
PMID:17637929 PMID:18706400 PMID:25280775 |
|
NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200 Ensembl chr X:79,695,809...79,696,200 Ensembl chr19:79,695,809...79,696,200
|
|
G
|
Mt2
|
metallothionein 2
|
increases expression
|
EXP ISO
|
Oleanolic Acid results in increased expression of MT2 mRNA; Oleanolic Acid results in increased expression of MT2A mRNA; Oleanolic Acid results in increased expression of MT2A protein
|
CTD |
PMID:17637929 PMID:18706400 |
|
NCBI chr19:10,837,934...10,838,708
Ensembl chr19:10,837,927...10,838,709
|
|
G
|
Mtor
|
mechanistic target of rapamycin kinase
|
decreases phosphorylation
|
ISO
|
Oleanolic Acid analog results in decreased phosphorylation of MTOR protein; Oleanolic Acid results in decreased phosphorylation of MTOR protein
|
CTD |
PMID:26612655 PMID:35690101 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435
|
|
G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
increases expression multiple interactions
|
EXP ISO
|
Oleanolic Acid results in increased expression of MYC mRNA [Oleanolic Acid analog binds to Succinic Acid] which results in decreased expression of MYC mRNA; [Oleanolic Acid analog binds to Succinic Acid] which results in decreased expression of MYC protein
|
CTD |
PMID:18706400 PMID:31401087 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions increases expression increases activity affects localization
|
ISO EXP
|
NFE2L2 protein affects the reaction [Oleanolic Acid results in increased activity of NQO1 protein]; NFE2L2 protein affects the reaction [Oleanolic Acid results in increased expression of NQO1 protein]; Oleanolic Acid promotes the reaction [Phalloidine results in increased expression of NFE2L2 mRNA]; Phalloidine promotes the reaction [Oleanolic Acid results in increased expression of NFE2L2 mRNA] Oleanolic Acid results in increased expression of NFE2L2 mRNA; Oleanolic Acid results in increased expression of NFE2L2 protein Oleanolic Acid inhibits the reaction [Ethanol results in decreased expression of NFE2L2 protein]; Oleanolic Acid promotes the reaction [Ethanol affects the localization of NFE2L2 protein] Oleanolic Acid inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of NFE2L2 protein]; Oleanolic Acid promotes the reaction [NFE2L2 protein results in increased expression of SREBF1 mRNA] Oleanolic Acid results in increased activity of NFE2L2 protein Oleanolic Acid affects the localization of NFE2L2 protein
|
CTD |
PMID:18706400 PMID:19283895 PMID:20100471 PMID:23948738 PMID:25111957 PMID:25280775 PMID:28796629 PMID:39984133 More...
|
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
multiple interactions
|
ISO
|
[Oleanolic Acid analog binds to Succinic Acid] which results in decreased expression of NFKB1 mRNA
|
CTD |
PMID:31401087 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
decreases phosphorylation multiple interactions
|
ISO
|
Oleanolic Acid analog results in decreased phosphorylation of NFKBIA protein; Oleanolic Acid results in decreased phosphorylation of NFKBIA protein Oleanolic Acid inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein]
|
CTD |
PMID:26612655 PMID:32894642 PMID:34364837 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
multiple interactions increases expression increases activity
|
ISO EXP
|
NFE2L2 protein affects the reaction [Oleanolic Acid results in increased activity of NQO1 protein]; NFE2L2 protein affects the reaction [Oleanolic Acid results in increased expression of NQO1 protein]; Phalloidine promotes the reaction [Oleanolic Acid results in increased expression of NQO1 mRNA] Oleanolic Acid results in increased expression of NQO1 mRNA; Oleanolic Acid results in increased expression of NQO1 protein
|
CTD |
PMID:18706400 PMID:19283895 PMID:23948738 PMID:25280775 PMID:39984133 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
G
|
Nr0b2
|
nuclear receptor subfamily 0, group B, member 2
|
decreases expression multiple interactions
|
ISO
|
Oleanolic Acid results in decreased expression of NR0B2 mRNA GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of NR0B2 mRNA]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of NR0B2 mRNA]
|
CTD |
PMID:37028458 |
|
NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
decreases expression multiple interactions
|
ISO
|
Oleanolic Acid results in decreased expression of NR1H4 mRNA; Oleanolic Acid results in decreased expression of NR1H4 protein dorsomorphin inhibits the reaction [Oleanolic Acid results in decreased expression of NR1H4 mRNA]; dorsomorphin inhibits the reaction [Oleanolic Acid results in decreased expression of NR1H4 protein]; GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of NR1H4 mRNA]; GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of NR1H4 protein]; HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of NR1H4 protein]]; NR1H4 protein inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 mRNA]; NR1H4 protein inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 mRNA]; NR1H4 protein inhibits the reaction [Oleanolic Acid results in decreased expression of CYP7A1 mRNA]; PRKAA1 protein affects the reaction [Oleanolic Acid results in decreased expression of NR1H4 mRNA]; PRKAA1 protein affects the reaction [Oleanolic Acid results in decreased expression of NR1H4 protein]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of NR1H4 mRNA]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of NR1H4 protein]; U 0126 inhibits the reaction [Oleanolic Acid results in decreased expression of NR1H4 mRNA]
|
CTD |
PMID:23948738 PMID:36846903 PMID:37028458 PMID:39030772 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389
|
|
G
|
Nr1i2
|
nuclear receptor subfamily 1, group I, member 2
|
multiple interactions affects localization
|
ISO
|
[Oleanolic Acid affects the localization of NR1I2 protein] which results in decreased expression of CDKN1B protein; [Oleanolic Acid affects the localization of NR1I2 protein] which results in decreased expression of FOXO1 protein; [Oleanolic Acid affects the localization of NR1I2 protein] which results in decreased expression of RBL2 protein; [Oleanolic Acid affects the localization of NR1I2 protein] which results in increased expression of CCND1 protein; [Oleanolic Acid affects the localization of NR1I2 protein] which results in increased expression of CCNE1 protein; [Oleanolic Acid affects the localization of NR1I2 protein] which results in increased expression of CYP3A11 protein; [Oleanolic Acid affects the localization of NR1I2 protein] which results in increased expression of GSTM2 protein; [Oleanolic Acid affects the localization of NR1I2 protein] which results in increased expression of PCNA protein; [Oleanolic Acid affects the localization of NR1I2 protein] which results in increased expression of UGT1A1 protein Oleanolic Acid affects the localization of and results in increased activity of NR1I2 protein
|
CTD |
PMID:38513930 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380
|
|
G
|
Nr1i3
|
nuclear receptor subfamily 1, group I, member 3
|
decreases expression
|
ISO
|
Oleanolic Acid results in decreased expression of NR1I3 mRNA
|
CTD |
PMID:23948738 |
|
NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370
|
|
G
|
Ocln
|
occludin
|
decreases expression
|
ISO
|
Oleanolic Acid results in decreased expression of OCLN protein
|
CTD |
PMID:39030772 |
|
NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411
|
|
G
|
Orm1
|
orosomucoid 1
|
increases expression
|
EXP
|
Oleanolic Acid results in increased expression of ORM1 mRNA
|
CTD |
PMID:18706400 |
|
NCBI chr 5:81,788,509...81,791,661
Ensembl chr 5:81,788,395...81,791,667
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
increases cleavage multiple interactions
|
ISO
|
Oleanolic Acid analog results in increased cleavage of PARP1 protein; Oleanolic Acid results in increased cleavage of PARP1 protein Oleanolic Acid inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein] Ascorbic Acid inhibits the reaction [Oleanolic Acid results in increased cleavage of PARP1 protein]; Oleanolic Acid inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]
|
CTD |
PMID:22678527 PMID:26612655 PMID:31306688 PMID:34364837 PMID:35690101 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Pcna
|
proliferating cell nuclear antigen
|
increases expression multiple interactions
|
ISO EXP
|
Oleanolic Acid results in increased expression of PCNA mRNA; Oleanolic Acid results in increased expression of PCNA protein [Oleanolic Acid affects the localization of NR1I2 protein] which results in increased expression of PCNA protein
|
CTD |
PMID:18706400 PMID:38513930 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901
|
|
G
|
Pik3c2g
|
phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma
|
multiple interactions
|
EXP
|
[Fructose co-treated with Oleanolic Acid] results in increased expression of PIK3C2G mRNA
|
CTD |
PMID:24704288 |
|
NCBI chr 4:174,215,527...174,583,378
Ensembl chr 4:174,215,527...174,581,705
|
|
G
|
Pik3ca
|
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha
|
decreases expression
|
ISO
|
Oleanolic Acid analog results in decreased expression of PIK3CA protein
|
CTD |
PMID:26612655 |
|
NCBI chr 2:117,103,643...117,177,411
Ensembl chr 2:117,143,468...117,177,411
|
|
G
|
Pink1
|
PTEN induced kinase 1
|
increases expression
|
ISO
|
Oleanolic Acid results in increased expression of PINK1 protein
|
CTD |
PMID:35690101 |
|
NCBI chr 5:155,813,838...155,825,950
Ensembl chr 5:155,813,838...155,825,950
|
|
G
|
Plau
|
plasminogen activator, urokinase
|
multiple interactions decreases secretion
|
ISO
|
[Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of PLAU protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of PLAU protein; [Ursolic Acid co-treated with Oleanolic Acid] results in decreased secretion of PLAU protein Oleanolic Acid results in decreased secretion of PLAU protein
|
CTD |
PMID:36191607 |
|
NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030
|
|
G
|
Plaur
|
plasminogen activator, urokinase receptor
|
multiple interactions
|
ISO
|
[Oleanolic Acid co-treated with Irinotecan] results in increased secretion of and results in decreased expression of PLAUR protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in increased secretion of and results in decreased expression of PLAUR protein; [Ursolic Acid co-treated with Oleanolic Acid] results in increased secretion of and results in decreased expression of PLAUR protein; Oleanolic Acid results in increased secretion of and results in decreased expression of PLAUR protein
|
CTD |
PMID:36191607 |
|
NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:89,178,453...89,198,130
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
decreases expression
|
ISO
|
Oleanolic Acid results in decreased expression of PPARA mRNA
|
CTD |
PMID:23948738 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
G
|
Ppif
|
peptidylprolyl isomerase F
|
multiple interactions
|
ISO
|
Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of PPIF protein]
|
CTD |
PMID:33465424 |
|
NCBI chr16:1,264,001...1,270,722
Ensembl chr16:1,263,541...1,316,954
|
|
G
|
Prdx1
|
peroxiredoxin 1
|
multiple interactions
|
ISO
|
Oleanolic Acid inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of PRDX1 protein]
|
CTD |
PMID:20100471 |
|
NCBI chr 5:135,383,906...135,399,504
Ensembl chr 5:135,383,906...135,399,504
|
|
G
|
Prkaa1
|
protein kinase AMP-activated catalytic subunit alpha 1
|
multiple interactions
|
ISO
|
PRKAA1 protein affects the reaction [Oleanolic Acid results in decreased expression of ABCB11 mRNA]; PRKAA1 protein affects the reaction [Oleanolic Acid results in decreased expression of ABCC2 mRNA]; PRKAA1 protein affects the reaction [Oleanolic Acid results in decreased expression of NR1H4 mRNA]; PRKAA1 protein affects the reaction [Oleanolic Acid results in decreased expression of NR1H4 protein]
|
CTD |
PMID:36846903 |
|
NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:55,967,351...56,003,450
|
|
G
|
Pten
|
phosphatase and tensin homolog
|
increases expression
|
ISO
|
Oleanolic Acid results in increased expression of PTEN protein
|
CTD |
PMID:20726234 |
|
NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
increases expression multiple interactions
|
ISO
|
Oleanolic Acid results in increased expression of PTGS2 mRNA [Oleanolic Acid analog binds to Succinic Acid] which results in decreased expression of PTGS2 mRNA; [Oleanolic Acid analog binds to Succinic Acid] which results in decreased expression of PTGS2 protein Oleanolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]; Oleanolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]
|
CTD |
PMID:18706400 PMID:26513295 PMID:31401087 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Rbl2
|
RB transcriptional corepressor like 2
|
decreases expression multiple interactions
|
ISO
|
Oleanolic Acid results in decreased expression of RBL2 protein [Oleanolic Acid affects the localization of NR1I2 protein] which results in decreased expression of RBL2 protein
|
CTD |
PMID:38513930 |
|
NCBI chr19:32,049,690...32,096,467
Ensembl chr19:32,049,691...32,096,411
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions decreases expression
|
ISO
|
[Oleanolic Acid analog binds to Succinic Acid] which results in decreased expression of RELA mRNA; Oleanolic Acid analog results in decreased expression of and affects the localization of RELA protein; Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of RELA protein] Oleanolic Acid analog results in decreased expression of RELA protein
|
CTD |
PMID:26362502 PMID:26612655 PMID:31401087 PMID:32894642 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Sele
|
selectin E
|
multiple interactions
|
ISO
|
Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of SELE protein]
|
CTD |
PMID:22386814 |
|
NCBI chr13:78,935,997...78,945,905
Ensembl chr13:78,936,036...78,945,903
|
|
G
|
Sirt1
|
sirtuin 1
|
multiple interactions decreases expression
|
ISO
|
GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of SIRT1 protein]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of SIRT1 protein] Oleanolic Acid results in decreased expression of SIRT1 mRNA; Oleanolic Acid results in decreased expression of SIRT1 protein
|
CTD |
PMID:37028458 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000
|
|
G
|
Slc10a1
|
solute carrier family 10 member 1
|
decreases expression
|
ISO
|
Oleanolic Acid results in decreased expression of SLC10A1 mRNA; Oleanolic Acid results in decreased expression of SLC10A1 protein
|
CTD |
PMID:23948738 |
|
NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:106,344,319...106,357,944
|
|
G
|
Slc51a
|
solute carrier family 51 member A
|
decreases expression
|
ISO
|
Oleanolic Acid results in decreased expression of SLC51A mRNA
|
CTD |
PMID:23948738 |
|
NCBI chr11:81,804,141...81,818,539
Ensembl chr11:81,803,972...81,818,539
|
|
G
|
Slc51b
|
SLC51 subunit beta
|
increases expression
|
ISO
|
Oleanolic Acid results in increased expression of SLC51B mRNA; Oleanolic Acid results in increased expression of SLC51B protein
|
CTD |
PMID:23948738 |
|
NCBI chr 8:74,827,047...74,835,109
Ensembl chr 8:74,827,047...74,835,109
|
|
G
|
Slco1a4
|
solute carrier organic anion transporter family, member 1a4
|
decreases expression
|
ISO
|
Oleanolic Acid results in decreased expression of SLCO1A4 mRNA
|
CTD |
PMID:23948738 |
|
NCBI chr 4:176,441,104...176,495,846
Ensembl chr 4:176,441,104...176,495,816
|
|
G
|
Slco1b2
|
solute carrier organic anion transporter family member 1B2
|
decreases expression multiple interactions
|
ISO
|
Oleanolic Acid results in decreased expression of SLCO1B2 protein Oleanolic Acid inhibits the reaction [Phalloidine results in increased expression of SLCO1B2 mRNA]
|
CTD |
PMID:23948738 PMID:25280775 |
|
NCBI chr 4:176,282,577...176,355,557
Ensembl chr 4:176,282,584...176,351,083
|
|
G
|
Smad3
|
SMAD family member 3
|
increases expression
|
ISO
|
Oleanolic Acid results in increased expression of SMAD3 mRNA
|
CTD |
PMID:39984133 |
|
NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324
|
|
G
|
Smad7
|
SMAD family member 7
|
decreases expression
|
ISO
|
Oleanolic Acid results in decreased expression of SMAD7 mRNA
|
CTD |
PMID:39984133 |
|
NCBI chr18:71,263,508...71,291,849
Ensembl chr18:71,263,508...71,291,849
|
|
G
|
Sod1
|
superoxide dismutase 1
|
increases expression multiple interactions
|
ISO EXP
|
Oleanolic Acid results in increased expression of SOD1 mRNA Oleanolic Acid inhibits the reaction [Ethanol results in decreased expression of SOD1 protein]
|
CTD |
PMID:18706400 PMID:25111957 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
G
|
Sqstm1
|
sequestosome 1
|
increases expression
|
ISO
|
Oleanolic Acid results in increased expression of SQSTM1 protein
|
CTD |
PMID:35690101 |
|
NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750
|
|
G
|
Srebf1
|
sterol regulatory element binding transcription factor 1
|
multiple interactions
|
ISO
|
Oleanolic Acid promotes the reaction [NFE2L2 protein results in increased expression of SREBF1 mRNA]
|
CTD |
PMID:28796629 |
|
NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164
|
|
G
|
Stat3
|
signal transducer and activator of transcription 3
|
increases expression multiple interactions
|
ISO
|
Oleanolic Acid results in increased expression of STAT3 mRNA Oleanolic Acid inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein] [Oleanolic Acid analog binds to Succinic Acid] which results in decreased expression of STAT3 mRNA
|
CTD |
PMID:18706400 PMID:31306688 PMID:31401087 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359
|
|
G
|
Stk11
|
serine/threonine kinase 11
|
multiple interactions increases phosphorylation
|
ISO
|
U 0126 inhibits the reaction [Oleanolic Acid results in increased phosphorylation of STK11 protein]
|
CTD |
PMID:36846903 |
|
NCBI chr 7:10,225,204...10,241,965
Ensembl chr 7:10,225,204...10,241,965
|
|
G
|
Tet3
|
tet methylcytosine dioxygenase 3
|
multiple interactions
|
ISO
|
Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of TET3 mRNA]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of TET3 protein]; TET3 protein inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; TET3 protein inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]]
|
CTD |
PMID:32894642 |
|
NCBI chr 4:117,425,106...117,525,495
Ensembl chr 4:117,429,857...117,520,486
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions increases expression
|
ISO
|
Oleanolic Acid inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA] Oleanolic Acid results in increased expression of TGFB1 mRNA
|
CTD |
PMID:21801858 PMID:39984133 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
multiple interactions
|
ISO
|
Oleanolic Acid analog inhibits the reaction [Carbon Tetrachloride results in increased expression of TIMP1 mRNA]
|
CTD |
PMID:17922224 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
G
|
Tjp1
|
tight junction protein 1
|
decreases expression
|
ISO
|
Oleanolic Acid results in decreased expression of TJP1 protein
|
CTD |
PMID:39030772 |
|
NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158
|
|
G
|
Tnf
|
tumor necrosis factor
|
increases expression multiple interactions
|
ISO
|
Oleanolic Acid results in increased expression of TNF mRNA Oleanolic Acid inhibits the reaction [Cisplatin results in increased expression of TNF protein]; Oleanolic Acid inhibits the reaction [Paraquat results in increased expression of TNF mRNA] Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of TNF protein]
|
CTD |
PMID:18706400 PMID:21801858 PMID:22386814 PMID:31306688 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tnfrsf1b
|
TNF receptor superfamily member 1B
|
increases expression
|
ISO
|
Oleanolic Acid results in increased expression of TNFRSF1B mRNA
|
CTD |
PMID:18706400 |
|
NCBI chr 5:162,356,250...162,387,411
Ensembl chr 5:162,353,848...162,387,411
|
|
G
|
Tomm20
|
translocase of outer mitochondrial membrane 20
|
decreases expression
|
ISO
|
Oleanolic Acid results in decreased expression of TOMM20 protein
|
CTD |
PMID:35690101 |
|
NCBI chr19:71,822,429...71,832,420
Ensembl chr19:71,822,411...71,832,510
|
|
G
|
Top1
|
DNA topoisomerase I
|
decreases activity decreases expression
|
ISO
|
Oleanolic Acid results in decreased activity of TOP1 protein Oleanolic Acid analog results in decreased expression of TOP1 protein
|
CTD |
PMID:10860928 PMID:26612655 |
|
NCBI chr 3:169,713,195...169,796,330
Ensembl chr 3:169,713,130...169,796,327
|
|
G
|
Top2a
|
DNA topoisomerase II alpha
|
decreases activity decreases expression
|
ISO
|
Oleanolic Acid results in decreased activity of TOP2A protein Oleanolic Acid analog results in decreased expression of TOP2A protein
|
CTD |
PMID:10860928 PMID:26612655 |
|
NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366
|
|
G
|
Tp53
|
tumor protein p53
|
multiple interactions
|
ISO
|
[Oleanolic Acid results in increased susceptibility to Doxorubicin] which affects the expression of TP53 mRNA
|
CTD |
PMID:37345903 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Trap1
|
TNF receptor-associated protein 1
|
multiple interactions
|
ISO
|
Oleanolic Acid inhibits the reaction [ochratoxin A results in decreased expression of TRAP1 protein]; TRAP1 protein affects the reaction [Oleanolic Acid inhibits the reaction [ochratoxin A results in decreased expression of BCL2 protein]]; TRAP1 protein affects the reaction [Oleanolic Acid inhibits the reaction [ochratoxin A results in decreased expression of TRAP1 protein]]; TRAP1 protein affects the reaction [Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of BAX protein]]; TRAP1 protein affects the reaction [Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of DDIT3 protein]]; TRAP1 protein affects the reaction [Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of HSPA5 protein]]
|
CTD |
PMID:33465424 |
|
NCBI chr10:11,971,259...12,005,306
Ensembl chr10:11,970,995...12,005,355
|
|
G
|
Trpv1
|
transient receptor potential cation channel, subfamily V, member 1
|
affects binding
|
EXP
|
Oleanolic Acid binds to TRPV1 protein
|
CTD |
PMID:30496739 |
|
NCBI chr10:58,349,936...58,375,021
Ensembl chr10:58,340,223...58,375,021
|
|
G
|
Ugt1a1
|
UDP glucuronosyltransferase family 1 member A1
|
increases expression multiple interactions
|
ISO
|
Oleanolic Acid results in increased expression of UGT1A1 protein [Oleanolic Acid affects the localization of NR1I2 protein] which results in increased expression of UGT1A1 protein
|
CTD |
PMID:38513930 |
|
NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Vcam1
|
vascular cell adhesion molecule 1
|
multiple interactions
|
ISO
|
Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of VCAM1 protein]
|
CTD |
PMID:22386814 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801
|
|
|
G
|
Adipoq
|
adiponectin, C1Q and collagen domain containing
|
multiple interactions
|
ISO
|
omaveloxolone analog inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of ADIPOQ protein]
|
CTD |
PMID:32410268 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169
|
|
G
|
Fth1
|
ferritin heavy chain 1
|
multiple interactions
|
ISO
|
omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of FTH1 mRNA]; omaveloxolone promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of FTH1 mRNA]
|
CTD |
PMID:32410268 |
|
NCBI chr 1:216,052,037...216,054,325
Ensembl chr 1:216,051,998...216,055,214
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
multiple interactions
|
ISO
|
[omaveloxolone analog co-treated with Streptozocin co-treated with Dietary Fats] results in increased expression of GPT protein
|
CTD |
PMID:32410268 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
G
|
Lep
|
leptin
|
multiple interactions
|
ISO
|
omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of LEP protein]
|
CTD |
PMID:32410268 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
multiple interactions
|
ISO
|
[omaveloxolone analog co-treated with Streptozocin co-treated with Dietary Fats] results in increased activity of NQO1 protein; [omaveloxolone co-treated with Streptozocin co-treated with Dietary Fats] results in increased activity of NQO1 protein; omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of NQO1 mRNA]; omaveloxolone promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of NQO1 mRNA]
|
CTD |
PMID:32410268 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
G
|
Srxn1
|
sulfiredoxin 1
|
multiple interactions
|
ISO
|
omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of SRXN1 mRNA]; omaveloxolone promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of SRXN1 mRNA]
|
CTD |
PMID:32410268 |
|
NCBI chr 3:161,064,812...161,070,372
Ensembl chr 3:161,059,931...161,088,765
|
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
affects activity
|
ISO
|
rubiarbonone C affects the activity of CYP3A4 protein
|
CTD |
PMID:30259074 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Cyp4f18
|
cytochrome P450, family 4, subfamily f, polypeptide 18
|
decreases activity multiple interactions
|
ISO
|
rubiarbonone C results in decreased activity of CYP4F3 protein alternative form rubiarbonone C inhibits the reaction [CYP4F3 protein alternative form results in increased hydroxylation of Arachidonic Acid]
|
CTD |
PMID:30259074 |
|
NCBI chr16:17,797,558...17,838,958
Ensembl chr16:17,740,001...17,838,958
|
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
ISO
|
soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]
|
CTD |
PMID:20923188 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
ISO
|
soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL6 protein]
|
CTD |
PMID:20923188 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
ISO
|
soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased degradation of and results in increased phosphorylation of NFKBIA protein]
|
CTD |
PMID:20923188 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
ISO
|
soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased activity of NOS2 protein]; soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased secretion of NOS2 protein]; soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of NOS2 protein]
|
CTD |
PMID:20923188 PMID:21397503 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
ISO
|
soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of PTGS2 protein]
|
CTD |
PMID:20923188 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
ISO
|
soyasaponin I inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]
|
CTD |
PMID:20923188 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Ren
|
renin
|
decreases activity
|
ISO
|
soyasaponin I results in decreased activity of REN protein
|
CTD |
PMID:19060406 PMID:20460744 |
|
NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543
|
|
G
|
St3gal4
|
ST3 beta-galactoside alpha-2,3-sialyltransferase 4
|
decreases expression
|
ISO
|
soyasaponin I results in decreased expression of ST3GAL4 mRNA
|
CTD |
PMID:15661230 |
|
NCBI chr 8:41,673,510...41,723,158
Ensembl chr 8:41,673,510...41,712,551
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO
|
soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]
|
CTD |
PMID:20923188 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
decreases phosphorylation
|
ISO
|
taraxasterol results in decreased phosphorylation of AKT1 protein
|
CTD |
PMID:35128947 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Casp3
|
caspase 3
|
increases cleavage
|
ISO
|
taraxasterol results in increased cleavage of CASP3 protein
|
CTD |
PMID:35128947 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Cdh1
|
cadherin 1
|
increases expression multiple interactions
|
ISO
|
taraxasterol results in increased expression of CDH1 protein Lithium Chloride inhibits the reaction [taraxasterol inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]]; taraxasterol inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]
|
CTD |
PMID:34219514 PMID:35128947 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565
|
|
G
|
Cdh2
|
cadherin 2
|
decreases expression multiple interactions
|
ISO
|
taraxasterol results in decreased expression of CDH2 protein Lithium Chloride inhibits the reaction [taraxasterol inhibits the reaction [TGFB1 protein results in increased expression of CDH2 protein]]; taraxasterol inhibits the reaction [TGFB1 protein results in increased expression of CDH2 protein]
|
CTD |
PMID:34219514 PMID:35128947 |
|
NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288
|
|
G
|
Ctnna1
|
catenin alpha 1
|
increases expression
|
ISO
|
taraxasterol results in increased expression of CTNNA1 protein
|
CTD |
PMID:35128947 |
|
NCBI chr18:27,002,330...27,135,009
Ensembl chr18:26,999,820...27,135,007
|
|
G
|
Ctnnb1
|
catenin beta 1
|
multiple interactions
|
ISO
|
taraxasterol inhibits the reaction [TGFB1 protein results in increased expression of CTNNB1 protein]
|
CTD |
PMID:34219514 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
multiple interactions
|
ISO
|
taraxasterol inhibits the reaction [TGFB1 protein results in increased expression of MMP2 protein]
|
CTD |
PMID:34219514 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions
|
ISO
|
taraxasterol inhibits the reaction [TGFB1 protein results in increased expression of MMP9 protein]
|
CTD |
PMID:34219514 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
increases cleavage
|
ISO
|
taraxasterol results in increased cleavage of PARP1 protein
|
CTD |
PMID:35128947 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Pik3r1
|
phosphoinositide-3-kinase regulatory subunit 1
|
decreases phosphorylation
|
ISO
|
taraxasterol results in decreased phosphorylation of PIK3R1 protein
|
CTD |
PMID:35128947 |
|
NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:34,612,946...34,626,347
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
ISO
|
Lithium Chloride inhibits the reaction [taraxasterol inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]]; Lithium Chloride inhibits the reaction [taraxasterol inhibits the reaction [TGFB1 protein results in increased expression of CDH2 protein]]; taraxasterol inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; taraxasterol inhibits the reaction [TGFB1 protein results in increased expression of CDH2 protein]; taraxasterol inhibits the reaction [TGFB1 protein results in increased expression of CTNNB1 protein]; taraxasterol inhibits the reaction [TGFB1 protein results in increased expression of MMP2 protein]; taraxasterol inhibits the reaction [TGFB1 protein results in increased expression of MMP9 protein]; taraxasterol inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; taraxasterol inhibits the reaction [TGFB1 protein results in increased expression of WNT3A protein]
|
CTD |
PMID:34219514 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Vim
|
vimentin
|
decreases expression multiple interactions
|
ISO
|
taraxasterol results in decreased expression of VIM protein taraxasterol inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]
|
CTD |
PMID:34219514 PMID:35128947 |
|
NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746
|
|
G
|
Wnt3a
|
Wnt family member 3A
|
multiple interactions
|
ISO
|
taraxasterol inhibits the reaction [TGFB1 protein results in increased expression of WNT3A protein]
|
CTD |
PMID:34219514 |
|
NCBI chr10:44,533,734...44,577,919
Ensembl chr10:44,533,734...44,577,919
|
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
decreases expression multiple interactions
|
ISO
|
Ursolic Acid results in decreased expression of ABCB1 mRNA; Ursolic Acid results in decreased expression of ABCB1 protein ABCB1 protein inhibits the reaction [Ursolic Acid results in increased susceptibility to Doxorubicin]
|
CTD |
PMID:33009882 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Acaca
|
acetyl-CoA carboxylase alpha
|
increases phosphorylation
|
ISO
|
Ursolic Acid results in increased phosphorylation of ACACA protein
|
CTD |
PMID:24802810 |
|
NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888
|
|
G
|
Ackr3
|
atypical chemokine receptor 3
|
decreases expression
|
ISO
|
Ursolic Acid results in decreased expression of ACKR3 mRNA; Ursolic Acid results in decreased expression of ACKR3 protein
|
CTD |
PMID:35786050 |
|
NCBI chr 9:98,247,300...98,258,877
Ensembl chr 9:98,246,605...98,260,214
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
decreases expression multiple interactions affects expression
|
ISO EXP
|
Ursolic Acid results in decreased expression of ACTA2 mRNA Ursolic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ACTA2 mRNA]; Ursolic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ACTA2 protein]; Ursolic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA]; Ursolic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] Ursolic Acid inhibits the reaction [Angiotensin II results in increased expression of ACTA2 mRNA]; Ursolic Acid inhibits the reaction [Angiotensin II results in increased expression of ACTA2 protein] Ursolic Acid affects the expression of ACTA2 protein
|
CTD |
PMID:35786050 PMID:39218321 PMID:39500482 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Aifm1
|
apoptosis inducing factor, mitochondria associated 1
|
increases localization decreases response to substance
|
ISO
|
Ursolic Acid results in increased localization of AIFM1 protein AIFM1 mutant form results in decreased susceptibility to Ursolic Acid
|
CTD |
PMID:20630652 |
|
NCBI chr X:132,528,107...132,567,237
Ensembl chr X:132,528,107...132,567,237
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
decreases phosphorylation
|
ISO
|
Ursolic Acid results in decreased phosphorylation of AKT1 protein
|
CTD |
PMID:19344998 PMID:24802810 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
App
|
amyloid beta precursor protein
|
multiple interactions
|
ISO
|
Ursolic Acid inhibits the reaction [APP protein modified form results in decreased expression of RPT-3 protein]; Ursolic Acid inhibits the reaction [APP protein modified form results in increased susceptibility to Serotonin]
|
CTD |
PMID:34902447 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971
|
|
G
|
Arg1
|
arginase 1
|
multiple interactions
|
ISO
|
Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of ARG1 mRNA]
|
CTD |
PMID:37019307 |
|
NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:22,295,322...22,307,713
|
|
G
|
Bak1
|
BCL2-antagonist/killer 1
|
increases activity
|
ISO
|
Ursolic Acid results in increased activity of BAK1 protein
|
CTD |
PMID:20630652 |
|
NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression multiple interactions
|
ISO
|
Ursolic Acid results in increased expression of BAX protein Ursolic Acid inhibits the reaction [ochratoxin A results in increased expression of BAX protein]
|
CTD |
PMID:16012738 PMID:24051192 PMID:36587836 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression increases phosphorylation multiple interactions
|
ISO
|
Ursolic Acid results in decreased expression of BCL2 mRNA; Ursolic Acid results in decreased expression of BCL2 protein Ursolic Acid results in increased phosphorylation of BCL2 protein [Ursolic Acid results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BECN1 protein]; Ursolic Acid inhibits the reaction [BCL2 protein binds to BECN1 protein]; Ursolic Acid inhibits the reaction [ochratoxin A results in decreased expression of BCL2 protein]
|
CTD |
PMID:16012738 PMID:24802810 PMID:28868958 PMID:36587836 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Becn1
|
beclin 1
|
multiple interactions
|
ISO
|
[Ursolic Acid results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BECN1 protein]; Ursolic Acid inhibits the reaction [BCL2 protein binds to BECN1 protein]
|
CTD |
PMID:24802810 |
|
NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions increases activity increases expression
|
ISO EXP
|
acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Ursolic Acid results in increased cleavage of and results in increased activity of CASP3 protein]; Ursolic Acid results in increased cleavage of and results in increased activity of CASP3 protein Ursolic Acid inhibits the reaction [Cisplatin results in increased expression of CASP3 protein] Ursolic Acid results in increased activity of CASP3 protein Ursolic Acid results in increased expression of CASP3 protein
|
CTD |
PMID:16012738 PMID:19329757 PMID:20005942 PMID:24051192 PMID:34569348 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp7
|
caspase 7
|
increases activity
|
ISO
|
Ursolic Acid results in increased activity of CASP7 protein
|
CTD |
PMID:19329757 |
|
NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512
|
|
G
|
Casp8
|
caspase 8
|
increases activity
|
ISO
|
Ursolic Acid results in increased activity of CASP8 protein
|
CTD |
PMID:20005942 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
multiple interactions
|
EXP
|
Ursolic Acid inhibits the reaction [Cisplatin results in increased expression of CASP9 protein]
|
CTD |
PMID:34569348 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cat
|
catalase
|
increases activity
|
ISO
|
Ursolic Acid results in increased activity of CAT protein
|
CTD |
PMID:24051192 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ccnd1
|
cyclin D1
|
decreases expression multiple interactions
|
ISO
|
Ursolic Acid results in decreased expression of CCND1 mRNA; Ursolic Acid results in decreased expression of CCND1 protein [Ursolic Acid co-treated with 2-Methoxyestradiol] results in decreased expression of CCND1 mRNA
|
CTD |
PMID:24566423 PMID:24802810 PMID:38044485 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Ccnd3
|
cyclin D3
|
decreases expression
|
ISO
|
Ursolic Acid results in decreased expression of CCND3 protein
|
CTD |
PMID:24802810 |
|
NCBI chr 9:20,891,696...20,987,199
Ensembl chr 9:20,891,704...20,987,033
|
|
G
|
Ccne1
|
cyclin E1
|
decreases expression
|
ISO
|
Ursolic Acid results in decreased expression of CCNE1 protein
|
CTD |
PMID:24802810 |
|
NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822
|
|
G
|
Cd86
|
CD86 molecule
|
multiple interactions
|
ISO
|
2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of CD86 mRNA]]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of CD86 mRNA]
|
CTD |
PMID:37019307 |
|
NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361
|
|
G
|
Cdc25b
|
cell division cycle 25B
|
affects binding
|
ISO
|
Ursolic Acid binds to CDC25B protein
|
CTD |
PMID:39180863 |
|
NCBI chr 3:138,860,148...138,870,287
Ensembl chr 3:138,860,130...138,870,492
|
|
G
|
Cdk4
|
cyclin-dependent kinase 4
|
decreases expression
|
ISO
|
Ursolic Acid results in decreased expression of CDK4 protein
|
CTD |
PMID:24802810 |
|
NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression
|
ISO
|
Ursolic Acid results in increased expression of CDKN1A protein
|
CTD |
PMID:24802810 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Cdkn1b
|
cyclin-dependent kinase inhibitor 1B
|
increases expression
|
ISO
|
Ursolic Acid results in increased expression of CDKN1B protein
|
CTD |
PMID:24802810 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
multiple interactions
|
EXP ISO
|
Ursolic Acid inhibits the reaction [Angiotensin II results in increased expression of COL1A1 mRNA] Ursolic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of COL1A1 mRNA]; Ursolic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of COL1A1 protein]; Ursolic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 mRNA]; Ursolic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 protein]
|
CTD |
PMID:39218321 PMID:39500482 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
G
|
Col3a1
|
collagen type III alpha 1 chain
|
multiple interactions
|
EXP
|
Ursolic Acid inhibits the reaction [Angiotensin II results in increased expression of COL3A1 mRNA]
|
CTD |
PMID:39218321 |
|
NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:54,866,632...54,903,232
|
|
G
|
Ctnnb1
|
catenin beta 1
|
multiple interactions decreases expression
|
ISO
|
[Ursolic Acid co-treated with 2-Methoxyestradiol] results in decreased expression of CTNNB1 mRNA; Ursolic Acid results in increased phosphorylation of and results in increased degradation of CTNNB1 protein Ursolic Acid results in decreased expression of CTNNB1 mRNA
|
CTD |
PMID:24566423 PMID:38044485 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662
|
|
G
|
Cxcl12
|
C-X-C motif chemokine ligand 12
|
decreases secretion
|
ISO
|
Ursolic Acid results in decreased secretion of CXCL12 protein
|
CTD |
PMID:35786050 |
|
NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627
|
|
G
|
Cxcl2
|
C-X-C motif chemokine ligand 2
|
multiple interactions
|
ISO
|
Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CXCL2 mRNA]
|
CTD |
PMID:26513295 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255
|
|
G
|
Cxcr4
|
C-X-C motif chemokine receptor 4
|
decreases expression
|
ISO
|
Ursolic Acid results in decreased expression of CXCR4 mRNA; Ursolic Acid results in decreased expression of CXCR4 protein
|
CTD |
PMID:35786050 |
|
NCBI chr13:42,630,383...42,634,288
Ensembl chr13:42,630,104...42,634,459
|
|
G
|
Cybb
|
cytochrome b-245 beta chain
|
multiple interactions
|
ISO
|
Ursolic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CYBB mRNA]; Ursolic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CYBB protein]; Ursolic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of CYBB mRNA]; Ursolic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of CYBB protein]
|
CTD |
PMID:39500482 |
|
NCBI chr X:16,030,596...16,065,065
Ensembl chr X:16,030,596...16,065,065
|
|
G
|
Cycs
|
cytochrome c, somatic
|
affects localization
|
ISO
|
Ursolic Acid affects the localization of CYCS protein
|
CTD |
PMID:16012738 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816 Ensembl chr18:80,982,668...80,984,816
|
|
G
|
Cyp2c6
|
cytochrome P450, family 2, subfamily C, polypeptide 6
|
multiple interactions decreases activity
|
ISO
|
Ursolic Acid inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin] Ursolic Acid results in decreased activity of CYP2C19 protein
|
CTD |
PMID:15043991 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798
|
|
G
|
Ddit3
|
DNA-damage inducible transcript 3
|
multiple interactions increases expression
|
ISO
|
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Ursolic Acid results in increased expression of DDIT3 protein]; Acetylcysteine inhibits the reaction [Ursolic Acid results in increased expression of DDIT3 protein]; EIF2AK3 mutant form inhibits the reaction [Ursolic Acid results in increased expression of DDIT3 protein]; ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in increased expression of DDIT3 protein]; Ursolic Acid inhibits the reaction [ochratoxin A promotes the reaction [bardoxolone methyl results in increased expression of DDIT3 protein]]; Ursolic Acid inhibits the reaction [ochratoxin A results in increased expression of DDIT3 protein] Ursolic Acid inhibits the reaction [Paclitaxel results in increased expression of DDIT3 mRNA]
|
CTD |
PMID:24802810 PMID:36587836 PMID:38437959 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
G
|
Edn1
|
endothelin 1
|
multiple interactions
|
ISO
|
Ursolic Acid inhibits the reaction [Choline results in increased expression of EDN1 protein]
|
CTD |
PMID:27567547 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687
|
|
G
|
Egfr
|
epidermal growth factor receptor
|
multiple interactions
|
ISO
|
Resveratrol promotes the reaction [Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]; Ursolic Acid promotes the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]]
|
CTD |
PMID:26100520 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358
|
|
G
|
Eif2ak3
|
eukaryotic translation initiation factor 2 alpha kinase 3
|
increases phosphorylation multiple interactions
|
ISO
|
Ursolic Acid results in increased phosphorylation of EIF2AK3 protein EIF2AK3 mutant form inhibits the reaction [Ursolic Acid results in increased expression of DDIT3 protein]; EIF2AK3 mutant form inhibits the reaction [Ursolic Acid results in increased phosphorylation of EIF2S1 protein]; Ursolic Acid inhibits the reaction [HSPA5 protein binds to EIF2AK3 protein]; Ursolic Acid inhibits the reaction [ochratoxin A results in increased phosphorylation of EIF2AK3 protein]
|
CTD |
PMID:24802810 PMID:36587836 |
|
NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:104,363,833...104,425,268
|
|
G
|
Eif2s1
|
eukaryotic translation initiation factor 2 subunit alpha
|
multiple interactions increases phosphorylation
|
ISO
|
EIF2AK3 mutant form inhibits the reaction [Ursolic Acid results in increased phosphorylation of EIF2S1 protein]; ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in increased phosphorylation of EIF2S1 protein]; Ursolic Acid inhibits the reaction [ochratoxin A results in increased phosphorylation of EIF2S1 protein]
|
CTD |
PMID:24802810 PMID:36587836 |
|
NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649
|
|
G
|
Eif4ebp1
|
eukaryotic translation initiation factor 4E binding protein 1
|
decreases expression
|
ISO
|
Ursolic Acid results in decreased expression of EIF4EBP1 protein
|
CTD |
PMID:24802810 |
|
NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874
|
|
G
|
Ern1
|
endoplasmic reticulum to nucleus signaling 1
|
multiple interactions increases activity
|
ISO
|
Ursolic Acid inhibits the reaction [ochratoxin A results in increased expression of ERN1 protein] Ursolic Acid results in increased activity of ERN1 protein
|
CTD |
PMID:24802810 PMID:36587836 |
|
NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791
|
|
G
|
Fap
|
fibroblast activation protein, alpha
|
decreases expression
|
ISO
|
Ursolic Acid results in decreased expression of FAP mRNA; Ursolic Acid results in decreased expression of FAP protein
|
CTD |
PMID:35786050 |
|
NCBI chr 3:67,547,398...67,616,271
Ensembl chr 3:67,546,921...67,617,601
|
|
G
|
Fcgr2a
|
Fc gamma receptor 2A
|
multiple interactions
|
ISO
|
Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of FCGR3 mRNA]
|
CTD |
PMID:37019307 |
|
NCBI chr13:85,813,516...85,830,269
Ensembl chr13:85,855,437...85,864,394 Ensembl chr13:85,855,437...85,864,394
|
|
G
|
Fcgr2b
|
Fc gamma receptor 2B
|
multiple interactions
|
ISO
|
Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of FCGR2B mRNA]
|
CTD |
PMID:37019307 |
|
NCBI chr13:85,725,897...85,740,517
Ensembl chr13:85,725,897...85,740,517
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
multiple interactions
|
ISO
|
Ursolic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of GPT protein]; Ursolic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein]; Ursolic Acid inhibits the reaction [Choline results in increased activity of GPT protein]
|
CTD |
PMID:27567547 PMID:39500482 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions
|
EXP
|
Ursolic Acid inhibits the reaction [Angiotensin II results in decreased expression of HMOX1 mRNA]
|
CTD |
PMID:39218321 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Hspa5
|
heat shock protein family A (Hsp70) member 5
|
increases expression multiple interactions
|
ISO
|
Ursolic Acid results in increased expression of HSPA5 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Ursolic Acid results in increased expression of HSPA5 protein]; Acetylcysteine inhibits the reaction [Ursolic Acid results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in increased expression of HSPA5 protein]; Ursolic Acid inhibits the reaction [HSPA5 protein binds to EIF2AK3 protein]; Ursolic Acid inhibits the reaction [ochratoxin A results in increased expression of HSPA5 protein]
|
CTD |
PMID:24802810 PMID:36587836 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790
|
|
G
|
Icam1
|
intercellular adhesion molecule 1
|
decreases expression
|
ISO
|
Ursolic Acid results in decreased expression of ICAM1 mRNA; Ursolic Acid results in decreased expression of ICAM1 protein
|
CTD |
PMID:20005942 PMID:21539908 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
G
|
Ifng
|
interferon gamma
|
multiple interactions
|
ISO
|
2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of PPARG protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of CD86 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 protein]]; 2-chloro-5-nitrobenzanilide promotes the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of CHIL3 mRNA]]; 2-chloro-5-nitrobenzanilide promotes the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 mRNA]]; 2-chloro-5-nitrobenzanilide promotes the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 protein]]; [Ursolic Acid co-treated with IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MRC1 mRNA; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of ARG1 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of CHIL3 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of PPARG protein]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 protein]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of CD86 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of FCGR2B mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of FCGR3 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 protein]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 protein]
|
CTD |
PMID:37019307 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
EXP
|
Ursolic Acid inhibits the reaction [Cisplatin results in increased expression of IL1B protein]
|
CTD |
PMID:34569348 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions decreases expression
|
ISO EXP
|
[Glucaric Acid co-treated with Ursolic Acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of IL6 mRNA]; Ursolic Acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of IL6 mRNA] Ursolic Acid inhibits the reaction [Cisplatin results in increased expression of IL6 protein] Ursolic Acid results in decreased expression of IL6 protein
|
CTD |
PMID:20869956 PMID:23835587 PMID:34569348 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Jun
|
Jun proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions
|
ISO
|
[Glucaric Acid co-treated with Ursolic Acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of JUN protein]; Resveratrol promotes the reaction [Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of JUN]]; Ursolic Acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of JUN protein]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of JUN]; Ursolic Acid promotes the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of JUN]]
|
CTD |
PMID:23835587 PMID:26100520 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285
|
|
G
|
Lep
|
leptin
|
increases expression
|
ISO
|
Ursolic Acid results in increased expression of LEP protein
|
CTD |
PMID:20869956 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661
|
|
G
|
Lonp1
|
lon peptidase 1, mitochondrial
|
multiple interactions
|
ISO
|
Ursolic Acid inhibits the reaction [ochratoxin A results in decreased expression of LONP1 protein]
|
CTD |
PMID:36587836 |
|
NCBI chr 9:1,534,581...1,546,908
Ensembl chr 9:1,534,584...1,547,427
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
EXP
|
bisphenol A diglycidyl ether inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK1 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:27274199 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
EXP
|
bisphenol A diglycidyl ether inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK3 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:27274199 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mapk8
|
mitogen-activated protein kinase 8
|
multiple interactions
|
EXP
|
bisphenol A diglycidyl ether inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK8 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK8 protein]
|
CTD |
PMID:27274199 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
G
|
Mapk9
|
mitogen-activated protein kinase 9
|
multiple interactions
|
EXP
|
bisphenol A diglycidyl ether inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK9 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK9 protein]
|
CTD |
PMID:27274199 |
|
NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228
|
|
G
|
Mir140
|
microRNA 140
|
increases expression
|
ISO
|
Ursolic Acid results in increased expression of MIR140 mRNA
|
CTD |
PMID:38044485 |
|
NCBI chr19:52,375,293...52,375,391
Ensembl chr19:52,375,293...52,375,391
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
multiple interactions decreases expression
|
ISO EXP
|
[Ursolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; [Ursolic Acid co-treated with Oleanolic Acid] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; Ursolic Acid results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 protein]]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 protein] Ursolic Acid results in decreased expression of MMP2 mRNA bisphenol A diglycidyl ether inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP2 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP2 protein]; Ursolic Acid inhibits the reaction [Angiotensin II results in increased expression of MMP2 mRNA]
|
CTD |
PMID:21539908 PMID:27274199 PMID:36191607 PMID:37019307 PMID:39218321 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
decreases expression multiple interactions
|
ISO EXP
|
Ursolic Acid results in decreased expression of MMP9 mRNA bisphenol A diglycidyl ether inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP9 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP9 protein] [Ursolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP9 protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased expression of MMP9 protein; [Ursolic Acid co-treated with Oleanolic Acid] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP9 protein; Ursolic Acid results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP9 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 protein]]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 protein]
|
CTD |
PMID:21539908 PMID:27274199 PMID:36191607 PMID:37019307 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Mrc1
|
mannose receptor, C type 1
|
multiple interactions
|
ISO
|
[Ursolic Acid co-treated with IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MRC1 mRNA
|
CTD |
PMID:37019307 |
|
NCBI chr17:82,157,725...82,239,411
Ensembl chr17:82,157,705...82,239,410
|
|
G
|
Mtor
|
mechanistic target of rapamycin kinase
|
multiple interactions decreases phosphorylation
|
ISO
|
ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in decreased phosphorylation of MTOR protein]
|
CTD |
PMID:24802810 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions
|
EXP
|
Ursolic Acid inhibits the reaction [Angiotensin II results in decreased expression of NFE2L2 mRNA]
|
CTD |
PMID:39218321 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
multiple interactions
|
ISO
|
[Ursolic Acid co-treated with Glucaric Acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of NFKB1 protein]
|
CTD |
PMID:23835587 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
ISO
|
Ursolic Acid analog results in decreased phosphorylation of and results in increased expression of NFKBIA protein
|
CTD |
PMID:26134000 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Nlrp3
|
NLR family, pyrin domain containing 3
|
multiple interactions
|
ISO
|
Ursolic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of NLRP3 mRNA]; Ursolic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of NLRP3 protein]; Ursolic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of NLRP3 mRNA]; Ursolic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of NLRP3 protein]
|
CTD |
PMID:39500482 |
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
decreases expression
|
ISO
|
Ursolic Acid results in decreased expression of NOS2 protein
|
CTD |
PMID:24051192 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Nos3
|
nitric oxide synthase 3
|
multiple interactions
|
ISO
|
Ursolic Acid inhibits the reaction [Choline results in increased expression of NOS3 protein]
|
CTD |
PMID:27567547 |
|
NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
increases cleavage
|
ISO
|
Ursolic Acid results in increased cleavage of PARP1 protein
|
CTD |
PMID:16012738 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Plau
|
plasminogen activator, urokinase
|
decreases secretion multiple interactions
|
ISO
|
Ursolic Acid results in decreased secretion of PLAU protein [Ursolic Acid co-treated with Irinotecan] results in decreased secretion of PLAU protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of PLAU protein; [Ursolic Acid co-treated with Oleanolic Acid] results in decreased secretion of PLAU protein
|
CTD |
PMID:36191607 |
|
NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030
|
|
G
|
Plaur
|
plasminogen activator, urokinase receptor
|
decreases expression multiple interactions
|
ISO
|
Ursolic Acid results in decreased expression of PLAUR protein [Ursolic Acid co-treated with Irinotecan] results in increased secretion of and results in decreased expression of PLAUR protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in increased secretion of and results in decreased expression of PLAUR protein; [Ursolic Acid co-treated with Oleanolic Acid] results in increased secretion of and results in decreased expression of PLAUR protein
|
CTD |
PMID:36191607 |
|
NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:89,178,453...89,198,130
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
multiple interactions
|
ISO EXP
|
2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of PPARG protein]]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of PPARG protein] bisphenol A diglycidyl ether inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of PPARG protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of PPARG protein]
|
CTD |
PMID:27274199 PMID:37019307 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
ISO
|
[Ursolic Acid co-treated with Glucaric Acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of PTGS2 mRNA]; Resveratrol promotes the reaction [Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2]]; Ursolic Acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of PTGS2 mRNA]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2]; Ursolic Acid promotes the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2]]
|
CTD |
PMID:23835587 PMID:26100520 PMID:26513295 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Ptpn1
|
protein tyrosine phosphatase, non-receptor type 1
|
decreases activity
|
ISO
|
Ursolic Acid results in decreased activity of PTPN1 protein
|
CTD |
PMID:27085377 PMID:29175190 PMID:30160205 PMID:36933777 |
|
NCBI chr 3:177,056,588...177,106,424
Ensembl chr 3:177,057,659...177,106,416
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
decreases expression
|
ISO
|
Ursolic Acid analog results in decreased expression of RELA mRNA; Ursolic Acid analog results in decreased expression of RELA protein
|
CTD |
PMID:26134000 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Rps6kb1
|
ribosomal protein S6 kinase B1
|
decreases expression
|
ISO
|
Ursolic Acid results in decreased expression of RPS6KB1 protein
|
CTD |
PMID:24802810 |
|
NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238
|
|
G
|
Sigmar1
|
sigma non-opioid intracellular receptor 1
|
increases expression multiple interactions
|
ISO
|
Ursolic Acid results in increased expression of SIGMAR1 protein Ursolic Acid inhibits the reaction [bardoxolone methyl results in decreased expression of SIGMAR1 protein]; Ursolic Acid inhibits the reaction [ochratoxin A results in decreased expression of SIGMAR1 protein]
|
CTD |
PMID:36587836 |
|
NCBI chr 5:61,700,021...61,702,799
Ensembl chr 5:61,700,021...61,702,855
|
|
G
|
Src
|
SRC proto-oncogene, non-receptor tyrosine kinase
|
multiple interactions
|
ISO
|
Resveratrol promotes the reaction [Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of SRC]]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of SRC]; Ursolic Acid promotes the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of SRC]]
|
CTD |
PMID:26100520 |
|
NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462
|
|
G
|
Stat3
|
signal transducer and activator of transcription 3
|
multiple interactions
|
ISO
|
Resveratrol promotes the reaction [Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of STAT3]]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of STAT3]; Ursolic Acid promotes the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of STAT3]]
|
CTD |
PMID:26100520 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
decreases expression multiple interactions
|
ISO EXP
|
Ursolic Acid results in decreased expression of TGFB1 protein Ursolic Acid inhibits the reaction [Angiotensin II results in increased expression of TGFB1 mRNA]
|
CTD |
PMID:21539908 PMID:39218321 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Tgfb3
|
transforming growth factor, beta 3
|
decreases expression multiple interactions
|
ISO
|
Ursolic Acid results in decreased expression of TGFB3 mRNA; Ursolic Acid results in decreased expression of TGFB3 protein [Ursolic Acid co-treated with 2-Methoxyestradiol] results in decreased expression of TGFB3 mRNA
|
CTD |
PMID:38044485 |
|
NCBI chr 6:111,435,170...111,457,646
Ensembl chr 6:111,435,170...111,456,946
|
|
G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
multiple interactions
|
EXP ISO
|
bisphenol A diglycidyl ether inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of TIMP1 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of TIMP1 protein] 2-chloro-5-nitrobenzanilide promotes the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 mRNA]]; 2-chloro-5-nitrobenzanilide promotes the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 protein]]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 protein]; Ursolic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TIMP1 mRNA]; Ursolic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TIMP1 protein]; Ursolic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TIMP1 mRNA]; Ursolic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TIMP1 protein]
|
CTD |
PMID:27274199 PMID:37019307 PMID:39500482 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
G
|
Tnf
|
tumor necrosis factor
|
decreases expression multiple interactions
|
ISO EXP
|
Ursolic Acid results in decreased expression of TNF protein Ursolic Acid inhibits the reaction [Cisplatin results in increased expression of TNF protein]
|
CTD |
PMID:24051192 PMID:34569348 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Top1
|
DNA topoisomerase I
|
decreases activity
|
ISO
|
Ursolic Acid results in decreased activity of TOP1 protein
|
CTD |
PMID:10860928 |
|
NCBI chr 3:169,713,195...169,796,330
Ensembl chr 3:169,713,130...169,796,327
|
|
G
|
Top2a
|
DNA topoisomerase II alpha
|
decreases activity
|
ISO
|
Ursolic Acid results in decreased activity of TOP2A protein
|
CTD |
PMID:10860928 |
|
NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
decreases expression
|
ISO
|
Ursolic Acid results in decreased expression of VEGFA protein
|
CTD |
PMID:24051192 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
G
|
Vim
|
vimentin
|
decreases expression
|
ISO
|
Ursolic Acid results in decreased expression of VIM mRNA; Ursolic Acid results in decreased expression of VIM protein
|
CTD |
PMID:35786050 |
|
NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746
|
|